Methods of producing two chain proteins in bacteria

ABSTRACT

Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.

CROSS REFERENCE TO RELATED APPLICATION(S)

This application claims the benefit of U.S. Provisional Application No.62/207,882, filed Aug. 20, 2015, and U.S. Provisional Application No.62/075,792, filed Nov. 5, 2014, which are incorporated herein byreference in their entirety.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file isincorporated herein by reference in its entirety: a computer readableform (CRF) of the Sequence Listing (file name: 146392024000SEQLIST.TXT,date recorded: Nov. 5, 2015, size: 49 KB).

FIELD

This disclosure relates to methods of producing recombinantpolypeptides, such as antibodies. More specifically, this disclosurerelates to methods of producing heterologous secretory proteins inbacteria through utilization of optimized expression vectors and cultureprocesses.

BACKGROUND

Recombinant protein production in prokaryotic host cells has been asource of many important therapeutic agents since the production ofhuman insulin in E. coli in 1978. As molecular biology tools andknowledge has advanced, the complexity of recombinant therapeutics hasalso increased. Production of these recombinant proteins requires thatthe products exhibit properties such as proper translation, folding,assembly, disulfide bonding, and transport to the periplasm. It is knownthat expression of many recombinant proteins, particularly those withdisulfide bonds (e.g., two chain proteins, including without limitationantibodies and antibody fragments), leads to the formation of inclusionbodies in prokaryotic host cells (Spadiut et al., Trends inBiotechnology, 32:54, 2014). Accordingly, there is a demand forexpression systems and processes for the recombinant production ofproperly folded and assembled two chain proteins in prokaryotic hostcells on an industrial scale.

Monoclonal antibodies represent one of the fastest growing types ofrecombinant therapeutic agent, with numerous monoclonal antibodiesalready approved or under review for the treatment of various diseases(Nelson et al., Nature Review Drug Discovery, 9:767, 2010). Traditionalmonoclonal antibodies bind a single target antigen. For many diseases,it may be advantageous to employ antibodies that bind more than onetarget antigen, i.e., multispecific antibodies. Such antibodies can beemployed in combinatorial approaches directed against multipletherapeutic targets (see, e.g., Bostrom et al., Science 323:1610, 2009;and Wu et al., Nature Biotechnology, 25:1290, 2007). For instance,bispecific antibodies can be produced that simultaneously bind anepitope expressed on the surface of a cancer cell and an epitopeexpressed on a T cell to induce T cell-mediated killing of tumor cells(Shalaby et al., Clinical Immunology, 74:185, 1995).

The use of bispecific antibodies in the clinic requires the ability toproduce two chain proteins in industrially relevant amounts. Whilevector components that improve recombinant protein production inprokaryotic host cells have been described (see, e.g., Schlapschy etal., Protein Engineering, Design and Selection, 19:385, 2006; andSimmons et al., Journal of Immunological Methods 263: 133, 2002), theresults described herein demonstrate that modifications to expressionvectors alone do not solve all of the production problems encounteredduring the manufacture of two chain proteins. There remains a need foroptimal methods for efficiently producing recombinant two chainproteins, such as antibody fragments and half-antibodies, on apreparative scale.

All references cited herein, including patent applications, patentpublications, and UniProtKB/Swiss-Prot Accession numbers are hereinincorporated by reference in their entirety, as if each individualreference were specifically and individually indicated to beincorporated by reference.

SUMMARY

In one aspect, provided herein are methods of producing a polypeptidecomprising two chains in a prokaryotic host cell, the method comprising:(a) culturing the host cell to express the two chains of thepolypeptide, whereby upon expression the two chains fold and assemble toform a biologically active polypeptide in the host cell; wherein thehost cell comprises a polynucleotide comprising (1) a firsttranslational unit encoding a first chain of the polypeptide; (2) asecond translational unit encoding a second chain of the polypeptide;and (3) a third translational unit encoding at least one chaperoneprotein selected from the group consisting of peptidyl-prolylisomerases, protein disulfide oxidoreductases, and combinations thereof;wherein the host cell is cultured in a culture medium under conditionscomprising: a growth phase comprising a growth temperature and a growthagitation rate, and a production phase comprising a productiontemperature and a production agitation rate, wherein the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the biologically active polypeptidefrom the host cell. Also provided are methods of producing a polypeptidecomprising two chains in a prokaryotic host cell, the method comprising:(a) culturing the host cell to express the two chains of the polypeptidein a culture medium under conditions comprising: a growth phasecomprising a growth temperature and a growth agitation rate, and aproduction phase comprising a production temperature and a productionagitation rate, whereby upon expression the two chains fold and assembleto form a biologically active polypeptide in the host cell; wherein thehost cell comprises a polynucleotide comprising (1) a firsttranslational unit encoding a first chain of the polypeptide; (2) asecond translational unit encoding a second chain of the polypeptide;and (3) a third translational unit encoding at least one chaperoneprotein selected from the group consisting of peptidyl-prolylisomerases, protein disulfide oxidoreductases, and combinations thereof;wherein the growth temperature is from 2 to 10° C. above the productiontemperature, and the growth agitation rate is from 50 to 250 rpm abovethe production agitation rate; and (b) recovering the biologicallyactive polypeptide from the host cell. Also provided are methods ofproducing a polypeptide comprising two chains in a prokaryotic hostcell, the method comprising: (a) culturing the host cell to express thetwo chains of the polypeptide, whereby upon expression the two chainsfold and assemble to form a biologically active polypeptide in the hostcell; wherein the host cell comprises a polynucleotide comprising: (1) afirst translational unit encoding a first chain of the polypeptide; (2)a second translational unit encoding a second chain of the polypeptide;(3) a third translational unit encoding a first chaperone protein; (4) afourth translational unit encoding a second chaperone protein; and (5) afifth translational unit encoding a third chaperone protein, wherein thefirst, second and third chaperone proteins are selected from the groupconsisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein the host cell iscultured in a culture medium under conditions comprising: a growth phasecomprising a growth temperature and a growth agitation rate, and aproduction phase comprising a production temperature and a productionagitation rate, wherein the growth temperature is from 2 to 10° C. abovethe production temperature, and the growth agitation rate is from 50 to250 rpm above the production agitation rate; and (b) recovering thebiologically active polypeptide from the host cell. Also provided aremethods of producing a polypeptide comprising two chains in aprokaryotic host cell, the method comprising: (a) culturing the hostcell to express the two chains of the polypeptide in a culture mediumunder conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,whereby upon expression the two chains fold and assemble to form abiologically active polypeptide in the host cell; wherein the host cellcomprises a polynucleotide comprising: (1) a first translational unitencoding a first chain of the polypeptide; (2) a second translationalunit encoding a second chain of the polypeptide; (3) a thirdtranslational unit encoding a first chaperone protein; (4) a fourthtranslational unit encoding a second chaperone protein; and (5) a fifthtranslational unit encoding a third chaperone protein, wherein thefirst, second and third chaperone proteins are selected from the groupconsisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the biologically active polypeptidefrom the host cell. In some embodiments, the polypeptide comprisesthree, four or five chains. In some embodiments, pH of the culturemedium is maintained at a pH in the range of between 6.7 and 7.3 duringthe production phase. In some embodiments, the polynucleotide furthercomprises three copies of a promoter, wherein a first copy is inoperable combination with the first translational unit, a second copy isin operable combination with the second translational unit, and a thirdcopy is in operable combination with the third translational unit todrive transcription of the first chain, the second chain and thechaperone protein. In some embodiments, two of the translational unitsencoding two of the three chaperone proteins are part of a singletranscriptional unit (bicistronic unit). In some embodiments, thepolynucleotide further comprises a promoter in operable combination witheach translational unit. In some embodiments, the promoter is aninducible promoter. In some embodiments, the inducible promoter is anIPTG-inducible promoter that drives transcription of the first chain,the second chain and the chaperone protein in the absence of IPTGinduction. In some embodiments, the inducible promoter is a Pho promoterthat drives transcription of the first chain, the second chain and thechaperone protein when phosphate in the culture medium has beendepleted. In some embodiments, the polynucleotide further comprises aselectable marker and the culture medium comprises a selection agentconsisting of a single antibiotic to cause the host cell to retain thepolynucleotide. In some embodiments, the first translational unitcomprises a first translation initiation region (TIR) in operablecombination with a coding region of the first chain, and the secondtranslational unit comprises a second translation initiation region(TIR) in operable combination with a coding region of the second chain,wherein the relative translation strength of the first and second TIR isfrom about 1.0 to about 3.0. In some embodiments, the at least onechaperone protein, or the first chaperone protein comprises apeptidyl-prolyl isomerase. In some embodiments, the peptidyl-prolylisomerase is an FkpA protein. In some embodiments, the FkpA is E. coliFkpA. In some embodiments, the at least one chaperone protein furthercomprises or one or both of the second chaperone protein and the thirdchaperone protein comprises a protein disulfide oxidoreductase. In someembodiments, the protein disulfide oxidoreductase is one or both of aDsbA protein and a DsbC protein. In some embodiments, the at least oneprotein disulfide oxidoreductase is one or both of E. coli DsbA and E.coli DsbC. In some embodiments, the prokaryotic host cell is agram-negative bacterium. In some embodiments, the gram-negativebacterium is E. coli. In some embodiments, the E. coli is of a straindeficient in endogenous protease activity. In some embodiments, the E.coli is a strain with a degpS210A mutation. In some embodiments, the E.coli is a strain with a genotype of W3110 ΔfhuA ΔphoA ilvG2096 (Val^(r))Δprc spr43H1 ΔdegP ΔmanA lacI^(Q) ΔompT ΔmenE degpS210A. In someembodiments, the polypeptide is heterologous to the host cell. In someembodiments, the polypeptide is a monomer of a heterodimer (e.g.,bi-specific antibody). In some embodiments, the two chains of thepolypeptide are linked to each other by at least one disulfide bond. Insome embodiments, the two chains of the polypeptide are linked to eachother by a polypeptide linker. In some embodiments, the polypeptide is amonovalent antibody in which the first chain and the second chaincomprise an immunoglobulin heavy chain and an immunoglobulin lightchain. In some embodiments, the immunoglobulin heavy chain is an IgG1 oran IgG4 isotype. In some embodiments, the monovalent antibody is capableof specifically binding an antigen. In some embodiments, the antigen isa cytokine. In some embodiments, the cytokine is selected from the groupconsisting of a chemokine, an interferon, an interleukin, a lymphokine,and tumour necrosis factor. In some embodiments, the growth factor is avascular endothelial growth factor. In some embodiments, the antigen isselected from the group consisting of IL-4, IL13, IL-14, IL-17, VEGFAand VEGFC. In some embodiments, the polypeptide is a secretory protein.In some embodiments, the secretory protein is recovered from theperiplasm of the host cell. In some embodiments, the antibody isrecovered from the periplasm of the host cell. In some embodiments, thegrowth temperature is in the range of about 30° C. to about 34° C.during the growth phase, and the production temperature in the range ofabout 25° C. to about 29° C. during the production phase. In someembodiments, the growth agitation rate is in the range of about 600 to800 rpm during the growth phase, and the production agitation rate is inthe range of about 300 to about 500 rpm during the production phase. Insome embodiments, the growth agitation rate is sufficient to achieve anoxygen uptake rate in the host cell during the growth phase of from 0.5to 2.5 mmol/L/min above a peak oxygen uptake rate in the host cellduring the production phase. In some embodiments, the peak oxygen uptakerate of the host cell during the growth phase is in the range of 3.5 to4.5 mmol/L/min, and the oxygen uptake rate of the host cell during theproduction phase is in the range of 1.0 to 3.0 mmol/L/min. In someembodiments, the growth agitation rate is from about 10% to about 40%higher than the production agitation rate.

In another aspect, provided herein are methods of producing a halfantibody comprising a heavy chain and a light chain in a prokaryotichost cell, the method comprising: (a) culturing the host cell to expressthe heavy chain and the light chain in a culture medium under conditionscomprising: a growth phase comprising a growth temperature and a growthagitation rate, and a production phase comprising a productiontemperature and a production agitation rate, whereby upon expression theheavy chain and the light chain assemble to form a half antibody in thehost cell; wherein the host cell comprises a polynucleotide comprising:(1) a first translational unit encoding the heavy chain of the halfantibody; (2) a second translational unit encoding the light chain ofthe half antibody; (3) a third translational unit encoding a firstchaperone protein; (4) a fourth translational unit encoding a secondchaperone protein; and (5) a fifth translational unit encoding a thirdchaperone protein, wherein the first, second and third chaperoneproteins are selected from the group consisting of peptidyl-prolylisomerases, protein disulfide oxidoreductases, and combinations thereof;wherein the growth temperature is from 2 to 10° C. above the productiontemperature, and the growth agitation rate is from 50 to 250 rpm abovethe production agitation rate; and (b) recovering the half antibody fromthe host cell. In some embodiments, the half antibody comprises at leastone hole-forming mutation or at least one knob-forming mutation. Alsoprovided are methods of producing an anti-IL13 half antibody comprisinga heavy chain and a light chain in a prokaryotic host cell, the methodcomprising: (a) culturing the host cell to express the heavy chain andthe light chain in a culture medium under conditions comprising: agrowth phase comprising a growth temperature and a growth agitationrate, and a production phase comprising a production temperature and aproduction agitation rate, wherein (i) the heavy chain comprises a heavychain variable domain comprising an HVR-H1 of SEQ ID NO:9, an HVR-H2 ofSEQ ID NO:10, and an HVR-H3 of SEQ ID NO:11; and (ii) the light chaincomprises a light chain variable domain comprising an HVR-L1 of SEQ IDNO:12, an HVR-L2 of SEQ ID NO:13, and an HVR-L3 of SEQ ID NO:14, wherebyupon expression the heavy chain and light chain assemble to form ananti-IL13 half antibody in the host cell; wherein the host cellcomprises a polynucleotide comprising: (1) a first translational unitencoding the heavy chain of the half antibody; (2) a secondtranslational unit encoding the light chain of the half antibody; (3) athird translational unit encoding a first chaperone protein; (4) afourth translational unit encoding a second chaperone protein; and (5) afifth translational unit encoding a third chaperone protein, wherein thefirst, second and third chaperone proteins are selected from the groupconsisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the anti-IL13 half antibody from thehost cell. In some embodiments, the anti-IL13 half antibody comprises atleast one knob-forming mutation. Also provided are methods of producingan anti-IL17 half antibody comprising a heavy chain and a light chain ina prokaryotic host cell, the method comprising: (a) culturing the hostcell to express the heavy chain and the light chain in a culture mediumunder conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,wherein (i) the heavy chain comprises a heavy chain variable domaincomprising an HVR-H1 of SEQ ID NO:20, an HVR-H2 of SEQ ID NO:21, and anHVR-H3 of SEQ ID NO:22; and (ii) the light chain comprises a light chainvariable domain comprising an HVR-L1 of SEQ ID NO:23, an HVR-L2 of SEQID NO:24, and an HVR-L3 of SEQ ID NO:25, whereby upon expression theheavy chain and the light chain assemble to form an anti-IL17 halfantibody in the host cell; wherein the host cell comprises apolynucleotide comprising: (1) a first translational unit encoding theheavy chain of the half antibody; (2) a second translational unitencoding the light chain of the half antibody; (3) a third translationalunit encoding a first chaperone protein; (4) a fourth translational unitencoding a second chaperone protein; and (5) a fifth translational unitencoding a third chaperone protein, wherein the first, second and thirdchaperone proteins are selected from the group consisting ofpeptidyl-prolyl isomerases, protein disulfide oxidoreductases, andcombinations thereof; wherein the growth temperature is from 2 to 10° C.above the production temperature, and the growth agitation rate is from50 to 250 rpm above the production agitation rate; and (b) recoveringthe anti-IL17 half antibody from the host cell. In some embodiments, theanti-IL17 half antibody comprises at least one hole-forming mutation. Insome embodiments, the polynucleotide further comprises three copies of apromoter, wherein a first copy is in operable combination with the firsttranslational unit, a second copy is in operable combination with thesecond translational unit, and a third copy is in operable combinationwith the third translational unit to drive transcription of the heavychain, the light chain and the chaperone protein. In some embodiments,the promoter is an inducible promoter. In some embodiments, theinducible promoter is an IPTG-inducible promoter that drivestranscription of the heavy chain, the light chain and the chaperoneprotein in the absence of IPTG induction. In some embodiments, theinducible promoter is a pho promoter that drives transcription of theheavy chain, the light chain and the chaperone protein when phosphate inthe culture medium has been depleted. In some embodiments, thepolynucleotide further comprises a selectable marker and the culturemedium comprises a selection agent consisting of a single antibiotic tocause the host cell to retain the monovalent antibody. In someembodiments, the first translational unit comprises a first translationinitiation region (TIR) in operable combination with a coding region ofthe heavy chain variable domain, and the second translational unitcomprises a second translation initiation region (TIR) in operablecombination with a coding region of the light chain variable domain,wherein the relative translation strength of the first and second TIR isfrom about 1.0 to about 3.0. In some embodiments, the at least onechaperone protein, or the first chaperone protein comprises apeptidyl-prolyl isomerase. In some embodiments, the peptidyl-prolylisomerase is an FkpA protein. In some embodiments, the FkpA is E. coliFkpA. In some embodiments, the at least one chaperone protein furthercomprises or one or both of the second chaperone protein and the thirdchaperone protein comprises a protein disulfide oxidoreductase. In someembodiments, the protein disulfide oxidoreductase is one or both of aDsbA protein and a DsbC protein. In some embodiments, the at least oneprotein disulfide oxidoreductase is one or both of E. coli DsbA and E.coli DsbC. In some embodiments, the prokaryotic host cell is agram-negative bacterium. In some embodiments, the gram-negativebacterium is E. coli. In some embodiments, the E. coli is of a straindeficient in endogenous protease activity. In some embodiments, the E.coli is a strain with a degpS210A mutation. In some embodiments, the E.coli is a strain with a genotype of W3110 ΔfhuA ΔphoA ilvG2096 (Val^(r))Δprc spr43H1 ΔdegP ΔmanA lacI^(Q) ΔompT ΔmenE degpS210A. In someembodiments, the growth temperature is in the range of about 30° C. toabout 34° C. during the growth phase, and the production temperature inthe range of about 25° C. to about 29° C. during the production phase.In some embodiments, the growth agitation rate is sufficient to achievean oxygen uptake rate in the host cell during the growth phase of from0.5 to 2.5 mmol/L/min above a peak oxygen uptake rate in the host cellduring the production phase. In some embodiments, the peak oxygen uptakerate of the host cell during the growth phase is in the range of 3.5 to4.5 mmol/L/min, and the oxygen uptake rate of the host cell during theproduction phase is in the range of 1.0 to 3.0 mmol/L/min. In someembodiments, the growth agitation rate is from about 10% to about 40%higher than the production agitation rate. Also provided are methods ofproducing a bi-specific antibody comprising a first half antibodycapable of binding a first antigen and a second half antibody capable ofbinding a second antigen, the method comprising: combining in a reducingcondition, the first half antibody with the second half antibody toproduce a bi-specific antibody, wherein the first half antibodycomprises at least one knob-forming mutation and the second halfantibody comprises at least one hole-forming mutation, and wherein boththe first half antibody and the second half antibody are produced by themethod of any one of the preceding embodiments. In some embodiments, thefirst half antigen and the second half antigen are different antigens.In some embodiments, the first half antibody is capable of bindingIL-13. In some embodiments, the second half antibody is capable ofbinding IL-17. In some embodiments, the method further comprises thestep of adding a reducing agent to achieve the reducing condition. Insome embodiments, the reducing agent is glutathione. In yet anotheraspect, provided herein are methods of producing a bispecific antibodycomprising a first half antibody capable of binding IL13 and a secondhalf antibody capable of binding IL17, the method comprising: (a)culturing a first prokaryotic host cell to express a first heavy chainand a first light chain of the first half antibody, wherein (i) thefirst heavy chain comprises a first heavy chain variable domaincomprising an HVR-H1 of SEQ ID NO:9, an HVR-H2 of SEQ ID NO:10, and anHVR-H3 of SEQ ID NO:11; and (ii) the first light chain comprises a firstlight chain variable domain comprising an HVR-L1 of SEQ ID NO:12, anHVR-L2 of SEQ ID NO:13, and an HVR-L3 of SEQ ID NO:14, whereby uponexpression the first heavy chain and the first light chain assemble toform the first half antibody in the host cell; and (a′) culturing asecond prokaryotic host cell to express a second heavy chain and asecond light chain of the second half antibody, wherein (i) the secondheavy chain comprises a second heavy chain variable domain comprising anHVR-H1 of SEQ ID NO:20, an HVR-H2 of SEQ ID NO:21, and an HVR-H3 of SEQID NO:22; and (ii) the second light chain comprises a second light chainvariable domain comprising an HVR-L1 of SEQ ID NO:23, an HVR-L2 of SEQID NO:24, and an HVR-L3 of SEQ ID NO:25, whereby upon expression thesecond heavy chain and the second light chain assemble to form thesecond half antibody in the host cell; wherein the first host cellcomprises a first polynucleotide comprising: (1) a first translationalunit encoding the first heavy chain; (2) a second translational unitencoding the first light chain; and the second host cell comprises asecond polynucleotide comprising: (1′) a third translational unitencoding the second heavy chain; (2′) a fourth translational unitencoding the second light chain; wherein both the first polynucleotideand the second polynucleotide further comprise: (3) a fifthtranslational unit encoding a first chaperone protein; (4) a sixthtranslational unit encoding a second chaperone protein; and (5) aseventh translational unit encoding a third chaperone protein, whereinthe first, second and third chaperone proteins are selected from thegroup consisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein both the first hostcell and the second host cell are separately cultured in a culturemedium under conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,wherein the growth temperature is from 2 to 10° C. above the productiontemperature, and the growth agitation rate is from 50 to 250 rpm abovethe production agitation rate; (b) recovering the first half antibodyfrom the first host cell; (b′) recovering the second half antibody fromthe second host cell; and (c) combining the first half antibody with thesecond half antibody in a reducing condition to produce a bi-specificantibody capable of binding to both IL-13 and IL-17. In someembodiments, the first half antibody comprises at least one knob-formingmutation, and the second half antibody comprises at least onehole-forming mutation. In some embodiments, the method further comprisesthe step of adding a reducing agent to achieve the reducing condition.In some embodiments, the reducing agent is glutathione. Also provided isa composition comprising the bi-specific antibody of any one of thepreceding embodiments. In some embodiments, the heavy chain variabledomain of the anti-IL13 half antibody comprises the amino acid sequenceof SEQ ID NO:7 and the light chain variable domain of the anti-IL13antibody comprises the amino acid sequence of SEQ ID NO:8. In someembodiments, the heavy chain of the anti-IL13 half antibody comprisesthe amino acid sequence of SEQ ID NO:15 or SEQ ID NO:16. In someembodiments, the light chain of the anti-IL13 half antibody comprisesthe amino acid sequence of SEQ ID NO:17. In some embodiments, the heavychain variable domain of the anti-IL17 half antibody comprises the aminoacid sequence of SEQ ID NO:18 and the light chain variable domain of theanti-IL17 half antibody comprises the amino acid sequence of SEQ IDNO:19. In some embodiments, the heavy chain of the anti IL17 halfantibody comprises the amino acid sequence of SEQ ID NO:26 or SEQ IDNO:27. In some embodiments, the light chain of the anti-IL17 halfantibody comprises the amino acid sequence of SEQ ID NO:28.

It is to be understood that one, some, or all of the properties of thevarious embodiments described herein may be combined to form otherembodiments of the present disclosure. These and other aspects of thedisclosure will become apparent to one of skill in the art. These andother embodiments of the disclosure are further described by thedetailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-C shows the production of total light chain (LC) and heavy chain(HC) subunits from the xIL13 half-antibody (hAb) production vector. FIG.1A provides a graph of total subunits for LCs and HCs produced fromTIR1,1 (black bars) and TIR2,2 (striped bars) production vectors, asmeasured by RP-HPLC. FIG. 1B provides a graph of total subunits producedfor LC and HC (black bars) or soluble LC and HC (gray bars) from theTIR1,1 production vectors. FIG. 1C provides a graph of total subunitsproduced for total LC and HC (black bars) or soluble LC and HC (graybars) from the TIR2,2 production vectors.

FIG. 2 shows the titer of the xIL13 hAb using TIR1,1 (black bar) orTIR2,2 (striped bar) hAb production vectors as measured by dual columnRP-HPLC.

FIG. 3A-B illustrates the folding and assembly of proteins in bacterialhost cells. FIG. 3A is a schematic depicting bacterial proteinproduction, illustrating the folding and assembly of proteins in theperiplasm using chaperones. FIG. 3B is a list of chaperone proteins,including peptidyl-prolyl isomerases (“Ppiases”), oxidoreducatases, andother chaperones.

FIG. 4A shows the compatible system used to screen FkpA variants. FIG.4B shows the generation of a single xIL13 plasmid (pxIL13.2.2.FkpAc13)encoding an antibody LC, HC, and FkpA.

FIG. 5A-B shows the production of the xVEGF IgG1 hAb upon titration ofFkpA expression. FIG. 5A depicts a Western blot showing hAb and solublemonomeric heavy chain accumulation upon expression of different levelsof FkpA, while a Coomassie-stained gel shows total soluble proteinproduction under each condition. FIG. 5B A graph shows the titer of hAbproduced upon expression of different levels of FkpA.

FIG. 6A-B shows the production of the xIL13 IgG4 hAb upon expression ofdifferent levels of FkpA. FIG. 6A provides a graph showing the titer ofthe xIL13 hAb produced using different vector systems, and isaccompanied by a Western blot showing hAb and soluble monomeric heavychain accumulation in each condition. FIG. 6B provides a graph showingthe amount of FkpA produced using different vector systems, and isaccompanied by a Western blot showing expression of FkpA in eachcondition. In both panels, “endogenous FkpA levels” refers to bacterialhost cells that do not contain a plasmid encoding FkpA; “compatible FkpAlevels” refers to expression of xIL13 and FkpA from separate(compatible) plasmids; and “single FkpA levels” refers to a singlevector expressing both xIL13 and FkpA.

FIG. 7A-B shows the production of the xIL4 IgG4 hAb upon inducibleexpression of FkpA. FIG. 7A depicts a Western blot showing hAb andsoluble monomeric heavy chain accumulation. FIG. 7B provides a graphshowing the titer of the xIL4 hAb produced using inducible expression ofFkpA, and is accompanied by a Western blot showing expression of FkpA.In both panels, sample 1 uses a TIR1,1 vector for the production of thexIL4 hAb and does not overexpress FkpA; sample 2 uses a TIR2,2 vectorfor the production of the xIL4 hAb and does not overexpress FkpA; sample3 uses TIR1,1 to produce the xIL4 hAb and IPTG to induce FkpAexpression; and sample 4 uses TIR2,2 to produce the xIL4 hAb and IPTG toinduce FkpA expression.

FIG. 8A-C shows the production of the xVEGFC IgG1 hAb upon expression ofFkpA. FIG. 8A provides a graph showing the titer of the xVEGFC hAbproduced using different vector systems. FIG. 8B depicts a gel showingtotal soluble protein production under both conditions, with FkpA bandsas labeled. FIG. 8C depicts a Western blot showing accumulation of thexVEGFC hAb and soluble monomeric heavy chain. In panels all panels,sample 1 uses a TIR2,2 vector for the production of the xVEGFC hAb anddoes not contain a plasmid for expression of FkpA; sample 2 uses aTIR2,2 vector for the production of the xIL4 hAb and IPTG to induce FkpAexpression.

FIG. 9 shows the compatible plasmid system employing the a first plasmidfor expression of the xIL13 hAb (pxIL13.2.2.FkpAc13) and a secondplasmid for expression of DsbA and DsbC (pJJ247).

FIG. 10 provides a graph showing the production of the xIL13 hAb overtime using the xIL13.2.2.FkpAc13 production plasmid and a compatibleplasmid for expression of DsbA and DsbC, with and without IPTGinduction.

FIG. 11A shows the xIL14 hAb compatible plasmid system. FIG. 11B showsthe generation of a single plasmid encoding the xIL14 hAb LC and HC,FkpA, DsbA, and DsbC.

FIG. 12A-B shows the production of the xIL4 hAb with the TIR1,1 orTIR2,2 vector in the absence of FkpA, DsbA, and DsbC expression (1 and2, as labeled); in the presence of IPTG-induced FkpA expression (3 and4, as labeled); and in the presence of a plasmid with FkpA, DsbA, andDsbC in the absence of IPTG (5 and 6, as labeled). FIG. 12A depicts aWestern blot showing accumulation of the xIL4 hAb and soluble monomericheavy chain under various conditions. FIG. 12B provides a graph showingthe titer of the xIL4 hAb produced under various conditions, and isaccompanied by a Western blot showing expression of FkpA.

FIG. 13 shows the production of the xVEGFC hAb with a TIR2,2 vector inthe absence of FkpA, DsbA, and DsbC expression (column 1); in thepresence of IPTG-induced FkpA expression (column 2); and in the presenceof a plasmid with FkpA, DsbA, and DsbC in the absence of IPTG (column3).

FIG. 14 shows the production of the xVEGFA IgG1 hAb with a TIR1,1 orTIR2,2 vector in the absence of FkpA, DsbA, and DsbC expression (1 and3, as labeled); and in the presence of a plasmid with FkpA, DsbA, andDsbC in the absence of IPTG (2 and 4, as labeled).

FIG. 15 shows the production of the xIL4 hAb with a TIR2,2 vector whenFkpA, DsbA, and DsbC are expressed from the same vector (“Single”) andwhen FkpA, DsbA and DsbC are expressed from a second compatible vector(“Compatible”), along with a negative control without the antibodyexpression vector and without DsbA, DsbC, and FkpA overexpression(“Control”). A Western blot shows expression of DsbA, DsbC, and FkpA.

FIG. 16A shows the xIL13 compatible plasmid system utilizing thepreviously described pxIL13.2.2.FkpAc13 production plasmid andcompatible oxidoreductase plasmid (pJJ247). FIG. 16B shows thegeneration of a single plasmid (MD157) incorporating the open readingframes (ORFs) from pxIL13.2.2.FkpAc13 and pJJ247.

FIG. 17 shows the production over time of the xIL13 hAb with the TIR2,2vector when FkpA, DsbA, and DsbC are expressed from the same vector(“Single”) and when DsbA and DsbC are expressed from a compatible vectorand FkpA is expressed from the xIL13.2.2.FkpAc13 vector (“Compatible”).These vectors use a phoA promoter to drive FkpA expression.

FIG. 18 shows the average oxygen uptake rate (OUR) over time in culturesgrown under fixed agitation rate of cells bearing two vectors: a TIR2,2vector expressing the xIL13 hAb and FkpA, and a vector expressing DsbAand DsbC under an IPTG-inducible promoter. OUR is shown for culturesgrown in the presence or absence of IPTG. Number of samples used foreach condition is provided (“N”).

FIG. 19 shows the average osmolality in cultures grown under fixedagitation rate of cells bearing two vectors: a TIR2,2 vector expressingthe xIL13 hAb and FkpA, and a vector expressing DsbA and DsbC under anIPTG-inducible promoter. Osmolality is shown for cultures grown in thepresence or absence of IPTG. Number of samples used for each conditionis provided (“N”).

FIG. 20 shows the average titer of the xIL13 hAb produced over time fromcells bearing two vectors: a TIR2,2 vector expressing the xIL13 hAb andFkpA, and a vector expressing DsbA and DsbC under an IPTG-induciblepromoter. Titer of antibody produced is shown for cultures grown in thepresence or absence of IPTG. Number of samples used for each conditionis provided (“N”).

FIG. 21 shows the average OUR over time in cultures grown underagitation at 650 rpm for 26 hours, then shifted to a lower agitationrate sufficient to achieve the labeled OUR set point. Cells bore twovectors: a TIR2,2 vector expressing the xIL13 hAb and FkpA, and a vectorexpressing DsbA and DsbC in the absence of IPTG. Number of samples usedfor each condition is provided (“N”).

FIG. 22 shows the average osmolality over time in cultures grown underagitation at 650 rpm for 26 hours, then shifted to a lower agitationrate sufficient to achieve the labeled OUR set point. Cells bore twovectors: a TIR2,2 vector expressing the xIL13 hAb and FkpA, and a vectorexpressing in the absence of IPTG. Number of samples used for eachcondition is provided (“N”).

FIG. 23 shows the average titer of the xIL13 hAb production at two timepoints (54 and 72 hours) in cultures grown under agitation at 650 rpmfor 26 hours, then shifted to a lower agitation rate sufficient toachieve the labeled OUR set point. Cells bore two vectors: a TIR2,2vector expressing the xIL13 hAb and FkpA, and a vector expressing DsbAand DsbC in the absence of IPTG. Number of samples used for eachcondition is provided (“N”).

FIG. 24 shows the average cell density (OD_(550nm)) over time ofcultures producing the xIL13 hAb from a TIR2,2 vector that also encodedFkpA driven by a phoA promoter and DsbA and DsbC driven by a tacIIpromoter in the absence of IPTG. Cultures were grown at a constanttemperature for both growth and production (Tg/Tp) phases of either 28°C. or 30° C. An agitation shift was performed 26 hours into thefermentation. Number of samples used for each condition is provided(“N”).

FIG. 25 shows the average OUR over time of cultures of cells producingthe xIL13 hAb from a TIR2,2 vector that also encoded FkpA driven by aphoA promoter and DsbA and DsbC driven by a tacII promoter in theabsence of IPTG. Cultures were grown at a constant temperature for bothgrowth and production (Tg/Tp) phases of either 28° C. or 30° C. Numberof samples used for each condition is provided (“N”).

FIG. 26 shows the average phosphate concentration over time in culturesof cells producing the xIL13 hAb from a TIR2,2 vector that also encodedFkpA driven by a phoA promoter and DsbA and DsbC driven by a tacIIpromoter in the absence of IPTG. Cultures were grown at a constanttemperature for both growth and production (Tg/Tp) phases of either 28°C. or 30° C. Number of samples used for each condition is provided(“N”).

FIG. 27 shows the average titer of the xIL13 hAb produced in cultures ofcells from a TIR2,2 vector that also encoded FkpA driven by a phoApromoter and DsbA and DsbC driven by a tacII promoter in the absence ofIPTG. Cultures were grown at a constant temperature for both growth andproduction (Tg/Tp) phases of either 28° C. or 30° C.

FIG. 28 shows the average cell density (OD_(550nm)) over time ofcultures producing the xIL13 hAb from a TIR2,2 vector that also encodedFkpA driven by a phoA promoter and DsbA and DsbC driven by a tacIIpromoter in the absence of IPTG. Cultures were grown at a constanttemperature of 28° C. or 30° C. (Tg/Tp 28° C. or Tg/Tp 30° C.,respectively), or grown at 30° C. during the growth phase, then shiftedto 28° C. for the production phase (Tg 30 Tp 28). Number of samples usedfor each condition is provided (“N”).

FIG. 29 shows the average phosphate concentration over time in culturesof cells producing the xIL13 hAb from a TIR2,2 vector that also encodedFkpA driven by a phoA promoter and DsbA and DsbC driven by a tacIIpromoter in the absence of IPTG. Cultures were grown at a constanttemperature of 28° C. or 30° C. (Tg/Tp 28° C. or Tg/Tp 30° C.,respectively), or grown at 30° C. during the growth phase, then shiftedto 28° C. for the production phase (Tg 30 Tp). Number of samples usedfor each condition is provided (“N”).

FIG. 30 shows the OUR over time of cultures of cells producing the xIL13hAb from a TIR2,2 vector that also encoded FkpA driven by a phoApromoter and DsbA and DsbC driven by a tacII promoter in the absence ofIPTG. Cultures were grown at a constant temperature of 28° C. or 30° C.(Tg/Tp 28° C. or Tg/Tp 30° C., respectively), or grown at 30° C. duringthe growth phase, then shifted to 28° C. for the production phase (Tg 30Tp 28). Number of samples used for each condition is provided (“N”).

FIG. 31 shows the average titer of xIL13 hAb produced over time from aTIR2,2 vector that also encoded FkpA driven by a phoA promoter and DsbAand DsbC driven by a tacII promoter in the absence of IPTG. Cultureswere grown at a constant temperature of 28° C. or 30° C., as labeled(Tg/Tp 28° C. or Tg/Tp 30° C., respectively), or grown at 30° C. duringthe growth phase, then shifted to 28° C. for the production phase (Tg 30Tp 28).

FIG. 32 shows the results of a partial factorial design of experiment(DoE) analysis of the xIL13 hAb titer with a single plasmid (MD157)under different process conditions identified by the pattern in theaccompanying table.

FIG. 33 shows the titer of xIL4 hAb produced from a TIR2,2 vector thatalso encoded FkpA, DsbA and DsbC driven by a tacII promoter in theabsence of IPTG. Cultures were grown at a constant temperature of 30° C.(Tg/Tp 30° C.), or grown at 34° C. during the growth phase, then shiftedto 25° C. for the production phase (Tg 34 Tp 25).

FIG. 34 shows the results of a partial factorial design of experiment(DoE) analysis of the xIL17 hAb titer with a single plasmid (MD341)under different process conditions identified by the pattern in theaccompanying table.

FIG. 35 shows the effects of first optimizing chaperone proteinco-expression and then optimizing the process steps (e.g., agitationrate, Tg, and Tp) on xIL13 hAb titer.

FIG. 36A shows the soluble xIL13 hAb titer from fermentations performedin the 66F8 and 67A6 host strains. FIG. 36B shows the total xIL13 lightchain and heavy chain concentrations at 72 hours in both the 66F8 and67A6 host strains. N=2 for both conditions.

FIG. 37A shows the soluble xIL4 hAb titer from fermentations performedin the 66F8 and 67A6 host strains at a constant fermentationtemperature. FIG. 37B shows the total soluble xIL4 hAb titer fromfermentations performed in the 66F8 and 67A6 host strains underfermentation conditions employing a temperature shift. N=2 for bothconditions.

FIG. 38A shows the xIL4 light chain titer and FIG. 38B shows the xIL4heavy chain titer from fermentations performed in the 66F8 and 67A6 hoststrains under fermentation conditions employing a temperature shift. N=2for both conditions.

FIG. 39 provides a map of the xIL33 hAb secretion plasmid. LC and HCopen reading frames were independently placed in operable combinationwith TIR2.

FIG. 40 illustrates accumulation of xIL33 hAb in fermentations performedin the absence of co-expression of the chaperones DsbA, DsbC, FkpA at aconstant temperature of 30° C. (base case), and in fermentationsperformed in the presence of the chaperones DsbA, DsbC and FkpAco-expression under the same process conditions (w/Chaperones).

FIG. 41 shows the aIL33 hAb titer differences from the Design ofExperiment (DoE) performed with the xIL33 hAb single plasmid containingthe chaperones FkpA, DsbA, DsbC. DoE factors included pH, growthtemperature (Tg), production temperature (Tp), and production phasetarget oxygen uptake rate (OUR).

FIG. 42 provides the nucleotide sequence of the TIR1 (SEQ ID NO:42),TIR2 (SEQ ID NO:43) and TIR3 (SEQ ID NO:44) FkpA signal sequencevariants. Single nucleotide substitutions were made in the thirdposition of specific codons and represent synonymous codon changes thatdo not alter the amino acid sequence of the FkpA signal peptide sequence(SEQ ID NO:45).

FIG. 43 shows the quantitative strength of the FkpA TIR variantsrelative to the TIR1 FkpA variant (plasmid 19).

FIG. 44 shows the accumulation of the xIL13 hAb in fermentationsperformed with the TIR1, TIR2 and TIR3 FkpA TIR variants. The titerproduced in each condition was 1.5, 2.5 and 4.0 g/L for the TIR1, TIR2and TIR3 variants, respectively.

FIG. 45 shows the accumulation of the xIL33 hAb in fermentationsperformed with the TIR1, TIR2 and TIR3 FkpA TIR variants.

FIG. 46 shows a plot of the accumulation of the xIL17 hAb infermentations performed with the TIR1, TIR2 and TIR3 FkpA variants.

FIG. 47A shows a plot of the accumulation of the xIL13 hAb infermentations performed with FkpA TIR variants. FIG. 47B shows the levelof FkpA present in the soluble fraction from the xIL13 hAb process atthe end of the fermentation.

FIG. 48A shows the oxygen uptake rates (OUR) for the altered oxygentransfer rate (OTR) and control fermentation conditions. The altered OTRand control fermentations achieved a similar peak OUR of about 5mmol/L/min and similar post agitation shift target OUR of 2.75mmol/L/min. FIG. 48B shows the growth profiles for the altered OTR andcontrol fermentation conditions. The altered OTR and controlfermentations had similar growth profiles and both achieved peak anOD₅₅₀ of 250. xIL13 hAb control (Ctrl) best condition=1 bar backpressure (BP), 20 standard liters per minute (SLPM), and an agitationrate shift of 650 to 475 rpm. The xIL13 hAb altered OTR condition=0.3bar back pressure, 13 SLPM, and an agitation rate shift of 880 to 650rpm.

FIG. 49 shows the xIL13 hAb accumulation profiles for the altered OTRand control conditions. The altered and control conditions had similaraccumulation profiles during fermentation and both achieved maximumaverage titers at 72 hours of 4.1 and 4.2 g/L, respectively.

DETAILED DESCRIPTION

The examples provided herein demonstrate that co-expression of one ormore specific chaperone proteins in combination with translational unitsencoding each chain of a multiple chain protein (e.g., light chain andheavy chain of a half-antibody) increases the production of an assembledmultiple chain protein in a prokaryotic host cell system. The examplesfurther demonstrate that subsequent process improvements, such asspecific temperatures and agitation rates for certain phases of thefermentation, result in significant enhancements in production androbustness beyond the expression vector improvements. Overall, themethods described herein achieve an at least 10-fold gain in productionof exemplary two chain polypeptides (e.g., half antibody).

In one aspect, provided herein are methods of producing a polypeptidecontaining two chains in a prokaryotic host cell by culturing the hostcell to express the two chains of the polypeptide, where upon expressionthe two chains fold and assemble to form a biologically activepolypeptide in the host cell; where the host cell contains apolynucleotide including (1) a first translational unit encoding a firstchain of the polypeptide; (2) a second translational unit encoding asecond chain of the polypeptide; and (3) a third translational unitencoding at least one chaperone protein selected from peptidyl-prolylisomerases, protein disulfide oxidoreductases, and combinations thereof;where the host cell is cultured in a culture medium under conditionsincluding: a growth phase including a growth temperature and a growthagitation rate, and a production phase including a productiontemperature and a production agitation rate, where the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the biologically active polypeptidefrom the host cell. In one aspect the polypeptide consists of twochains, while in another aspect the polypeptide comprises three, four,five or more chains.

In another aspect, provided herein are methods of producing apolypeptide containing two chains in a prokaryotic host cell byculturing the host cell to express the two chains of the polypeptide,where upon expression the two chains fold and assemble to form abiologically active polypeptide in the host cell; where the host cellcontains a polynucleotide including (1) a first translational unitencoding a first chain of the polypeptide; (2) a second translationalunit encoding a second chain of the polypeptide; (3) a thirdtranslational unit encoding a first chaperone protein; (4) a fourthtranslational unit encoding a second chaperone protein; and (5) a fifthtranslational unit encoding a third chaperone protein, where the first,second, and third chaperone proteins are selected from peptidyl-prolylisomerases, protein disulfide oxidoreductases, and combinations thereof;where the host cell is cultured in a culture medium under conditionsincluding: a growth phase including a growth temperature and a growthagitation rate, and a production phase including a productiontemperature and a production agitation rate, where the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the biologically active polypeptidefrom the host cell. In one aspect the polypeptide consists of twochains, while in another aspect the polypeptide comprises three, four,five or more chains.

I. DEFINITIONS

Before describing the disclosure in detail, it is to be understood thatthis disclosure is not limited to particular compositions or biologicalsystems, which can, of course, vary. It is also to be understood thatthe terminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting.

As used in this specification and the appended claims, the singularforms “a”, “an” and “the” include plural referents unless the contentclearly dictates otherwise. Thus, for example, reference to “a molecule”optionally includes a combination of two or more such molecules, and thelike.

The term “about” as used herein refers to the usual error range for therespective value readily known to the skilled person in this technicalfield. Reference to “about” a value or parameter herein includes (anddescribes) embodiments that are directed to that value or parameter perse. At a maximum, the term “about” as used herein in reference to avalue, encompasses from 90% to 110% of that value (e.g., relativetranslation strength of a first and second TIR of about 1.0 to about 3.0refers to a relative translation strength in the range of between 0.9and 3.3).

It is understood that aspects and embodiments of the disclosuredescribed herein include “comprising,” “consisting,” and “consistingessentially of” aspects and embodiments.

The term “polypeptide comprising two chains,” (the terms “two chainprotein” and “two chain polypeptide” may also be used interchangeablyherein), as used herein is intended to refer to any polypeptidecontaining more than one distinct polypeptide chain. In someembodiments, a two chain protein may include a macromolecular complex oftwo or more polypeptides linked together through one or moreintermolecular linkages, including without limitation a disulfide bond.In some embodiments, a two chain protein may include a singlepolypeptide with amino acid sequences belonging to two distinctpolypeptide chains (e.g., an antibody heavy chain and an antibody lightchain) linked by a polypeptide linker. In this case, a two chain proteinmay physically represent a single chain, but two or more portions of thesingle chain may functionally behave as if they are two separate proteinchains. For example, a single chain antibody may include a functionalheavy chain and a functional light chain that, while joined by apolypeptide linker, nonetheless fold and assemble as if they wereseparate polypeptides associated only by intermolecular linkages (e.g.,one or more disulfide bonds).

The term “vector,” as used herein, is intended to refer to a nucleicacid molecule capable of transporting another nucleic acid to which ithas been linked. One type of vector is a “plasmid”, which refers to acircular double stranded DNA loop into which additional DNA segments maybe ligated. Another type of vector is a phage vector. Another type ofvector is a viral vector, wherein additional DNA segments may be ligatedinto the viral genome. Certain vectors are capable of autonomousreplication in a host cell into which they are introduced (e.g.,bacterial vectors having a bacterial origin of replication and episomalmammalian vectors). Other vectors (e.g., non-episomal mammalian vectors)can be integrated into the genome of a host cell upon introduction intothe host cell, and thereby are replicated along with the host genome.Moreover, certain vectors are capable of directing the expression ofgenes to which they are operatively linked. Such vectors are referred toherein as “recombinant expression vectors” (or simply, “recombinantvectors”). In general, expression vectors of utility in recombinant DNAtechniques are often in the form of plasmids. In the presentspecification, “plasmid” and “vector” may be used interchangeably as theplasmid is the most commonly used form of vector.

The term “cistron,” as used herein, is intended to refer to a geneticelement broadly equivalent to a translational unit comprising thenucleotide sequence coding for a polypeptide chain and adjacent controlregions. A “cistron” may include, for example, one or more open-readingframes, a translational initiation region (TIR; as defined hereinbelow), a signal sequence and a termination region.

A “polycistronic” expression vector refers to a single vector thatcontains and expresses multiple cistrons under the regulatory control ofone single promoter. A common example of polycistronic vector is a“dicistronic” vector that contains and expresses two differentpolypeptides under the control of one promoter. Upon expression of adicistronic or polycistronic vector, multiple genes are firsttranscribed as a single transcriptional unit, and then translatedseparately.

A “transcriptional unit” refers to a polynucleotide that is transcribedas a single RNA transcript. A “translational unit” refers to apolynucleotide that encodes and, when translated, produces apolypeptide. As described above, a polycistronic polynucleotide maycontain a single transcriptional unit with multiple translational units.

A “separate cistron” expression vector according to the presentdisclosure refers to a single vector comprising at least two separatepromoter-cistron pairs, wherein each cistron is under the control of itsown promoter. Upon expression of a separate cistron expression vector,both transcription and translation processes of different genes areseparate and independent.

A “chaperone protein” as used herein refers to any protein that aids inthe folding or assembly of other macromolecules, including withoutlimitation two chain proteins. Generally, chaperone proteins may act bymany different mechanisms to promote protein folding or assembly. Forexample, chaperone proteins may promote protein folding and/or assembly,catalyze the formation of intrachain disulfide bonds, promote proteinun-folding and/or disassembly (e.g., of aggregated or misfolded proteinsor multiprotein complexes), prevent aggregation, aid in proteindegradation, and so forth.

The “translation initiation region” or TIR or translational initiationregion or translational initiation sequence, as used herein refers to anucleic acid region providing the efficiency of translational initiationof a gene of interest. In general, a TIR within a particular cistronencompasses the ribosome binding site (RBS) and sequences 5′ and 3′ toRBS. The RBS is defined to contain, minimally, the Shine-Dalgarno regionand the start codon (AUG). Accordingly, a TIR also includes at least aportion of the nucleic acid sequence to be translated. Preferably, a TIRof the disclosure includes a secretion signal sequence encoding a signalpeptide that precedes the sequence encoding for the light or heavy chainwithin a cistron. A TIR variant contains sequence variants (particularlysubstitutions) within the TIR region that alter the property of the TIR,such as its translational strength as defined herein below. Preferably,a TIR variant of the disclosure contains sequence substitutions withinthe first 2 to about 14, preferably about 4 to 12, more preferably about6 codons of the secretion signal sequence that precedes the sequenceencoding for the light or heavy chain within a cistron.

The term “translational strength” as used herein refers to a measurementof a secreted polypeptide in a control system wherein one or morevariants of a TIR is used to direct secretion of a polypeptide and theresults compared to the wild-type TIR or some other control under thesame culture and assay conditions. Without being limited to any onetheory, “translational strength” as used herein can include, for exampleand without limitation, a measure of mRNA stability, efficiency ofribosome binding to the ribosome binding site, and so forth.

“Secretion signal sequence” or “signal sequence” refers to a nucleicacid sequence encoding for a short signal peptide that can be used todirect a newly synthesized protein of interest through a cellularmembrane, usually the inner membrane or both inner and outer membranesof prokaryotes. As such, the protein of interest such as theimmunoglobulin light or heavy chain polypeptide is secreted into theperiplasm of the prokaryotic host cells or into the culture medium. Thesignal peptide encoded by the secretion signal sequence may beendogenous to the host cells, or they may be exogenous, including signalpeptides native to the polypeptide to be expressed. Secretion signalsequences are typically present at the amino terminus of a polypeptideto be expressed, and are typically removed enzymatically betweenbiosynthesis and secretion of the polypeptide from the cytoplasm. Thus,the signal peptide is usually not present in a mature protein product.

“Operably linked” refers to a juxtaposition of two or more components,wherein the components so described are in a relationship permittingthem to function in their intended manner. For example, a promoter isoperably linked to a coding sequence if it acts in cis to control ormodulate the transcription of the linked sequence. Generally, but notnecessarily, the DNA sequences that are “operably linked” are contiguousand, where necessary to join two protein coding regions or in the caseof a secretory leader, contiguous and in the reading frame. However,although an operably linked promoter is generally located upstream ofthe coding sequence, it is not necessarily contiguous with it. Operablylinked enhancers can be located upstream, within or downstream of codingsequences and at considerable distances from the promoter. Linking isaccomplished by recombinant methods known in the art, e.g., using PCRmethodology, by annealing, or by ligation at convenient restrictionsites. If convenient restriction sites do not exist, then syntheticoligonucleotide adaptors or linkers are used in accord with conventionalpractice.

“Regulatory elements” as used herein, refer to nucleotide sequencespresent in cis, necessary for transcription and translation of apolynucleotide encoding a heterologous polypeptide into polypeptides.The transcriptional regulatory elements normally comprise a promoter 5′of the gene sequence to be expressed, transcriptional initiation andtermination sites, and polyadenylation signal sequence. The term“transcriptional initiation site” refers to the nucleic acid in theconstruct corresponding to the first nucleic acid incorporated into theprimary transcript, i.e., the mRNA precursor; the transcriptionalinitiation site may overlap with the promoter sequences.

A “promoter” refers to a polynucleotide sequence that controlstranscription of a gene or sequence to which it is operably linked. Apromoter includes signals for RNA polymerase binding and transcriptioninitiation. The promoters used will be functional in the cell type ofthe host cell in which expression of the selected sequence iscontemplated. A large number of promoters including constitutive,inducible and repressible promoters from a variety of different sources,are well known in the art (and identified in databases such as GenBank)and are available as or within cloned polynucleotides (from, e.g.,depositories such as ATCC as well as other commercial or individualsources). With inducible promoters, the activity of the promoterincreases or decreases in response to a signal, e.g., the presence ofIPTG or phosphate depletion.

The term “host cell” (or “recombinant host cell”), as used herein, isintended to refer to a cell that has been genetically altered, or iscapable of being genetically altered by introduction of an exogenouspolynucleotide, such as a recombinant plasmid or vector. It should beunderstood that such terms are intended to refer not only to theparticular subject cell but to the progeny of such a cell. Becausecertain modifications may occur in succeeding generations due to eithermutation or environmental influences, such progeny may not, in fact, beidentical to the parent cell, but are still included within the scope ofthe term “host cell” as used herein.

The term “pharmaceutical formulation” refers to a preparation which isin such form as to permit the biological activity of the activeingredient to be effective, and which contains no additional componentswhich are unacceptably toxic to a subject to which the formulation wouldbe administered. Such formulations are sterile. “Pharmaceuticallyacceptable” excipients (vehicles, additives) are those which canreasonably be administered to a subject mammal to provide an effectivedose of the active ingredient employed.

A “subject” or an “individual” for purposes of treatment refers to anyanimal classified as a mammal, including humans, domestic and farmanimals, and zoo, sports, or pet animals, such as dogs, horses, cats,cows, etc. Preferably, the mammal is human.

The term “antibody” herein is used in the broadest sense andspecifically covers monoclonal antibodies (including full lengthmonoclonal antibodies), polyclonal antibodies, multispecific antibodies(e.g., bispecific antibodies), and antibody fragments so long as theyexhibit the desired biological activity.

An “isolated” antibody is one which has been identified and separatedand/or recovered from a component of its natural environment.Contaminant components of its natural environment are materials whichwould interfere with research, diagnostic or therapeutic uses for theantibody, and may include enzymes, hormones, and other proteinaceous ornonproteinaceous solutes. In some embodiments, an antibody is purified(1) to greater than 95% by weight of antibody as determined by, forexample, the Lowry method, and in some embodiments, to greater than 99%by weight; (2) to a degree sufficient to obtain at least 15 residues ofN-terminal or internal amino acid sequence by use of, for example, aspinning cup sequenator, or (3) to homogeneity by SDS-PAGE underreducing or nonreducing conditions using, for example, Coomassie blue orsilver stain. Isolated antibody includes the antibody in situ withinrecombinant cells since at least one component of the antibody's naturalenvironment will not be present. Ordinarily, however, isolated antibodywill be prepared by at least one purification step.

“Native antibodies” are usually heterotetrameric glycoproteins of about150,000 daltons, composed of two identical light (L) chains and twoidentical heavy (H) chains. Each light chain is linked to a heavy chainby one covalent disulfide bond, while the number of disulfide linkagesvaries among the heavy chains of different immunoglobulin isotypes. Eachheavy and light chain also has regularly spaced intrachain disulfidebridges. Each heavy chain has at one end a variable domain (V_(H))followed by a number of constant domains. Each light chain has avariable domain at one end (V_(L)) and a constant domain at its otherend; the constant domain of the light chain is aligned with the firstconstant domain of the heavy chain, and the light chain variable domainis aligned with the variable domain of the heavy chain. Particular aminoacid residues are believed to form an interface between the light chainand heavy chain variable domains.

The term “constant domain” refers to the portion of an immunoglobulinmolecule having a more conserved amino acid sequence relative to theother portion of the immunoglobulin, the variable domain, which containsthe antigen binding site. The constant domain contains the C_(H)1,C_(H)2 and C_(H)3 domains (collectively, CH) of the heavy chain and theCHL (or CL) domain of the light chain.

The “variable region” or “variable domain” of an antibody refers to theamino-terminal domains of the heavy or light chain of the antibody. Thevariable domain of the heavy chain may be referred to as “V_(H).” Thevariable domain of the light chain may be referred to as “V_(L).” Thesedomains are generally the most variable parts of an antibody and containthe antigen-binding sites.

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areused in the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not evenly distributedthroughout the variable domains of antibodies. It is concentrated inthree segments called hypervariable regions (HVRs) both in thelight-chain and the heavy-chain variable domains. The more highlyconserved portions of variable domains are called the framework regions(FR). The variable domains of native heavy and light chains eachcomprise four FR regions, largely adopting a beta-sheet configuration,connected by three HVRs, which form loops connecting, and in some casesforming part of, the beta-sheet structure. The HVRs in each chain areheld together in close proximity by the FR regions and, with the HVRsfrom the other chain, contribute to the formation of the antigen-bindingsite of antibodies (see Kabat et al., Sequences of Proteins ofImmunological Interest, Fifth Edition, National Institute of Health,Bethesda, Md. (1991)). The constant domains are not involved directly inthe binding of an antibody to an antigen, but exhibit various effectorfunctions, such as participation of the antibody in antibody-dependentcellular toxicity.

The “light chains” of antibodies (immunoglobulins) from any mammalianspecies can be assigned to one of two clearly distinct types, calledkappa (“κ”) and lambda (“λ”), based on the amino acid sequences of theirconstant domains.

The term IgG “isotype” or “subclass” as used herein is meant any of thesubclasses of immunoglobulins defined by the chemical and antigeniccharacteristics of their constant regions.

Depending on the amino acid sequences of the constant domains of theirheavy chains, antibodies (immunoglobulins) can be assigned to differentclasses. There are five major classes of immunoglobulins: IgA, IgD, IgE,IgG, and IgM, and several of these may be further divided intosubclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. Theheavy chain constant domains that correspond to the different classes ofimmunoglobulins are called α, γ, ε, γ, and μ, respectively. The subunitstructures and three-dimensional configurations of different classes ofimmunoglobulins are well known and described generally in, for example,Abbas et al. Cellular and Mol. Immunology, 4th ed. (W.B. Saunders, Co.,2000). An antibody may be part of a larger fusion molecule, formed bycovalent or non-covalent association of the antibody with one or moreother proteins or peptides.

The terms “full length antibody,” “intact antibody” and “whole antibody”are used herein interchangeably to refer to an antibody in itssubstantially intact form, not antibody fragments as defined below. Theterms particularly refer to an antibody with heavy chains that containan Fc region.

A “naked antibody” for the purposes herein is an antibody that is notconjugated to a cytotoxic moiety or radiolabel.

“Antibody fragments” comprise a portion of an intact antibody,preferably comprising the antigen binding region thereof. In someembodiments, the antibody fragment described herein is anantigen-binding fragment. Examples of antibody fragments include Fab,Fab′, F(ab′)₂, and Fv fragments; diabodies; linear antibodies;single-chain antibody molecules; and multispecific antibodies formedfrom antibody fragments.

Papain digestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab′)₂ fragment thathas two antigen-combining sites and is still capable of cross-linkingantigen.

“Fv” is the minimum antibody fragment which contains a completeantigen-binding site. In one embodiment, a two-chain Fv species consistsof a dimer of one heavy- and one light-chain variable domain in tight,non-covalent association. In a single-chain Fv (scFv) species, oneheavy- and one light-chain variable domain can be covalently linked by aflexible peptide linker such that the light and heavy chains canassociate in a “dimeric” structure analogous to that in a two-chain Fvspecies. It is in this configuration that the three HVRs of eachvariable domain interact to define an antigen-binding site on thesurface of the VH-VL dimer. Collectively, the six HVRs conferantigen-binding specificity to the antibody. However, even a singlevariable domain (or half of an Fv comprising only three HVRs specificfor an antigen) has the ability to recognize and bind antigen, althoughat a lower affinity than the entire binding site.

The Fab fragment contains the heavy- and light-chain variable domainsand also contains the constant domain of the light chain and the firstconstant domain (CH1) of the heavy chain. Fab′ fragments differ from Fabfragments by the addition of a few residues at the carboxy terminus ofthe heavy chain CH1 domain including one or more cysteines from theantibody hinge region. Fab′-SH is the designation herein for Fab′ inwhich the cysteine residue(s) of the constant domains bear a free thiolgroup. F(ab′)₂ antibody fragments originally were produced as pairs ofFab′ fragments which have hinge cysteines between them. Other chemicalcouplings of antibody fragments are also known.

“Single-chain Fv” or “scFv” antibody fragments comprise the VH and VLdomains of antibody, wherein these domains are present in a singlepolypeptide chain. Generally, the scFv polypeptide further comprises apolypeptide linker between the VH and VL domains which enables the scFvto form the desired structure for antigen binding. For a review of scFv,see, e.g., Pluckthün, in The Pharmacology of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds., (Springer-Verlag, New York, 1994), pp.269-315.

The term “diabodies” refers to antibody fragments with twoantigen-binding sites, which fragments comprise a heavy-chain variabledomain (VH) connected to a light-chain variable domain (VL) in the samepolypeptide chain (VH-VL). By using a linker that is too short to allowpairing between the two domains on the same chain, the domains areforced to pair with the complementary domains of another chain andcreate two antigen-binding sites. Diabodies may be bivalent orbispecific. Diabodies are described more fully in, for example, EP404,097; WO 1993/01161; Hudson et al., Nat. Med. 9:129-134 (2003); andHollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).Triabodies and tetrabodies are also described in Hudson et al., Nat.Med. 9:129-134 (2003).

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,e.g., the individual antibodies comprising the population are identicalexcept for possible mutations, e.g., naturally occurring mutations, thatmay be present in minor amounts. Thus, the modifier “monoclonal”indicates the character of the antibody as not being a mixture ofdiscrete antibodies. In certain embodiments, such a monoclonal antibodytypically includes an antibody comprising a polypeptide sequence thatbinds a target, wherein the target-binding polypeptide sequence wasobtained by a process that includes the selection of a single targetbinding polypeptide sequence from a plurality of polypeptide sequences.For example, the selection process can be the selection of a uniqueclone from a plurality of clones, such as a pool of hybridoma clones,phage clones, or recombinant DNA clones. It should be understood that aselected target binding sequence can be further altered, for example, toimprove affinity for the target, to humanize the target bindingsequence, to improve its production in cell culture, to reduce itsimmunogenicity in vivo, to create a multispecific antibody, etc., andthat an antibody comprising the altered target binding sequence is alsoa monoclonal antibody of this disclosure. In contrast to polyclonalantibody preparations, which typically include different antibodiesdirected against different determinants (epitopes), each monoclonalantibody of a monoclonal antibody preparation is directed against asingle determinant on an antigen. In addition to their specificity,monoclonal antibody preparations are advantageous in that they aretypically uncontaminated by other immunoglobulins.

The modifier “monoclonal” indicates the character of the antibody asbeing obtained from a substantially homogeneous population ofantibodies, and is not to be construed as requiring production of theantibody by any particular method. For example, the monoclonalantibodies to be used in accordance with the disclosure may be made by avariety of techniques, including, for example, expression in aprokaryotic host cell, the hybridoma method (e.g., Kohler and Milstein,Nature, 256:495-97 (1975); Hongo et al., Hybridoma, 14 (3): 253-260(1995), Harlow et al., Antibodies: A Laboratory Manual, (Cold SpringHarbor Laboratory Press, 2nd ed. 1988); Hammerling et al., in:Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N. Y.,1981)), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567),phage-display technologies (see, e.g., Clackson et al., Nature, 352:624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Sidhuet al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol.340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284 (1-2):119-132 (2004), and technologies for producing human or human-likeantibodies in animals that have parts or all of the human immunoglobulinloci or genes encoding human immunoglobulin sequences (see, e.g., WO1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741; Jakobovits etal., Proc. Natl. Acad. Sci. USA 90: 2551 (1993); Jakobovits et al.,Nature 362: 255-258 (1993); Bruggemann et al., Year in Immunol. 7:33(1993); U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126;5,633,425; and 5,661,016; Marks et al., Bio/Technology 10: 779-783(1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature368: 812-813 (1994); Fishwild et al., Nature Biotechnol. 14: 845-851(1996); Neuberger, Nature Biotechnol. 14: 826 (1996); and Lonberg andHuszar, Intern. Rev. Immunol. 13: 65-93 (1995).

The monoclonal antibodies herein specifically include “chimeric”antibodies in which a portion of the heavy and/or light chain isidentical with or homologous to corresponding sequences in antibodiesderived from a particular species or belonging to a particular antibodyclass or subclass, while the remainder of the chain(s) is identical withor homologous to corresponding sequences in antibodies derived fromanother species or belonging to another antibody class or subclass, aswell as fragments of such antibodies, so long as they exhibit thedesired biological activity (see, e.g., U.S. Pat. No. 4,816,567; andMorrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)).Chimeric antibodies include PRIMATTZED® antibodies wherein theantigen-binding region of the antibody is derived from an antibodyproduced by, e.g., immunizing macaque monkeys with the antigen ofinterest.

“Humanized” forms of non-human (e.g., murine) antibodies are chimericantibodies that contain minimal sequence derived from non-humanimmunoglobulin. In one embodiment, a humanized antibody is a humanimmunoglobulin (recipient antibody) in which residues from a HVR of therecipient are replaced by residues from a HVR of a non-human species(donor antibody) such as mouse, rat, rabbit, or nonhuman primate havingthe desired specificity, affinity, and/or capacity. In some instances,FR residues of the human immunoglobulin are replaced by correspondingnon-human residues. Furthermore, humanized antibodies may compriseresidues that are not found in the recipient antibody or in the donorantibody. These modifications may be made to further refine antibodyperformance. In general, a humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the hypervariable loops correspondto those of a non-human immunoglobulin, and all or substantially all ofthe FRs are those of a human immunoglobulin sequence. The humanizedantibody optionally will also comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details, see, e.g., Jones et al., Nature321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); andPresta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, e.g.,Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998);Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross,Curr. Op. Biotech. 5:428-433 (1994); and U.S. Pat. Nos. 6,982,321 and7,087,409.

A “human antibody” is one which possesses an amino acid sequence whichcorresponds to that of an antibody produced by a human and/or has beenmade using any of the techniques for making human antibodies asdisclosed herein. This definition of a human antibody specificallyexcludes a humanized antibody comprising non-human antigen-bindingresidues. Human antibodies can be produced using various techniquesknown in the art, including phage-display libraries. Hoogenboom andWinter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol.,222:581 (1991). Also available for the preparation of human monoclonalantibodies are methods described in Cole et al., Monoclonal Antibodiesand Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J.Immunol., 147(1):86-95 (1991). See also van Dijk and van de Winkel,Curr. Opin. Pharmacol., 5: 368-74 (2001). Human antibodies can beprepared by administering the antigen to a transgenic animal that hasbeen modified to produce such antibodies in response to antigenicchallenge, but whose endogenous loci have been disabled, e.g., immunizedxenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 regardingXENOMOUSE™ technology). See also, for example, Li et al., Proc. Natl.Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodiesgenerated via a human B-cell hybridoma technology.

A “species-dependent antibody” is one which has a stronger bindingaffinity for an antigen from a first mammalian species than it has for ahomologue of that antigen from a second mammalian species. Normally, thespecies-dependent antibody “binds specifically” to a human antigen(e.g., has a binding affinity (Kd) value of no more than about 1×10⁻⁷ M,preferably no more than about 1×10⁻⁸ M and preferably no more than about1×10⁻⁹ M) but has a binding affinity for a homologue of the antigen froma second nonhuman mammalian species which is at least about 50 fold, orat least about 500 fold, or at least about 1000 fold, weaker than itsbinding affinity for the human antigen. The species-dependent antibodycan be any of the various types of antibodies as defined above, butpreferably is a humanized or human antibody.

The term “hypervariable region,” “HVR,” or “HV,” when used herein refersto the regions of an antibody variable domain which are hypervariable insequence and/or form structurally defined loops. Generally, antibodiescomprise six HVRs; three in the VH (H1, H2, H3), and three in the VL(L1, L2, L3). In native antibodies, H3 and L3 display the most diversityof the six HVRs, and H3 in particular is believed to play a unique rolein conferring fine specificity to antibodies. See, e.g., Xu et al.,Immunity 13:37-45 (2000); Johnson and Wu, in Methods in MolecularBiology 248:1-25 (Lo, ed., Human Press, Totowa, N. J., 2003). Indeed,naturally occurring camelid antibodies consisting of a heavy chain onlyare functional and stable in the absence of light chain. See, e.g.,Hamers-Casterman et al., Nature 363:446-448 (1993); Sheriff et al.,Nature Struct. Biol. 3:733-736 (1996).

A number of HVR delineations are in use and are encompassed herein. TheKabat Complementarity Determining Regions (CDRs) are based on sequencevariability and are the most commonly used (Kabat et al., Sequences ofProteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991)). Chothia refersinstead to the location of the structural loops (Chothia and Lesk J.Mol. Biol. 196:901-917 (1987)). The AbM HVRs represent a compromisebetween the Kabat HVRs and Chothia structural loops, and are used byOxford Molecular's AbM antibody modeling software. The “contact” HVRsare based on an analysis of the available complex crystal structures.The residues from each of these HVRs are noted below.

TABLE 1a Antibody Hypervariable Regions Loop Kabat AbM Chothia ContactL1 L24-L34 L24-L34 L26-L32 L30-L36 L2 L50-L56 L50-L56 L50-L52 L46-L55 L3L89-L97 L89-L97 L91-L96 L89-L96 H1 H31-H35B H26-H35B H26-H32 H30-H35B(Kabat Numbering) H1 H31-H35 H26-H35 H26-H32 H30-H35 (Chothia Numbering)H2 H50-H65 H50-H58 H53-H55 H47-H58 H3 H95-H102 H95-H102 H96-H101H93-H101

HVRs may comprise “extended HVRs” as follows: 24-36 or 24-34 (L1), 46-56or 50-56 (L2) and 89-97 or 89-96 (L3) in the VL and 26-35 (H1), 50-65 or49-65 (H2) and 93-102, 94-102, or 95-102 (H3) in the VH. The variabledomain residues are numbered according to Kabat et al., supra, for eachof these definitions.

“Framework” or “FR” residues are those variable domain residues otherthan the HVR residues as herein defined.

The term “variable domain residue numbering as in Kabat” or “amino acidposition numbering as in Kabat,” and variations thereof, refers to thenumbering system used for heavy chain variable domains or light chainvariable domains of the compilation of antibodies in Kabat et al.,supra. Using this numbering system, the actual linear amino acidsequence may contain fewer or additional amino acids corresponding to ashortening of, or insertion into, a FR or HVR of the variable domain.For example, a heavy chain variable domain may include a single aminoacid insert (residue 52a according to Kabat) after residue 52 of H2 andinserted residues (e.g. residues 82a, 82b, and 82c, etc. according toKabat) after heavy chain FR residue 82. The Kabat numbering of residuesmay be determined for a given antibody by alignment at regions ofhomology of the sequence of the antibody with a “standard” Kabatnumbered sequence.

The Kabat numbering system is generally used when referring to a residuein the variable domain (approximately residues 1-107 of the light chainand residues 1-113 of the heavy chain) (e.g., Kabat et al., Sequences ofImmunological Interest. 5th Ed. Public Health Service, NationalInstitutes of Health, Bethesda, Md. (1991)). The “EU numbering system”or “EU index” is generally used when referring to a residue in animmunoglobulin heavy chain constant region (e.g., the EU index reportedin Kabat et al., supra). The “EU index as in Kabat” refers to theresidue numbering of the human IgG1 EU antibody.

The expression “linear antibodies” refers to the antibodies described inZapata et al. (1995 Protein Eng, 8(10):1057-1062). Briefly, theseantibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1) which,together with complementary light chain polypeptides, form a pair ofantigen binding regions. Linear antibodies can be bispecific ormonospecific.

II. MOLECULAR OPTIMIZATION

Provided herein are methods of producing a polypeptide containing twochains in a prokaryotic host cell by culturing the host cell to expressthe two chains of the polypeptide, where upon expression the two chainsfold and assemble to form a biologically active polypeptide in the hostcell; where the host cell contains a polynucleotide including (1) afirst translational unit encoding a first chain of the polypeptide; (2)a second translational unit encoding a second chain of the polypeptide;and (3) a third translational unit encoding at least one chaperoneprotein selected from peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof. Also provided herein aremethods of producing a polypeptide containing two chains in aprokaryotic host cell by culturing the host cell to express the twochains of the polypeptide, where upon expression the two chains fold andassemble to form a biologically active polypeptide in the host cell;where the host cell contains a polynucleotide including (1) a firsttranslational unit encoding a first chain of the polypeptide; (2) asecond translational unit encoding a second chain of the polypeptide;(3) a third translational unit encoding a first chaperone protein; (4) afourth translational unit encoding a second chaperone protein; and (5) afifth translational unit encoding a third chaperone protein, where thefirst, second, and third chaperone proteins are selected frompeptidyl-prolyl isomerases, protein disulfide oxidoreductases, andcombinations thereof.

In some embodiments, a host cell is cultured to express the two chainsof a polypeptide, where upon expression the two chains fold and assembleto form a biologically active polypeptide in the host cell. As usedherein, two chain folding and assembly may refer to any or all stepsthat promote the ultimate adoption of proper three-dimensional two chainprotein conformation, two chain protein assembly, or both. Folding andassembly may refer to the folding and assembly of each chain into itsproper conformation and folding, or it may refer to the folding andassembly of the complex created by the intermolecular linkage of twoprotein chains. Similarly, each chain may fold and assemble to form abiologically active polypeptide, or the complex created by theintermolecular linkage of two protein chains may fold and assemble toform, as a whole, a biologically active polypeptide.

A biologically active polypeptide may refer to any polypeptide that isable to carry out a function ascribed to the polypeptide. Functions ofbiologically active polypeptides may include, without limitation, properfolding or assembly, binding or other interaction with anothermacromolecule, and enzymatic activity. By way of illustration, abiologically active antibody may refer to an antibody that is able tocarry out at least one function ascribed to antibodies, includingwithout limitation binding to an epitope or possessing a property of anantibody Fc region, as described in further detail below.

Chaperone Proteins

In some embodiments, a polynucleotide of the present disclosure containsa translational unit encoding at least one chaperone protein. Asdescribed above, a chaperone protein may refer to any protein that aidsin the folding or assembly of other macromolecules, including withoutlimitation two chain proteins. Examples of chaperone proteins mayinclude without limitation peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and heat shock proteins (such as Hsp60, Hsp70, Hsp90,and Hsp100 proteins). Chaperone proteins may also aid in transportingproteins across membranes, e.g., translocation of polypeptide chainsacross the plasma membrane or endoplasmic reticulum membrane.

In some embodiments, a chaperone protein may be a peptidyl-prolylisomerase. Peptidyl-prolyl isomerase (the terms “prolyl isomerase,”“rotamase,” and “PPiase” may be used interchangeably herein) may referto any enzyme catalyzing the interconversion of cis and trans isomers ofproline or prolyl-iminopeptide bonds. The EC number for this reaction isEC 5.2.1.8. Any protein known or predicted to catalyze the reactiondescribed by this EC number may be a peptidyl-prolyl isomerase of thepresent disclosure. Peptidyl-prolyl isomerase activity may also bedescribed by the GO term ID GO:0003755. Any protein known or predictedto possess the molecular function described by this GO term ID may be apeptidyl-prolyl isomerase of the present disclosure.

Peptidyl-prolyl isomerase activity is known in the art to promoteprotein folding and assembly. In some embodiments, peptidyl-prolylisomerases may aid in protein folding and assembly by converting transprolyl bonds to cis prolyl bonds for proteins whose properly foldedstructure includes a cis prolyl bond. Some peptidyl-prolyl isomerasesare also known to enhance the folding and assembly of proteins that lackcis prolyl bonds (Bothmann H and Pluckthun A 2000 J. Biol. Chem.275:17100). In some embodiments, peptidyl-prolyl isomerases may aid inprotein folding and assembly of proteins that lack cis prolyl bonds.Thus, while peptidyl-prolyl isomerase activity may serve as a functionalcharacteristic to identify a chaperone protein useful for the methodsdescribed herein, the utility of a peptidyl-prolyl isomerase is notnecessarily limited to its catalytic activity per se.

In some embodiments, the peptidyl-prolyl isomerase is an FkpA protein.In some embodiments, the FkpA protein is E. coli FkpA. An E. coli FkpAmay refer to any polypeptide encoded by an fkpA gene in any strain orisolate of bacteria belonging to the species E. coli. In someembodiments, E. coli FkpA refers a protein encoded by an fkpA genedescribed by EcoGene Accession Number EG12900. In some embodiments, E.coli FkpA refers a protein having the sequence described by the NCBIRefSeq Accession Number NP_417806.

Other FkpA proteins are known in the art. Examples of FkpA proteins mayinclude, without limitation, S. boydii peptidyl-prolyl isomerase (NCBIRefSeq No. WP_000838252), C. youngae peptidyl-prolyl isomerase (NCBIRefSeq No. WP_006687366), K. oxytoca peptidyl-prolyl isomerase (NCBIRefSeq No. WP_004125943), S. enterica peptidyl-prolyl isomerase (NCBIRefSeq No. WP_000838233), K. pneumoniae peptidyl-prolyl isomerase (NCBIRefSeq No. WP_019704642), S. cerevisiae FPR3p (NCBI RefSeq No.NP_013637), M. musculus Fkpb1a (NCBI RefSeq No. NP_032045), M. musculusFkpb2 (NCBI RefSeq No. NP_032046), H. sapiens FKBP2 (NCBI RefSeq No.NP_001128680), and D. melanogaster CG14715 (NCBI RefSeq No. NP_650101).In some embodiments, an FkpA protein of the present disclosure has atleast about 80%, at least about 81%, at least about 82%, at least about83%, at least about 84%, at least about 85%, at least about 86%, atleast about 87%, at least about 88%, at least about 89%, at least about90%, at least about 91%, at least about 92%, at least about 93%, atleast about 94%, at least about 95%, at least about 96%, at least about97%, at least about 98%, or at least about 99% identity to E. coli FkpA.

In some embodiments, a chaperone protein may be a protein disulfideoxidoreductase. Protein disulfide oxidoreductase (the terms “proteindisulfide isomerase” and “thiol-disulfide isomerase” may be usedinterchangeably herein) may refer to any enzyme catalyzing therearrangement of disulfide bonds in proteins. For example, a proteindisulfide oxidoreductase may catalyze the oxidation of cysteines to formdisulfide bonds in proteins. A protein disulfide oxidoreductase may alsocatalyze the isomerization of mispaired disulfide bonds in proteins. TheEC number for this reaction is EC 5.3.4.1. Any protein known orpredicted to catalyze the reaction described by this EC number may be aprotein disulfide oxidoreductase of the present disclosure. Proteindisulfide oxidoreductase activity may also be described by the GO termID GO:0015035. Any protein known or predicted to possess the molecularfunction described by this GO term ID may be a protein disulfideoxidoreductase of the present disclosure.

Protein disulfide oxidoreductase activity is known in the art to promoteprotein folding and assembly. For example, protein disulfideoxidoreductase activity promotes the formation of proper intramolecularand intermolecular disulfide bonds during protein folding and assembly.In particular, protein disulfide oxidoreductase activity is importantfor proteins with disulfide bonds that are expressed in the periplasm ofprokaryotic cells.

In some embodiments, the protein disulfide oxidoreductase is a DsbAprotein. In some embodiments, the DsbA protein is E. coli DsbA. An E.coli DsbA may refer to any polypeptide encoded by a dsbA gene in anystrain or isolate of bacteria belonging to the species E. coli. In someembodiments, E. coli DsbA refers a protein encoded by a dsbA genedescribed by EcoGene Accession Number EG11297. In some embodiments, E.coli DsbA refers a protein having the sequence described by the NCBIRefSeq Accession Number NP_418297.

Other DsbA proteins are known in the art. Examples of DsbA proteins mayinclude, without limitation, S. flexneri thiol-disulfide isomerase (NCBIRefSeq No. WP_000725335), S. dysenteriae thiol-disulfide isomerase (NCBIRefSeq No. WP_000725348), C. youngae thiol-disulfide isomerase (NCBIRefSeq No. WP_006686108), and S. enterica thiol-disulfide isomerase(NCBI RefSeq No. WP_023240584). In some embodiments, a DsbA protein ofthe present disclosure has at least about 80%, at least about 81%, atleast about 82%, at least about 83%, at least about 84%, at least about85%, at least about 86%, at least about 87%, at least about 88%, atleast about 89%, at least about 90%, at least about 91%, at least about92%, at least about 93%, at least about 94%, at least about 95%, atleast about 96%, at least about 97%, at least about 98%, or at leastabout 99% identity to E. coli DsbA.

In some embodiments, the protein disulfide oxidoreductase is a DsbCprotein. In some embodiments, the DsbC protein is E. coli DsbC. An E.coli DsbC may refer to any polypeptide encoded by a dsbC gene in anystrain or isolate of bacteria belonging to the species E. coli. In someembodiments, E. coli DsbC refers a protein encoded by a dsbC genedescribed by EcoGene Accession Number EG11070. In some embodiments, E.coli DsbC refers a protein having the sequence described by the NCBIRefSeq Accession Number NP_417369.

Other DsbC proteins are known in the art. Examples of DsbC proteins mayinclude, without limitation, S. sonnei protein-disulfide isomerase (NCBIRefSeq No. WP_000715206), S. dysenteriae protein-disulfide isomerase(NCBI RefSeq No. WP_000715209), E. fergusonii protein-disulfideisomerase (NCBI RefSeq No. WP_000715225), S. bongori thiol:disulfideinterchange protein DsbC (NCBI RefSeq No. WP_020845161), and S. entericaprotein disulfide isomerase DsbC (NCBI RefSeq No. WP_023183515). In someembodiments, a DsbC protein of the present disclosure has at least about80%, at least about 81%, at least about 82%, at least about 83%, atleast about 84%, at least about 85%, at least about 86%, at least about87%, at least about 88%, at least about 89%, at least about 90%, atleast about 91%, at least about 92%, at least about 93%, at least about94%, at least about 95%, at least about 96%, at least about 97%, atleast about 98%, or at least about 99% identity to E. coli DsbC.

To determine the percent identity of two amino acid sequences, or of twonucleic acid sequences, the sequences are aligned for optimal comparisonpurposes (e.g., gaps can be introduced in one or both of a first and asecond amino acid or nucleic acid sequence for optimal alignment andnon-homologous sequences can be disregarded for comparison purposes). Inone embodiment, the length of a reference sequence aligned forcomparison purposes is at least 50%, typically at least 75%, and evenmore typically at least 80%, 85%, 90%, 95% or 100% of the length of thereference sequence. The amino acid residues or nucleotides atcorresponding amino acid positions or nucleotide positions are thencompared. When a position in the first sequence is occupied by the sameamino acid residue or nucleotide as the corresponding position in thesecond sequence, then the molecules are identical at that position (asused herein amino acid or nucleic acid “identity” is equivalent to aminoacid or nucleic acid “homology”).

The percent identity between the two sequences is a function of thenumber of identical positions shared by the sequences, taking intoaccount the number of gaps, and the length of each gap, which need to beintroduced for optimal alignment of the two sequences. For sequencecomparison, typically one sequence acts as a reference sequence, towhich test sequences are compared. When using a sequence comparisonalgorithm, test and reference sequences are entered into a computer,subsequence coordinates are designated, if necessary, and sequencealgorithm program parameters are designated. Default program parameterscan be used, or alternative parameters can be designated. The sequencecomparison algorithm then calculates the percent sequence identities forthe test sequences relative to the reference sequence, based on theprogram parameters. When comparing two sequences for identity, it is notnecessary that the sequences be contiguous, but any gap would carry withit a penalty that would reduce the overall percent identity. For blastn,the default parameters are Gap opening penalty=5 and Gap extensionpenalty=2. For blastp, the default parameters are Gap opening penalty=11and Gap extension penalty=1.

A “comparison window”, as used herein, includes reference to a segmentof any one of the number of contiguous positions selected from the groupconsisting of from 20 to 600, usually about 50 to about 200, moreusually about 100 to about 150 in which a sequence may be compared to areference sequence of the same number of contiguous positions after thetwo sequences are optimally aligned. Methods of alignment of sequencesfor comparison are well-known in the art. Optimal alignment of sequencesfor comparison can be conducted using known algorithms (e.g., by thelocal homology algorithm of Smith and Waterman, Adv Appl Math, 2:482,1981; by the homology alignment algorithm of Needleman and Wunsch, J MolBiol, 48:443, 1970; by the search for similarity method of Pearson andLipman, Proc Natl Acad Sci USA, 85:2444, 1988; by computerizedimplementations of these algorithms FASTDB (Intelligenetics), BLAST(National Center for Biomedical Information), GAP, BESTFIT, FASTA, andTFASTA in the Wisconsin Genetics Software Package (Genetics ComputerGroup, Madison, Wis.), or by manual alignment and visual inspection.

A preferred example of an algorithm that is suitable for determiningpercent sequence identity and sequence similarity is the FASTA algorithm(Pearson and Lipman, Proc Natl Acad Sci USA, 85:2444, 1988; and Pearson,Methods Enzymol, 266:227-258, 1996). Preferred parameters used in aFASTA alignment of DNA sequences to calculate percent identity areoptimized, BL50 Matrix 15:−5, k-tuple=2; joining penalty=40,optimization=28; gap penalty −12, gap length penalty=−2; and width=16.

Another preferred example of algorithms suitable for determining percentsequence identity and sequence similarity are the BLAST and BLAST 2.0algorithms (Altschul et al., Nuc Acids Res, 25:3389-3402, 1977; andAltschul et al., J Mol Biol, 215:403-410, 1990, respectively). BLAST andBLAST 2.0 are used, with the parameters described herein, to determinepercent sequence identity for the nucleic acids and proteins of thedisclosure. Software for performing BLAST analyses is publicly availablethrough the National Center for Biotechnology Information website. Thisalgorithm involves first identifying high scoring sequence pairs (HSPs)by identifying short words of length W in the query sequence, whicheither match or satisfy some positive-valued threshold score T whenaligned with a word of the same length in a database sequence. T isreferred to as the neighborhood word score threshold. These initialneighborhood word hits act as seeds for initiating searches to findlonger HSPs containing them. The word hits are extended in bothdirections along each sequence for as far as the cumulative alignmentscore can be increased. Cumulative scores are calculated using, fornucleotide sequences, the parameters M (reward score for a pair ofmatching residues; always >0) and N (penalty score for mismatchingresidues; always <0). For amino acid sequences, a scoring matrix is usedto calculate the cumulative score. Extension of the word hits in eachdirection are halted when: the cumulative alignment score falls off bythe quantity X from its maximum achieved value; the cumulative scoregoes to zero or below, due to the accumulation of one or morenegative-scoring residue alignments; or the end of either sequence isreached. The BLAST algorithm parameters W, T, and X determine thesensitivity and speed of the alignment. The BLASTN program (fornucleotide sequences) uses as defaults a word length (W) of 11, anexpectation (E) of 10, M=5, N=−4 and a comparison of both strands. Foramino acid sequences, the BLASTP program uses as defaults a word lengthof 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix(Henikoff and Henikoff, Proc Natl Acad Sci USA, 89:10915, 1989)alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparisonof both strands.

The BLAST algorithm also performs a statistical analysis of thesimilarity between two sequences (See, e.g., Karlin and Altschul, ProcNatl Acad Sci USA, 90:5873-5787, 1993). One measure of similarityprovided by the BLAST algorithm is the smallest sum probability (P(N)),which provides an indication of the probability by which a match betweentwo nucleotide or amino acid sequences would occur by chance. Forexample, a nucleic acid is considered similar to a reference sequence ifthe smallest sum probability in a comparison of the test nucleic acid tothe reference nucleic acid is less than about 0.2, more preferably lessthan about 0.01, and most preferably less than about 0.001.

Another example of a useful algorithm is PILEUP. PILEUP creates amultiple sequence alignment from a group of related sequences usingprogressive, pairwise alignments to show relationship and percentsequence identity. It also plots a tree or dendogram showing theclustering relationships used to create the alignment. PILEUP uses asimplification of the progressive alignment method (Feng and Doolittle,J Mol Evol, 35:351-360, 1987), employing a method similar to a publishedmethod (Higgins and Sharp, CABIOS 5:151-153, 1989). The program canalign up to 300 sequences, each of a maximum length of 5,000 nucleotidesor amino acids. The multiple alignment procedure begins with thepairwise alignment of the two most similar sequences, producing acluster of two aligned sequences. This cluster is then aligned to thenext most related sequence or cluster of aligned sequences. Two clustersof sequences are aligned by a simple extension of the pairwise alignmentof two individual sequences. The final alignment is achieved by a seriesof progressive, pairwise alignments. The program is run by designatingspecific sequences and their amino acid or nucleotide coordinates forregions of sequence comparison and by designating the programparameters. Using PILEUP, a reference sequence is compared to other testsequences to determine the percent sequence identity relationship usingthe following parameters: default gap weight (3.00), default gap lengthweight (0.10), and weighted end gaps. PILEUP can be obtained from theGCG sequence analysis software package, e.g., version 7.0 (Devereaux etal., Nuc Acids Res, 12:387-395, 1984).

Another preferred example of an algorithm that is suitable for multipleDNA and amino acid sequence alignments is the CLUSTALW program (Thompsonet al., Nucl Acids. Res, 22:4673-4680, 1994). ClustalW performs multiplepairwise comparisons between groups of sequences and assembles them intoa multiple alignment based on homology. Gap open and Gap extensionpenalties were 10 and 0.05 respectively. For amino acid alignments, theBLOSUM algorithm can be used as a protein weight matrix (Henikoff andHenikoff, Proc Natl Acad Sci USA, 89:10915-10919, 1992).

Expression Cassettes and Vectors

In some embodiments, a host cell contains a polynucleotide including (1)a first translational unit encoding a first chain of the polypeptide;(2) a second translational unit encoding a second chain of thepolypeptide; and (3) a third translational unit encoding at least onechaperone protein selected from peptidyl-prolyl isomerases, proteindisulfide oxidoreductases, and combinations thereof. In someembodiments, a host cell contains a polynucleotide including (1) a firsttranslational unit encoding a first chain of the polypeptide; (2) asecond translational unit encoding a second chain of the polypeptide;(3) a third translational unit encoding a first chaperone protein; (4) afourth translational unit encoding a second chaperone protein; and (5) afifth translational unit encoding a third chaperone protein, where thefirst, second, and third chaperone proteins are selected frompeptidyl-prolyl isomerases, protein disulfide oxidoreductases, andcombinations thereof. It is a discovery of the present disclosure thatincreased production of properly folded and assembled two chain proteinsmay be achieved using a single plasmid system (i.e., a singlepolynucleotide containing translational units encoding each chain of thetwo chain protein and one or more translational units encoding one ormore chaperone proteins) or a compatible plasmid system (i.e., a firstpolynucleotide containing translational units encoding each chain of thetwo chain protein and a second polynucleotide containing one or moretranslational units encoding one or more chaperone proteins).

In some embodiments, the polynucleotide further contains three copies ofa promoter, where a first copy is in operable combination with the firsttranslational unit, a second copy is in operable combination with thesecond translational unit, and a third copy is in operable combinationwith the third translational unit to drive transcription of the firstchain, the second chain and the chaperone protein. In some embodiments,two of the translational units encoding two of the three chaperoneproteins are part of a single translational unit. In some embodiments,the polynucleotide further contains a promoter in operable combinationwith each translational unit.

In some embodiments, the promoter is an inducible promoter. As describedabove, the activity of an inducible promoter increases or decreases inresponse to a signal. For example, an inducible promoter may promotetranscription in response to the presence of a signal, such as IPTG. Aninducible promoter may promote transcription in response to the absenceof a signal, such as phosphate. In either of these scenarios, the amountof transcription may or may not be proportional to the amount of signal,or the deficiency thereof. Numerous examples of inducible promoterssuitable for prokaryotic host cells are known in the art. These mayinclude, without limitation, lac, tac, trc, trp, pho, recA, tetA, nar,phage P_(L), cspA, T7, and P_(BAD) promoters (see Terpe K. 2006 Appl.Microbiol. Biotechnol. 72:211 for more detailed description). In someembodiments, three copies of an inducible promoter are used to driveexpression of separate translational units, e.g., both chains of a twochain protein and a chaperone protein, in a coordinated manner.

In some embodiments, the inducible promoter is an IPTG-induciblepromoter. An IPTG-inducible promoter may refer to any polynucleotidesequence that promotes transcription in a manner responsive to isopropylβ-D-1-thiogalactopyranoside (IPTG) or any other lactose derivative thatis able to promote transcription from the lac operon (e.g.,allolactose). Many examples of IPTG-inducible promoters are known in theart, including without limitation tac (e.g., tacI, tacII, etc.)promoters, lac promoters, and derivatives thereof (e.g., lacUV5, taclac,and so forth).

In some embodiments, the inducible promoter is an IPTG-induciblepromoter that drives transcription of the first chain, the second chainand the chaperone protein. It is a surprising discovery of the presentdisclosure that an IPTG-inducible promoter regulating expression of achaperone protein may, without induction by IPTG, promote expression ofthe chaperone protein at a level that promotes a higher product titer,as compared to expression of the chaperone protein when theIPTG-inducible promoter is induced by IPTG.

In some embodiments, the inducible promoter is a pho promoter thatdrives transcription of the first chain, the second chain and thechaperone protein when phosphate in the culture medium has beendepleted. A pho promoter may refer to any polynucleotide sequence thatpromotes transcription in a manner responsive to extracellular phosphate(for example, inorganic phosphate). For example, the phosphate (Pho)regulon in E. coli includes protein components that sense extracellularphosphate and, in response to phosphate levels, regulate the expressionof numerous downstream genes through Pho promoters (see Hsieh Y J andWanner B L 2010 Curr. Opin. Microbiol. 13(2):198 for more detaileddescription). When bacteria are grown in a culture medium, expression ofthis Pho regulon is known to be repressed when phosphate (e.g.,inorganic phosphate, Pi) is available in the medium and induced whenphosphate has been depleted. One non-limiting example of a pho promoterused in the methods described herein is the E. coli phoA promoter. Thispromoter is widely known and used in the art to regulate recombinantprotein expression in prokaryotic host cells in a manner dependent uponthe concentration of phosphate in the cell culture medium (see Lubke Cet al. 1995 Enzyme Microb. Technol. 17(10):923 for more detaileddescription).

In some embodiments, the polynucleotide further contains a selectablemarker and the culture medium includes a selection agent with a singleantibiotic to cause the host cell to retain the polynucleotide.Advantageously, the methods described herein allow the production of thechains of a two chain protein with co-expression of one or morechaperone proteins such that the translational units encoding each ofthese components are all included in a single polynucleotide (e.g., anexpression plasmid or a single plasmid system as described herein). Theadvantage of such a system is that since all of these components areencoded by the same plasmid, only one selectable marker is required forthe maintenance of these polynucleotides in a prokaryotic host cell.

A selectable marker may refer to any polynucleotide that encodes aprotein that promotes the survival of a host cell when the cellundergoes selection, i.e., any condition used to preferentially increasethe abundance of cell(s) bearing a selectable marker relative to theabundance of cell(s) lacking the selectable marker. Examples ofselectable markers are genes that promote host cell survival in thepresence of an antibiotic. Numerous selectable markers and correspondingselection agents with single antibiotics are known in the art. Forexample and without limitation, many selectable markers andcorresponding antibiotics are described and cited in Jang C W andMagnuson T 2013 PLoS ONE 8(2):e57075. In some embodiments, a selectablemarker may refer to a gene (e.g., a gene expressed from a plasmid) thatcomplements a gene deletion present within the host cell's genome. Inthese examples, when the cell undergoes selection (i.e., growth under acondition that requires the activity of the gene deleted from the hostgenome), the copy of the gene supplied by the plasmid complements thedeficiency of the host genome, thereby selecting for cell(s) bearing theexogenous complementing gene. Such genes may include auxotrophic markersor genes required to produce a specific nutrient lacking in a cellmedium, examples of which are further described herein. Severalexemplary selectable markers and antibiotics are further describedbelow.

In some embodiments, the first translational unit includes a firsttranslation initiation region (TIR) in operable combination with acoding region of the first chain, and the second translational unitincludes a second translation initiation region (TIR) in operablecombination with a coding region of the second chain. Translationalinitiation regions (TIRs) are known to be important for translation ofrecombinant proteins in prokaryotic host cells (see, e.g., Simmons L Cand Yansura D G 1996 Nat. Biotechnol. 14:629 and Vimberg V et al. 2007BMC Mol. Biol. 8:100). A TIR may determine the efficiency of translationof a translational unit. A TIR typically includes translational unitfeatures such as the initiation codon, Shine-Dalgarno (SD) sequence, andtranslational enhancers. A TIR may further include a secretion signalsequence that encodes a signal peptide. The sequence and spacing betweenfeatures of a TIR may regulate translational initiation efficiency.

In some embodiments, the relative translation strength of the first andsecond TIR is from about 1.0 to about 3.0. Described herein are vectorsthat include translational units encoding each chain of a two chainprotein, and each translational unit may include a TIR. As used herein,“translational strength” may refer to the production of a polypeptidethrough translation of a translational unit. This production may dependupon a number of features, including without limitation mRNAtranslation, mRNA stability, efficiency of ribosomal binding to an mRNA,and the folding, assembly, and/or translocation of a polypeptide encodedthereby. Relative translational strength may refer to the production ofa polypeptide encoded by a translational unit with a specific orexperimental TIR, as compared to the production of a polypeptide encodedby a translational unit with a wild-type or control TIR, when both theexperimental TIR and the control TIR are expressed by a similarprokaryotic host cell (e.g., same genus and species) cultured under thesame conditions. Further description of TIRs may be found in U.S. Pat.No. 8,361,744.

Recombinant Polypeptides

Certain aspects of the present disclosure relate to methods of producingpolypeptides with two chains. Advantageously, the methods describedherein may be useful for promoting the expression, folding and assemblyof many different types of proteins, particularly those with disulfidebonds, such as two chain proteins as described above. Particular twochain proteins are described below, but the methods described herein arenot limited to these particular embodiments. As used herein, two chainproteins may include proteins containing more than one distinctpolypeptide chain. Although many embodiments described herein involvetwo chain proteins with two polypeptide chains, two chain proteins withmore than two polypeptide chains (e.g., three or more polypeptides) arecontemplated and may be produced by the methods described herein. Asdescribed above, two chain proteins made of a single polypeptide chainthat otherwise associate as they would if they were two distinctpolypeptide chains (e.g., single chain antibodies, single chain variablefragments, and the like) are also contemplated and may be produced bythe methods described herein.

In some embodiments, the two chains of a two chain polypeptide of thepresent disclosure are linked to each other by at least one disulfidebond. Disulfide bonds may refer to any covalent bond linking two thiolgroups. Disulfide bonds in polypeptides typically form between the thiolgroups of cysteine residues. Polypeptide disulfide bonds are known inthe art to be important for the folding and assembly of manypolypeptides, such as two chain proteins of the present disclosure.Polypeptide disulfide bonds may include disulfide bonds between cysteineresidues in a single polypeptide chain (i.e., intramolecular orintra-chain disulfide bonds). Polypeptide disulfide bonds may alsoinclude disulfide bonds between cysteine residues found on separatepolypeptide chains (i.e., intermolecular or inter-chain disulfidebonds). Therefore, in some embodiments, two chains of a two chainpolypeptide are linked to each other by at least one disulfide bond.

Disulfide bonds are known in the art to be important for the folding andassembly of antibodies and antibody fragments. Different antibodyisotopes, and different subclasses within an isotope, are known topossess different patterns of disulfide bonds. For example, IgGantibodies may contain 12 intra-chain disulfide bonds, one inter-chaindisulfide bond between each light chain and its corresponding heavychain, and between 2 and 11 inter-chain disulfide bonds between heavychains, depending upon the particular IgG subclass (see Liu H and May K2012 MAbs. 4(1):17 for more detailed description). IgM (see, e.g.,Wiersma E J and Shulman M J 1995 J. Immunol. 154(10):5265), IgE (see,e.g., Helm B A et al. 1991 Eur. J. Immunol. 21(6):1543), IgA (see, e.g.,Chintalacharuvu K R et al. 2002 J. Immunol. 169(9):5072), and IgD (see,e.g., Shin S U et al. 1992 Hum. Antibodies Hybridomas 3(2):65) are alsoknown to form disulfide bonds during folding and assembly.

In some embodiments, a two chain polypeptide of the present disclosureis heterologous to the host cell. As used herein, a heterologouspolypeptide when used in reference to a host cell may refer to anypolypeptide that is not endogenously expressed in the host cell, i.e.,when the host cell is isolated from nature. A heterologous polypeptidemay also refer to a polypeptide that may be expressed endogenously bythe host cell, but is expressed under different regulation than when thehost cell is isolated from nature. Examples of different regulation mayinclude without limitation a different amount of expression, expressionin response to a different stimulus, or any other altered context ofexpression, such as by use of a heterologous promoter, such as aninducible promoter.

In some embodiments, a two chain polypeptide of the present disclosureis a monomer of a heterodimer. As used herein, a heterodimer may referto any polypeptide complex that contains two distinct polypeptides orpolypeptide complexes in operable linkage. A non-limiting example of aheterodimer is a bispecific or bivalent antibody composed of twodistinct antibody monomers (i.e., a light chain-heavy chain pair inoperable linkage). In this example, the folding and assembly of a firstheavy chain-light chain pair recognizing a first antigen produces afirst antibody monomer. The folding and assembly of a second heavychain-light chain pair recognizing a second antigen produces a secondantibody monomer. These monomers may be assembled by any means known inthe art (described below in more detail with respect to bispecificantibodies) to form a heterodimer. For more details on an illustrativeexample of heterodimeric antibody formation, see Ridgway J B B et al.1996 Protein Eng. 9(7):617.

In some embodiments, a two chain polypeptide of the present disclosureis a monovalent antibody in which the first chain and the second chainrepresent an immunoglobulin heavy chain and an immunoglobulin lightchain. As used herein, a monovalent antibody may refer to anypolypeptide complex made from an antibody heavy chain and an antibodylight chain operably linked together to form a heavy chain-light chainpair in which the heavy chain-light chain pair is not operably linked toa second heavy chain-light chain pair. The term “half-antibody (hAb)”may be used interchangeably herein.

In some embodiments, a monovalent antibody of the present disclosure iscapable of specifically binding an antigen. As used herein, the term“binds”, “specifically binding an,” or is “specific for” refers tomeasurable and reproducible interactions such as binding between atarget (i.e., and an antibody, which is determinative of the presence ofthe target in the presence of a heterogeneous population of moleculesincluding biological molecules. For example, an antibody that binds toor specifically binds to a target (which can be an epitope) is anantibody that binds this target with greater affinity, avidity, morereadily, and/or with greater duration than it binds to other targets. Inone embodiment, the extent of binding of an antibody to an unrelatedtarget is less than about 10% of the binding of the antibody to thetarget as measured, e.g., by a radioimmunoassay (RIA). In certainembodiments, an antibody that specifically binds to a target has adissociation constant (Kd) of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, or ≦0.1 nM.In certain embodiments, an antibody specifically binds to an epitope ona protein that is conserved among the protein from different species. Inanother embodiment, specific binding can include, but does not require,exclusive binding.

In some embodiments, a two chain polypeptide of the present disclosureis a secretory protein. As used herein, a secretory protein may refer toany protein that is secreted by a host cell into the host cell periplasmor extracellular milieu. A secretory protein may be a protein that isendogenously secreted by a host cell, or a secretory protein may be aprotein that is not endogenously secreted by a host cell but is modifiedin such a way as to promote its secretion. For example, the presence ofa signal sequence, typically found at the N-terminus of a polypeptide,may direct a polypeptide to the secretory pathway for secretion.Numerous signal sequences are known in the art and may be useful forpromoting the secretion of a secretory protein or allowing the secretionof protein not naturally secreted by a host cell; see, e.g., Picken etal., Infect. Immun. 42:269-275 (1983); Simmons and Yansura, NatureBiotechnology 14:629-634 (1996); and Humphreys D P et al. 2000 ProteinExpr. Purif. 20(2):252. One non-limiting example of a signal sequence isa heat stable enterotoxin II (STII) signal sequence.

In some embodiments, a secretory protein of the present disclosure isrecovered from the periplasm of the host cell. Periplasm is known in theart to refer to the space between the inner or cytoplasmic membrane andthe outer membrane of a Gram-negative bacterial cell. Without wishing tobe bound to theory, it is thought that the periplasm is an oxidizingenvironment that favors the formation of disulfide bonds. Therefore, itmay be advantageous to localize a polypeptide with disulfide bonds aspart of its properly folded and assembled structure (e.g., a two chainprotein of the present disclosure) to the periplasm (see Schlapschy M etal. 2006 Protein Eng. Des. Sel. 19(8):385 for more detaileddescription).

Numerous methods for recovering a periplasmic protein are known in theart. One non-limiting example of large-scale purification of periplasmicproteins is described in European Patent No. EP1356052 B1 (see, e.g.,Example 4). Periplasmic proteins may be recovered by extracting aperiplasmic fraction from a spheroblast preparation (see, e.g.,Schlapschy M et al. 2006 Protein Eng. Des. Sel. 19(8):385). Once aperiplasmic extract has been generated, periplasmic proteins may bepurified by any standard protein purification technique known in theart, such as affinity purification, chromatography, and the like.

Antibodies

The two chain proteins described herein may be prepared by any suitabletechniques known in the art. One exemplary class of two chain proteinsis the antibody. As described below, antibodies are prepared usingtechniques available in the art for generating antibodies, exemplarymethods of which are described in more detail in the following sections.One of skill in the art will recognize that many of the methodsdescribed below may be applied to two chain proteins other thanantibodies.

The antibody is directed against an antigen of interest (e.g., andwithout limitation, PD-L1 (such as a human PD-L1), HER2, or CD3 (such asa human CD3), IL13, IL4, VEGFC, VEGFA, and VEGF). Preferably, theantigen is a biologically important polypeptide and administration ofthe antibody to a mammal suffering from a disorder can result in atherapeutic benefit in that mammal.

IL13 and IL17 Antibodies

In some embodiments, the antibody of the present disclosure is directedagainst interleukin-13 (referred to herein as IL-13 or IL13). Forexample, the antibody may be a monovalent antibody or “half-antibody”directed against IL13, a full antibody comprising two monovalent heavychain-light chain pairs directed against IL13 (e.g., two identicalmonovalent heavy chain-light chain pairs; two monovalent heavychain-light chain pairs, each comprising different HVRs or CDRs thatrecognize identical epitopes of IL13; or two monovalent heavychain-light chain pairs, each comprising different HVRs or CDRs thatrecognize non-overlapping or partially overlapping epitopes of IL13), ora bispecific antibody comprising a heavy chain-light chain pair directedagainst IL13 and a heavy chain-light chain pair directed against adifferent antigen.

Examples of IL13 polypeptides are known in the art. In some embodiments,the IL13 polypeptide is a human IL13 polypeptide. In some embodiments,the IL13 polypeptide is a precursor form of IL13. A non-limiting exampleof a precursor form of an IL13 polypeptide is a human IL13 precursor, asrepresented by Swiss-Prot Accession No. P35225.2. In some embodiments,the IL13 polypeptide comprises the sequence:

(SEQ ID NO: 1) MALLLTTVIA LTCLGGFASP GPVPPSTALRELIEEL VNITQNQKAPLCNGSMVWSI NLTAGMYCAA LESLINVSGC SAIEKTQRML SGFCPHKVSA GQFSSLHVRD TKIEVAQFVK DLLLHLKKLF REGRFN.

In other embodiments, the IL13 is a mature form of IL13 (e.g., lacking asignal sequence). In some embodiments, the IL13 polypeptide comprisesthe sequence:

(SEQ ID NO: 2) SPGPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA GMYCAALESL INVSGCSAIE KTQRMLSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL HLKKLFREGR FN.

In some embodiments, the antibody of the present disclosure is directedagainst interleukin-17 (referred to herein as IL-17 or IL17). Forexample, the antibody may be a monovalent antibody or “half-antibody”directed against IL17, a full antibody comprising two monovalent heavychain-light chain pairs directed against IL17 (e.g., two identicalmonovalent heavy chain-light chain pairs; two monovalent heavychain-light chain pairs, each comprising different HVRs or CDRs thatrecognize identical epitopes of IL17; or two monovalent heavychain-light chain pairs, each comprising different HVRs or CDRs thatrecognize non-overlapping or partially overlapping epitopes of IL17), ora bispecific antibody comprising a heavy chain-light chain pair directedagainst IL17 and a heavy chain-light chain pair directed against adifferent antigen.

There are six members in the IL17 family: IL17A, IL17B, IL17C, IL7D,IL17E and IL17F. IL17 is sometimes used in the field to refer to IL17A,the prototype of the IL17 family. IL17A and IL17F share the highestsequence homology among all IL17 family members. Members of the IL17family form homodimers, e.g., IL17AA and IL17FF. In addition, IL17A andIL17F form heterodimers (e.g., IL17AF). See e.g., Gaffen, S. L., 2009,Nature Review 9:556-567; Hymowitz et al., 2001, EMBO J. 20:5332-41; andWO 2005/010044, incorporated herein by reference in their entirety. Incertain embodiments, the antibody of the present disclosure is directedagainst IL17A. In certain embodiments, the antibody of the presentdisclosure is directed against IL17F. In certain embodiments, theanti-IL17 antibody or antibody that binds IL17 refers to an antibodythat binds IL17AA, FF and AF (or IL17A F cross reactive antibody). Incertain embodiments, the antibody of the present disclosure cross-reactswith both IL17A and IL17F (e.g., anti-IL17AA, AF, and FF). For a furtherdescription of IL17AA, IL17FF, and IL17AF antibodies see, e.g., U.S.Pat. No. 8,715,669.

Examples of IL17 polypeptides (e.g., IL17A or IL17F) are known in theart. In some embodiments, the IL17A polypeptide is a human IL17Apolypeptide. In some embodiments, the IL17A polypeptide is a precursorform of IL17A. A non-limiting example of a precursor form of an IL17Apolypeptide is a human IL17A precursor, as represented by Swiss-ProtAccession No. Q16552.1. In some embodiments, the IL17A polypeptidecomprises the sequence:

(SEQ ID NO: 3) MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPI VHHVA 

In other embodiments, the IL17A is a mature form of IL17A (e.g., lackinga signal sequence). In some embodiments, the IL17A polypeptide comprisesthe sequence:

(SEQ ID NO: 4) GITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA.

In some embodiments, the IL17F polypeptide is a human IL17F polypeptide.In some embodiments, the IL17F polypeptide is a precursor form of IL17F.A non-limiting example of a precursor form of an IL17F polypeptide is ahuman IL17F precursor, as represented by Swiss-Prot Accession No.Q96PD4.3. In some embodiments, the IL17F polypeptide comprises thesequence:

(SEQ ID NO: 5) MTVKTLHGPAMVKYLLLSILGLAFLSEAAARKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTV GCTCVTPVIHHVQ 

In other embodiments, the IL17F is a mature form of IL17F (e.g., lackinga signal sequence). In some embodiments, the IL17F polypeptide comprisesthe sequence:

(SEQ ID NO: 6) RKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ.

In some embodiments, provided herein is an anti-IL13 antibody comprisinga heavy chain variable domain and a light chain variable domain,wherein:

(a) the heavy chain variable domain comprises an HVR-H1, HVR-H2 and anHVR-H3 sequence having at least 85% sequence identity to AYSVN (SEQ IDNO:9), MIWGDGKIVYNSALKS (SEQ ID NO:10) and DGYYPYAMDN (SEQ ID NO:11),respectively, and/or

(b) the light chain variable domain comprises an HVR-L1, HVR-L2 and anHVR-L3 sequence having at least 85% sequence identity to RASKSVDSYGNSFMH(SEQ ID NO:12), LASNLES (SEQ ID NO:13) and QQNNEDPRT (SEQ ID NO:14),respectively.

In a specific aspect, the sequence identity is at least 86%, 87%, 88%,89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% ascompared to a reference sequence.

In some embodiments, the anti-IL13 antibody comprises a heavy chainvariable domain sequence of SEQ ID NO:7 and/or a light chain variabledomain sequence of SEQ ID NO:8. In a still further embodiment, providedis an isolated anti-IL13 antibody comprising a heavy chain and/or alight chain sequence, wherein:

(a) the heavy chain variable domain sequence has at least 85%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%sequence identity to the reference heavy chain sequence:

(SEQ ID NO: 7) EVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGY YPYAMDNWGQGSLVTVSS,and/or

(b) the light chain variable domain sequence has at least 85%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%sequence identity to the reference light chain sequence:

(SEQ ID NO: 8) DIVLTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPR TFGGGTKVEIKR.

In some embodiments, provided herein is an anti-IL17A F cross reactiveantibody comprising a heavy chain variable domain and a light chainvariable domain, wherein:

(a) the heavy chain variable domain comprises an HVR-H1, HVR-H2 and anHVR-H3 sequence having at least 85% sequence identity to DYAMH (SEQ IDNO:20), GINWSSGGIGYADSVKG (SEQ ID NO:21) and DIGGFGEFYWNFGL (SEQ IDNO:22), respectively, and/or

(b) the light chain variable domain comprises an HVR-L1, HVR-L2 and anHVR-L3 sequence having at least 85% sequence identity to RASQSVRSYLA(SEQ ID NO:23), DASNRAT (SEQ ID NO:24) and QQRSNWPPAT (SEQ ID NO:25),respectively.

In a specific aspect, the sequence identity is at least 86%, 87%, 88%,89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% ascompared to a reference sequence.

In some embodiments, the anti-IL17A F cross reactive antibody comprisesa heavy chain variable domain sequence of SEQ ID NO:18 and/or a lightchain variable domain sequence of SEQ ID NO:19. In a still furtherembodiment, provided is an isolated anti-IL17A F cross reactive antibodycomprising a heavy chain and/or a light chain sequence, wherein:

(a) the heavy chain sequence has at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% or 100% sequence identityto the reference heavy chain sequence:

(SEQ ID NO: 18) EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,and/or

(b) the light chain sequences has at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% or 100% sequence identityto the reference light chain sequence:

(SEQ ID NO: 19) EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFG GGTKVEIK.

In one aspect of the invention, multispecific antibodies are provided,wherein the antibodies comprise a first monovalent or half antibody anda second monovalent or half antibody, wherein the first half-antibodycomprises a first VH/VL unit that binds IL-17 and the second halfantibody comprises a second VH/VL unit that binds IL-13. In someembodiments, the first half antibody does not bind IL-13, and the secondhalf antibody does not bind IL-17. In certain particular embodiments,the multispecific antibody provided herein binds to IL-17AA, IL-17AF andIL-17FF, inhibits IL-17AA-, IL-17AF, and IL-17FF-induced activity, andinhibits IL-13-induced activity. In certain such embodiments, theanti-IL-13/IL-17AA, AF and FF bispecific antibody advantageously blocksactivities induced by all of IL-17A and F cytokines as opposed toactivities induced by IL-17A or IL-17F alone. In some embodiments, amultispecific antibody provided herein binds to IL-17AA, IL-17AF, andIL-17FF. In some embodiments, the IL-17AA-induced activity isIL-17AA-induced gene expression and/or proliferation of cells in vivo orin vitro. In some embodiments, the IL-17AF-induced activity isIL-17AF-induced gene expression and/or proliferation of cells in vivo orin vitro. In some such embodiments, the IL-17FF-induced activity isIL-17FF-induced gene expressing and/or proliferation of cells in vivo orin vitro. In some embodiments, the IL-13-induced activity isIL-13-induced gene expression and/or proliferation of cells in vivo orin vitro. In some embodiments, a multispecific antibody provided hereindoes not inhibit binding of IL-13 to IL-13Rα1.

In some embodiments, the anti-IL13/IL17AA AF FF bispecific antibody (oranti-IL13/IL17 bispecific antibody) comprises a first half antibody anda second half antibody, wherein the first half-antibody comprises afirst VH/VL unit that binds IL-17AA, AF and FF and the second halfantibody comprises a second VH/VL unit that binds IL-13, wherein thefirst VH/VL unit comprises HVR-H1 comprising the amino acid sequence ofSEQ ID NO: 20, HVR-H2 comprising the amino acid sequence of SEQ ID NO:21, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22, HVR-L1comprising the amino acid sequence of SEQ ID NO: 23, HVR-L2 comprisingthe amino acid sequence of SEQ ID NO: 24, and HVR-L3 comprising theamino acid sequence of SEQ ID NO: 25, and wherein the second VH/VL unitcomprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:9,HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, HVR-H3comprising the amino acid sequence of SEQ ID NO: 11, HVR-L1 comprisingthe amino acid sequence of SEQ ID NO: 12, HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 13, and HVR-L3 comprising the amino acidsequence of SEQ ID NO: 14. In some embodiments, the first half antibodydoes not bind IL-13, and the second half antibody does not bind IL-17.See U.S. Pat. No. 8,715,669; U.S. Pat. No. 8,771,697; U.S. Pat. No.8,088,618; and PCT/US2015/017168.

In some embodiments, the first VH/VL unit comprises a VH sequence havingat least 95%, at least 96%, at least 97%, at least 98%, or at least 99%sequence identity to the amino acid sequence of SEQ ID NO:18 and a VLsequence having at least 95%, at least 96%, at least 97%, at least 98%,or at least 99% sequence identity to the amino acid sequence of SEQ IDNO:19, and wherein the second VH/VL unit comprises a VH sequence havingat least 95%, at least 96%, at least 97%, at least 98%, or at least 99%sequence identity to the amino acid sequence of SEQ ID NO:7 and a VLsequence having at least 95%, at least 96%, at least 97%, at least 98%,or at least 99% sequence identity to the amino acid sequence of SEQ IDNO:8. In some embodiments, a multispecific antibody is provided, whereinthe first VH/VL unit comprises a VH sequence having the amino acidsequence of SEQ ID NO:18 and a VL sequence having the amino acidsequence of SEQ ID NO:19, and wherein the second VH/VL unit comprises aVH sequence having the amino acid sequence of SEQ ID NO:7 and a VLsequence having the amino acid sequence of SEQ ID NO:8.

In certain embodiments, the first half antibody that binds IL17AA AF andFF comprises a heavy chain comprising the amino acid sequence of SEQ IDNO:26 and a light chain comprising the amino acid sequence of SEQ IDNO:28; and the second half antibody that binds IL13 comprises a heavychain comprising the amino acid sequence of SEQ ID NO:15 and a lightchain comprising the amino acid sequence of SEQ ID NO:17. In certainembodiments, the first half antibody that binds IL17AA AF and FFcomprises a heavy chain comprising the amino acid sequence of SEQ IDNO:27 and a light chain comprising the amino acid sequence of SEQ IDNO:28; and the second half antibody that binds IL13 comprises a heavychain comprising the amino acid sequence of SEQ ID NO:16 and a lightchain comprising the amino acid sequence of SEQ ID NO:17.

In some embodiments, the CH3 and/or CH2 domains of an antibody of thepresent disclosure are from an IgG (e.g., IgG1 subtype, IgG2 subtype,IgG2A subtype, IgG2B subtype, IgG3, subtype, or IgG4 subtype). In someembodiments, the CH3 and/or CH2 domains of an antibody of the presentdisclosure may comprise one or more knob- or hole-forming mutations,such as those described in Table 2 below.

In certain embodiments, the CH3 and/or CH2 domains of an antibody of thepresent disclosure are from an IgG4 subtype. In some embodiments, theIgG4 CH3 and/or CH2 domains of an antibody of the present disclosure maycomprise one or more additional mutations, including without limitationan S228P mutation (EU numbering).

Further provided herein are polynucleotide sequences encoding anantibody heavy/light-chain variable domain or heavy/light chain of thepresent disclosure. In certain embodiments, an anti-IL13 antibody of thepresent disclosure (e.g., a half antibody that binds IL13) comprises aheavy chain variable domain encoded by a polynucleotide sequencecomprising SEQ ID NO:29 and/or a light chain variable domain encoded bya polynucleotide sequence comprising SEQ ID NO:30. In certainembodiments, an anti-IL13 antibody of the present disclosure (e.g., ahalf antibody that binds IL13) comprises a heavy chain encoded by apolynucleotide sequence comprising SEQ ID NO:31 or SEQ ID NO:32 and/or alight chain variable domain encoded by a polynucleotide sequencecomprising SEQ ID NO:33. In certain embodiments, an anti-IL17A F crossreactive antibody of the present disclosure (e.g., a half antibody thatbinds IL17AA, AF, and FF) comprises a heavy chain variable domainencoded by a polynucleotide sequence comprising SEQ ID NO:34 and/or alight chain variable domain encoded by a polynucleotide sequencecomprising SEQ ID NO:35. In certain embodiments, an anti-IL17A F crossreactive antibody of the present disclosure (e.g., a half antibody thatbinds IL17AA, AF, and FF) comprises a heavy chain encoded by apolynucleotide sequence comprising SEQ ID NO:36 or SEQ ID NO:37 and/or alight chain variable domain encoded by a polynucleotide sequencecomprising SEQ ID NO:38.

In some embodiments, an antibody of the present disclosure may contain apolypeptide sequence that is codon optimized for expression in aparticular host cell, e.g., a prokaryotic host cell such as E. coli. Forexample, in some embodiments, an anti-IL17AF antibody of the presentdisclosure (e.g., a half antibody that binds IL17AA, AF, and FF)comprises a heavy chain encoded by a polynucleotide sequence comprisingSEQ ID NO:39 or SEQ ID NO:40 and/or a light chain variable domainencoded by a polynucleotide sequence comprising SEQ ID NO:41.

Antibody Properties

In certain embodiments, an antibody provided herein has a dissociationconstant (Kd) of ≦1 μM, ≦150 nM, ≦100 nM, ≦50 nM, ≦10 nM, ≦1 nM, ≦0.1nM, ≦0.01 nM, or ≦0.001 nM (e.g. 10⁻⁸M or less, e.g. from 10⁻⁸M to10⁻¹³M, e.g., from 10⁻⁹M to 10⁻¹³ M).

In one embodiment, Kd is measured by a radiolabeled antigen bindingassay (RIA) performed with the Fab version of an antibody of interestand its antigen as described by the following assay. Solution bindingaffinity of Fabs for antigen is measured by equilibrating Fab with aminimal concentration of (¹²⁵I)-labeled antigen in the presence of atitration series of unlabeled antigen, then capturing bound antigen withan anti-Fab antibody-coated plate (see, e.g., Chen et al., J. Mol. Biol.293:865-881(1999)). To establish conditions for the assay, MICROTITER®multi-well plates (Thermo Scientific) are coated overnight with 5 μg/mlof a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate(pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin inPBS for two to five hours at room temperature (approximately 23° C.). Ina non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [¹²⁵I]-antigen aremixed with serial dilutions of a Fab of interest. The Fab of interest isthen incubated overnight; however, the incubation may continue for alonger period (e.g., about 65 hours) to ensure that equilibrium isreached. Thereafter, the mixtures are transferred to the capture platefor incubation at room temperature (e.g., for one hour). The solution isthen removed and the plate washed eight times with 0.1% polysorbate 20(TWEEN-20®) in PBS. When the plates have dried, 150 μl/well ofscintillant (MICROSCINT-20™; Packard) is added, and the plates arecounted on a TOPCOUNT™ gamma counter (Packard) for ten minutes.Concentrations of each Fab that give less than or equal to 20% ofmaximal binding are chosen for use in competitive binding assays.

According to another embodiment, Kd is measured using surface plasmonresonance assays using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore,Inc., Piscataway, N.J.) at 25° C. with immobilized antigen CM5 chips at˜10 response units (RU). Briefly, carboxymethylated dextran biosensorchips (CM5, BIACORE, Inc.) are activated withN-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) andN-hydroxysuccinimide (NHS) according to the supplier's instructions.Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 μg/ml (˜0.2μM) before injection at a flow rate of 5 μl/minute to achieveapproximately 10 response units (RU) of coupled protein. Following theinjection of antigen, 1 M ethanolamine is injected to block unreactedgroups. For kinetics measurements, two-fold serial dilutions of Fab(0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20(TWEEN-20™) surfactant (PBST) at 25° C. at a flow rate of approximately25 μl/min. Association rates (k_(on)) and dissociation rates (k_(off))are calculated using a simple one-to-one Langmuir binding model(BIACORE® Evaluation Software version 3.2) by simultaneously fitting theassociation and dissociation sensorgrams. The equilibrium dissociationconstant (Kd) is calculated as the ratio k_(off)/k_(on). See, e.g., Chenet al., J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 10⁶ M⁻¹s⁻¹ by the surface plasmon resonance assay above, then the on-rate canbe determined by using a fluorescent quenching technique that measuresthe increase or decrease in fluorescence emission intensity(excitation=295 nm; emission=340 nm, 16 nm band-pass) at 25° C. of a 20nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence ofincreasing concentrations of antigen as measured in a spectrometer, suchas a stop-flow equipped spectrophometer (Aviv Instruments) or a8000-series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with astirred cuvette.

(i) Antigen Preparation

Soluble antigens or fragments thereof, optionally conjugated to othermolecules, can be used as immunogens for generating antibodies. Fortransmembrane molecules, such as receptors, fragments of these (e.g. theextracellular domain of a receptor) can be used as the immunogen.Alternatively, cells expressing the transmembrane molecule can be usedas the immunogen. Such cells can be derived from a natural source (e.g.cancer cell lines) or may be cells which have been transformed byrecombinant techniques to express the transmembrane molecule. Otherantigens and forms thereof useful for preparing antibodies will beapparent to those in the art.

(ii) Certain Antibody-Based Methods

Polyclonal antibodies are preferably raised in animals by multiplesubcutaneous (sc) or intraperitoneal (ip) injections of the relevantantigen and an adjuvant. It may be useful to conjugate the relevantantigen to a protein that is immunogenic in the species to be immunized,e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, orsoybean trypsin inhibitor using a bifunctional or derivatizing agent,for example, maleimidobenzoyl sulfosuccinimide ester (conjugationthrough cysteine residues), N-hydroxysuccinimide (through lysineresidues), glutaraldehyde, succinic anhydride, SOCl₂, or R¹N═C═NR, whereR and R¹ are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, orderivatives by combining, e.g., 100 μg or 5 μg of the protein orconjugate (for rabbits or mice, respectively) with 3 volumes of Freund'scomplete adjuvant and injecting the solution intradermally at multiplesites. One month later the animals are boosted with ⅕ to 1/10 theoriginal amount of peptide or conjugate in Freund's complete adjuvant bysubcutaneous injection at multiple sites. Seven to 14 days later theanimals are bled and the serum is assayed for antibody titer. Animalsare boosted until the titer plateaus. Preferably, the animal is boostedwith the conjugate of the same antigen, but conjugated to a differentprotein and/or through a different cross-linking reagent. Conjugatesalso can be made in recombinant cell culture as protein fusions. Also,aggregating agents such as alum are suitably used to enhance the immuneresponse.

Monoclonal antibodies of the disclosure can be made using the hybridomamethod first described by Kohler et al., Nature, 256:495 (1975), andfurther described, e.g., in Hongo et al., Hybridoma, 14 (3): 253-260(1995), Harlow et al., Antibodies: A Laboratory Manual, (Cold SpringHarbor Laboratory Press, 2nd ed. 1988); Hammerling et al., in:Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N. Y.,1981), and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) regardinghuman-human hybridomas. Additional methods include those described, forexample, in U.S. Pat. No. 7,189,826 regarding production of monoclonalhuman natural IgM antibodies from hybridoma cell lines. Human hybridomatechnology (Trioma technology) is described in Vollmers and Brandlein,Histology and Histopathology, 20(3):927-937 (2005) and Vollmers andBrandlein, Methods and Findings in Experimental and ClinicalPharmacology, 27(3):185-91 (2005). Once desired monoclonal antibodieshave been isolated from hybridomas, polynucleotides encoding them may besubcloned into a prokaryotic expression vector, and antibodies may beproduced by expression in a prokaryotic host cell by any of the methodsdescribed herein.

(iii) Library-Derived Antibodies

Antibodies of the disclosure may be isolated by screening combinatoriallibraries for antibodies with the desired activity or activities. Forexample, a variety of methods are known in the art for generating phagedisplay libraries and screening such libraries for antibodies possessingthe desired binding characteristics such as the methods described inExample 3. Additional methods are reviewed, e.g., in Hoogenboom et al.in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., HumanPress, Totowa, N. J., 2001) and further described, e.g., in theMcCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marksand Bradbury, in Methods in Molecular Biology 248:161-175 (Lo, ed.,Human Press, Totowa, N. J., 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093 (2004);Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); andLee et al., J. Immunol. Methods 284(1-2): 119-132(2004).

In certain phage display methods, repertoires of VH and VL genes areseparately cloned by polymerase chain reaction (PCR) and recombinedrandomly in phage libraries, which can then be screened forantigen-binding phage as described in Winter et al., Ann. Rev. Immunol.,12: 433-455 (1994). Phage typically display antibody fragments, eitheras single-chain Fv (scFv) fragments or as Fab fragments. Libraries fromimmunized sources provide high-affinity antibodies to the immunogenwithout the requirement of constructing hybridomas. Alternatively, thenaive repertoire can be cloned (e.g., from human) to provide a singlesource of antibodies to a wide range of non-self and also self-antigenswithout any immunization as described by Griffiths et al., EMBO J, 12:725-734 (1993). Finally, naive libraries can also be made syntheticallyby cloning unrearranged V-gene segments from stem cells, and using PCRprimers containing random sequence to encode the highly variable CDR3regions and to accomplish rearrangement in vitro, as described byHoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992). Patentpublications describing human antibody phage libraries include, forexample: U.S. Pat. No. 5,750,373, and US Patent Publication Nos.2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598,2007/0237764, 2007/0292936, and 2009/0002360.

Antibodies or antibody fragments isolated from human antibody librariesare considered human antibodies or human antibody fragments herein.

(iv) Chimeric, Humanized and Human Antibodies

In certain embodiments, an antibody provided herein is a chimericantibody. Certain chimeric antibodies are described, e.g., in U.S. Pat.No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA,81:6851-6855 (1984)). In one example, a chimeric antibody comprises anon-human variable region (e.g., a variable region derived from a mouse,rat, hamster, rabbit, or non-human primate, such as a monkey) and ahuman constant region. In a further example, a chimeric antibody is a“class switched” antibody in which the class or subclass has beenchanged from that of the parent antibody. Chimeric antibodies includeantigen-binding fragments thereof.

In certain embodiments, a chimeric antibody is a humanized antibody.Typically, a non-human antibody is humanized to reduce immunogenicity tohumans, while retaining the specificity and affinity of the parentalnon-human antibody. Generally, a humanized antibody comprises one ormore variable domains in which HVRs, e.g., CDRs, (or portions thereof)are derived from a non-human antibody, and FRs (or portions thereof) arederived from human antibody sequences. A humanized antibody optionallywill also comprise at least a portion of a human constant region. Insome embodiments, some FR residues in a humanized antibody aresubstituted with corresponding residues from a non-human antibody (e.g.,the antibody from which the HVR residues are derived), e.g., to restoreor improve antibody specificity or affinity.

Humanized antibodies and methods of making them are reviewed, e.g., inAlmagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and arefurther described, e.g., in Riechmann et al., Nature 332:323-329 (1988);Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S.Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri etal., Methods 36:25-34 (2005) (describing SDR (a-CDR) grafting); Padlan,Mol. Immunol. 28:489-498 (1991) (describing “resurfacing”); Dall'Acquaet al., Methods 36:43-60 (2005) (describing “FR shuffling”); and Osbournet al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer,83:252-260 (2000) (describing the “guided selection” approach to FRshuffling).

Human framework regions that may be used for humanization include butare not limited to: framework regions selected using the “best-fit”method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); frameworkregions derived from the consensus sequence of human antibodies of aparticular subgroup of light or heavy chain variable regions (see, e.g.,Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta etal. J. Immunol., 151:2623 (1993)); human mature (somatically mutated)framework regions or human germline framework regions (see, e.g.,Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and frameworkregions derived from screening FR libraries (see, e.g., Baca et al., J.Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem.271:22611-22618 (1996)).

In certain embodiments, an antibody provided herein is a human antibody.Human antibodies can be produced using various techniques known in theart. Human antibodies are described generally in van Dijk and van deWinkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin.Immunol. 20:450-459 (2008). Human antibodies can be made, for exampleand without limitation, by expression in a prokaryotic host cell from aprokaryotic expression vector by any of the methods described herein.

Human antibodies may also be generated by isolating Fv clone variabledomain sequences selected from human-derived phage display libraries.Such variable domain sequences may then be combined with a desired humanconstant domain. Techniques for selecting human antibodies from antibodylibraries are described below.

(v) Antibody Fragments

Antibody fragments may be generated by traditional means, such asenzymatic digestion, or by recombinant techniques. In certaincircumstances there are advantages of using antibody fragments, ratherthan whole antibodies. The smaller size of the fragments allows forrapid clearance, and may lead to improved access to solid tumors. For areview of certain antibody fragments, see Hudson et al. (2003) Nat. Med.9:129-134.

Various techniques have been developed for the production of antibodyfragments. Traditionally, these fragments were derived via proteolyticdigestion of intact antibodies (see, e.g., Morimoto et al., Journal ofBiochemical and Biophysical Methods 24:107-117 (1992); and Brennan etal., Science, 229:81 (1985)). However, these fragments can now beproduced directly by recombinant host cells. Fab, Fv and ScFv antibodyfragments can all be expressed in and secreted from E. coli, thusallowing the facile production of large amounts of these fragments.Antibody fragments can be isolated from the antibody phage librariesdiscussed above. Alternatively, Fab′-SH fragments can be directlyrecovered from E. coli and chemically coupled to form F(ab′)₂ fragments(Carter et al., Bio/Technology 10:163-167 (1992)). According to anotherapproach, F(ab′)₂ fragments can be isolated directly from recombinanthost cell culture. Fab and F(ab′)₂ fragment with increased in vivohalf-life comprising salvage receptor binding epitope residues aredescribed in U.S. Pat. No. 5,869,046. Other techniques for theproduction of antibody fragments will be apparent to the skilledpractitioner. In certain embodiments, an antibody is a single chain Fvfragment (scFv). See WO 93/16185; U.S. Pat. Nos. 5,571,894; and5,587,458. Fv and scFv are the only species with intact combining sitesthat are devoid of constant regions; thus, they may be suitable forreduced nonspecific binding during in vivo use. scFv fusion proteins maybe constructed to yield fusion of an effector protein at either theamino or the carboxy terminus of an scFv. See Antibody Engineering, ed.Borrebaeck, supra. The antibody fragment may also be a “linearantibody”, e.g., as described in U.S. Pat. No. 5,641,870, for example.Such linear antibodies may be monospecific or bispecific.

(vi) Multispecific Antibodies

Multispecific antibodies have binding specificities for at least twodifferent epitopes, where the epitopes are usually from differentantigens. While such molecules normally will only bind two differentepitopes (i.e. bispecific antibodies, BsAbs), antibodies with additionalspecificities such as trispecific antibodies are encompassed by thisexpression when used herein. Bispecific antibodies can be prepared asfull length antibodies or antibody fragments (e.g. F(ab′)₂ bispecificantibodies).

Methods for making bispecific antibodies are known in the art.Traditional production of full length bispecific antibodies is based onthe coexpression of two immunoglobulin heavy chain-light chain pairs,where the two chains have different specificities (Millstein et al.,Nature, 305:537-539 (1983)). Because of the random assortment ofimmunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of 10 different antibody molecules, of whichonly one has the correct bispecific structure. Purification of thecorrect molecule, which is usually done by affinity chromatographysteps, is rather cumbersome, and the product yields are low. Similarprocedures are disclosed in WO 93/08829, and in Traunecker et al., EMBOJ., 10:3655-3659 (1991).

One approach known in the art for making bispecific antibodies is the“knobs-into-holes” or “protuberance-into-cavity” approach (see, e.g.,U.S. Pat. No. 5,731,168). In this approach, two immunoglobulinpolypeptides (e.g., heavy chain polypeptides) each comprise aninterface. An interface of one immunoglobulin polypeptide interacts witha corresponding interface on the other immunoglobulin polypeptide,thereby allowing the two immunoglobulin polypeptides to associate. Theseinterfaces may be engineered such that a “knob” or “protuberance” (theseterms may be used interchangeably herein) located in the interface ofone immunoglobulin polypeptide corresponds with a “hole” or “cavity”(these terms may be used interchangeably herein) located in theinterface of the other immunoglobulin polypeptide. In some embodiments,the hole is of identical or similar size to the knob and suitablypositioned such that when the two interfaces interact, the knob of oneinterface is positionable in the corresponding hole of the otherinterface. Without wishing to be bound to theory, this is thought tostabilize the heteromultimer and favor formation of the heteromultimerover other species, for example homomultimers. In some embodiments, thisapproach may be used to promote the heteromultimerization of twodifferent immunoglobulin polypeptides, creating a bispecific antibodycomprising two immunoglobulin polypeptides with binding specificitiesfor different epitopes.

In some embodiments, a knob may be constructed by replacing a smallamino acid side chain with a larger side chain. In some embodiments, ahole may be constructed by replacing a large amino acid side chain witha smaller side chain. Knobs or holes may exist in the originalinterface, or they may be introduced synthetically. For example, knobsor holes may be introduced synthetically by altering the nucleic acidsequence encoding the interface to replace at least one “original” aminoacid residue with at least one “import” amino acid residue. Methods foraltering nucleic acid sequences may include standard molecular biologytechniques well known in the art. The side chain volumes of variousamino acid residues are shown in the following table. In someembodiments, original residues have a small side chain volume (e.g.,alanine, asparagine, aspartic acid, glycine, serine, threonine, orvaline), and import residues for forming a knob are naturally occurringamino acids and may include arginine, phenylalanine, tyrosine, andtryptophan. In some embodiments, original residues have a large sidechain volume (e.g., arginine, phenylalanine, tyrosine, and tryptophan),and import residues for forming a hole are naturally occurring aminoacids and may include alanine, serine, threonine, and valine.

TABLE 1b Properties of amino acid residues Accessible One-letterMass^(a) Volume^(b) surface area^(c) Amino Acid abbreviation (daltons)(Å³) (Å²) Alanine (Ala) A 71.08 88.6 115 Arginine (Arg) R 156.20 173.4225 Asparagine (Asn) N 114.11 117.7 160 Aspartic Acid (Asp) D 115.09111.1 150 Cysteine (Cys) C 103.14 108.5 135 Glutamine (Gln) Q 128.14143.9 180 Glutamic Acid (Glu) E 129.12 138.4 190 Glycine (Gly) G 57.0660.1 75 Histidine (His) H 137.15 153.2 195 Isoleucine (Ile) I 113.17166.7 175 Leucine (Leu) L 113.17 166.7 170 Lysine (Lys) K 128.18 168.6200 Methionine (Met) M 131.21 162.9 185 Phenylalanine (Phe) F 147.18189.9 210 Proline (Pro) P 97.12 122.7 145 Serine (Ser) S 87.08 89.0 115Threonine (Thr) T 101.11 116.1 140 Tryptophan (Trp) W 186.21 227.8 255Tyrosine (Tyr) Y 163.18 193.6 230 Valine (Val) V 99.14 140.0 155^(a)Molecular weight of amino acid minus that of water. Values fromHandbook of Chemistry and Physics, 43^(rd) ed. Cleveland, ChemicalRubber Publishing Co., 1961. ^(b)Values from A. A. Zamyatnin, Prog.Biophys. Mol. Biol. 24: 107-123, 1972. ^(c)Values from C. Chothia, J.Mol. Biol. 105: 1-14, 1975. The accessible surface area is defined inFIGS. 6-20 of this reference.

In some embodiments, original residues for forming a knob or hole areidentified based on the three-dimensional structure of theheteromultimer. Techniques known in the art for obtaining athree-dimensional structure may include X-ray crystallography and NMR.In some embodiments, the interface is the CH3 domain of animmunoglobulin constant domain. In these embodiments, the CH3/CH3interface of human IgG₁ involves sixteen residues on each domain locatedon four anti-parallel β-strands. Without wishing to be bound to theory,mutated residues are preferably located on the two central anti-parallelβ-strands to minimize the risk that knobs can be accommodated by thesurrounding solvent, rather than the compensatory holes in the partnerCH3 domain. In some embodiments, the mutations forming correspondingknobs and holes in two immunoglobulin polypeptides correspond to one ormore pairs provided in the following table.

TABLE 2 Exemplary sets of corresponding knob-and hole-forming mutationsCH3 of first immunoglobulin CH3 of second immunoglobulin T366Y Y407TT366W Y407A T366W T366S:L368A:Y407V F405A T394W Y407T T366Y T366Y:F405AT394W:Y407T T366W:F405W T394S:Y407A F405W:Y407A T366W:T394S F405W T394SMutations are denoted by the original residue, followed by the positionusing the Kabat numbering system, and then the import residue (allresidues are given in single-letter amino acid code). Multiple mutationsare separated by a colon.

In some embodiments, an immunoglobulin polypeptide comprises a CH3domain comprising one or more amino acid substitutions listed in Table 2above. In some embodiments, a bispecific antibody comprises a firstimmunoglobulin polypeptide comprising a CH3 domain comprising one ormore amino acid substitutions listed in the left column of Table 2, anda second immunoglobulin polypeptide comprising a CH3 domain comprisingone or more corresponding amino acid substitutions listed in the rightcolumn of Table 2. As a non-limiting example of a knob-and-hole-formingpair, in some embodiments, a bispecific antibody comprises a firstimmunoglobulin polypeptide comprising a CH3 domain comprising a T366Wmutation, and a second immunoglobulin polypeptide comprising a CH3domain comprising T366S, L368A, and Y407V mutations.

Following mutation of the DNA as discussed above, polynucleotidesencoding modified immunoglobulin polypeptides with one or morecorresponding knob- or hole-forming mutations may be expressed andpurified using standard recombinant techniques and cell systems known inthe art. See, e.g., U.S. Pat. Nos. 5,731,168; 5,807,706; 5,821,333;7,642,228; 7,695,936; 8,216,805; U.S. Pub. No. 2013/0089553; and Spiesset al., Nature Biotechnology 31: 753-758, 2013. Modified immunoglobulinpolypeptides may be produced using prokaryotic host cells, such as E.coli. Corresponding knob- and hole-bearing immunoglobulin polypeptidesmay be expressed in host cells in co-culture and purified together as aheteromultimer, or they may be expressed in single cultures, separatelypurified, and assembled in vitro. In some embodiments, two strains ofbacterial host cells (one expressing an immunoglobulin polypeptide witha knob, and the other expressing an immunoglobulin polypeptide with ahole) are co-cultured using standard bacterial culturing techniquesknown in the art. In some embodiments, the two strains may be mixed in aspecific ratio, e.g., so as to achieve equal expression levels inculture. In some embodiments, the two strains may be mixed in a 50:50,60:40, or 70:30 ratio. After polypeptide expression, the cells may belysed together, and protein may be extracted. Standard techniques knownin the art that allow for measuring the abundance of homo-multimeric vs.hetero-multimeric species may include size exclusion chromatography. Insome embodiments, each modified immunoglobulin polypeptide is expressedseparately using standard recombinant techniques, recovered, andassembled together in vitro. As described in greater detail below,assembly may be achieved, for example, by purifying each modifiedimmunoglobulin polypeptide, mixing and incubating them together in equalmass, reducing disulfides (e.g., by treating with dithiothreitol),concentrating, and reoxidizing the polypeptides. Formed bispecificantibodies may be purified using standard techniques includingcation-exchange chromatography and measured using standard techniquesincluding size exclusion chromatography. For a more detailed descriptionof these methods, see Speiss et al., Nat Biotechnol 31:753-8, 2013.

Each half-antibody can have either a knob (protuberance) or a hole(cavity) engineered into the heavy chain as described in U.S. Pat. No.7,642,228. Briefly, a CH3 knob mutant can be generated first. A libraryof CH3 hole mutants can be then created by randomizing residues 366, 368and 407 that are in proximity to the knob on the partner CH3 domain. Incertain embodiments, the knob mutation comprises T366W, and the holemutations comprise T366S, L368A and Y407V in an IgG1 or IgG4 backbone.Equivalent mutations in other immunoglobulin isotypes can be made by oneskilled in the art. Further, the skilled artisan will readily appreciatethat it is preferred that the two half-antibodies used for thebispecific antibody be of the same isotype.

Half-antibodies containing either the knob or hole mutations aregenerated in separate cultures by expressing the heavy and light chainsconstructs in a bacterial host cell, (e.g., E. coli). Each half-antibodycan be purified separately by Protein A affinity chromatography.Clarified cell extracts from the knob and hole half-antibody can bepurified by a HiTrap MABSELECT SURE™ column. Protein A purified halfantibodies with different specificity can be assembled to form abispecific antibody in a redox reaction in vitro in the presence of areducing agent.

Any suitable methods can be used to prepare a desired reducingcondition. For example, a desired reducing condition can be prepared byadding a reductant/reducing agent to the reaction (such as an assemblymixture of the invention). Suitable reductants include withoutlimitation dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP),thioglycolic acid, ascorbic acid, thiol acetic acid, glutathione (GSH),Beta-MercaptoEthylAmine, cysteine/cystine, GSH/glutathione disulfide(GSSG), cysteamine/cystamine, glycylcysteine, and beta-mercaptoethanol,preferably GSH. In certain particular embodiments, the reductant is aweak reductant including without limitation GSH,Beta-MercaptoEthylAmine, cysteine/cystine, GSH/GSSG,cysteamine/cystamine, glycylcysteine, and beta-mercaptoethanol,preferably GSH. In certain preferred embodiments, the reductant is GSH.In certain embodiments, the reductant is not DTT. It is within theability of one of ordinary skill in the art to select suitablereductants at suitable concentrations and under suitable experimentalconditions to achieve in a reaction the desired reducing condition. Forexample, 10 mM L-reduced glutathione in a solution with a bispecificantibody protein concentration of 10 g/L at 20° C. will result in astarting redox potential of about −400 mV. For example, glutathioneadded to an assembly mixture creates a weakly reducing condition that isadvantageous for knob-into-hole bispecific assembly. Other reductants ina similar class such as BMEA (Beta-MercaptoEthylAmine) may have asimilar effect. See WO2013/055958, incorporated herein by reference inits entirety. The reducing condition of the reaction can be estimatedand measured using any suitable methods known in the art. For example,the reducing condition can be measured using a resazurin indicator(discolorization from blue to colorless in reducing conditions). Formore precise measurement, a redox-potential meter (such as an ORPElectrode made by BROADLEY JAMES®) can be used.

In certain particular embodiments, the reducing condition is a weakreducing condition. The term “weak reductant” or “weak reducingcondition” as used herein refers to a reducing agent or a reducingcondition prepared by the reducing agent having a negative oxidationpotential at 25° C. The oxidation potential of the reductant ispreferably between −50 to −600 mV, −100 to −600 mV, −200 to −600 mV,−100 to −500 mV, −150 to −300 mV, more preferably between about −300 to−500 mV, most preferably about −400 mV, when the pH is between 7 and 9,and the temperature is between 15° C. and 39° C. One skilled in the artwill be able to select suitable reductants for preparing a desiredreducing condition. The skilled researcher will recognize that a strongreductant, i.e., one that has a more negative oxidation potential thanabove mentioned reductants for the same concentration, pH andtemperature, may be used at a lower concentration. In a preferredembodiment, the proteins will be able to form disulfide bonds in thepresence of the reductant when incubated under the above-recitedconditions. Examples of a weak reductant include without limitationglutathione, Beta-MercaptoEthylAmine, cystine/cysteine, GSH/GSSG,cysteamine/cystamine, glycylcysteine, and beta-mercaptoethanol. Incertain embodiments, an oxidation potential similar to that of 200×molar ratio of GSH:Antibody can be used as a point of reference for aweakly reducing condition at which efficient assembly using otherreductants can be expected.

Glutathione concentrations can be expressed in terms of molarity or interms of molar ratio or molar excess with respect to the amount of thehalf-antibodies present in the assembly mixture. Using a target molarratio of reductant controls for the protein concentration in theassembly mixture; this prevents over reducing or under reducing as aresult of variable protein concentrations. In certain other embodiments,the reductant is added to the assembly mixture in 2-600×, 2-200×,2-300×, 2-400×, 2-500×, 2-20×, 2-8×, 20-50×, 50-600×, 50-200×, or100-300× molar excess, preferably 50-400×, more preferably 100-300×, andmost preferably 200×, molar excess with respect to the total amount ofthe half antibodies. In certain embodiments, the assembly mixture has apH of between 7 and 9, preferably pH 8.5.

In certain embodiments, the cultures of the first half antibody andsecond half antibody can be combined and subsequently lysed in thecombined cultures. The released first half antibody and second halfantibody in the combination can form a bispecific antibody in a reducingcondition. See WO 2011/133886, incorporated herein by reference in itsentirety.

According to a different approach, antibody variable domains with thedesired binding specificities (antibody-antigen combining sites) arefused to immunoglobulin constant domain sequences. The fusion preferablyis with an immunoglobulin heavy chain constant domain, comprising atleast part of the hinge, CH2, and CH3 regions. It is typical to have thefirst heavy-chain constant region (CH1) containing the site necessaryfor light chain binding, present in at least one of the fusions. DNAsencoding the immunoglobulin heavy chain fusions and, if desired, theimmunoglobulin light chain, are inserted into separate expressionvectors, and are co-transfected into a suitable host organism. Thisprovides for great flexibility in adjusting the mutual proportions ofthe three polypeptide fragments in embodiments when unequal ratios ofthe three polypeptide chains used in the construction provide theoptimum yields. It is, however, possible to insert the coding sequencesfor two or all three polypeptide chains in one expression vector whenthe expression of at least two polypeptide chains in equal ratiosresults in high yields or when the ratios are of no particularsignificance.

In one embodiment of this approach, the bispecific antibodies arecomposed of a hybrid immunoglobulin heavy chain with a first bindingspecificity in one arm, and a hybrid immunoglobulin heavy chain-lightchain pair (providing a second binding specificity) in the other arm. Itwas found that this asymmetric structure facilitates the separation ofthe desired bispecific compound from unwanted immunoglobulin chaincombinations, as the presence of an immunoglobulin light chain in onlyone half of the bispecific molecule provides for a facile way ofseparation. This approach is disclosed in WO 94/04690. For furtherdetails of generating bispecific antibodies see, for example, Suresh etal., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO96/27011, the interfacebetween a pair of antibody molecules can be engineered to maximize thepercentage of heterodimers which are recovered from recombinant cellculture. One interface comprises at least a part of the C_(H)3 domain ofan antibody constant domain. In this method, one or more small aminoacid side chains from the interface of the first antibody molecule arereplaced with larger side chains (e.g. tyrosine or tryptophan).Compensatory “cavities” of identical or similar size to the large sidechain(s) are created on the interface of the second antibody molecule byreplacing large amino acid side chains with smaller ones (e.g. alanineor threonine). This provides a mechanism for increasing the yield of theheterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or “heteroconjugate”antibodies. For example, one of the antibodies in the heteroconjugatecan be coupled to avidin, the other to biotin. Such antibodies have, forexample, been proposed to target immune system cells to unwanted cells(U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may bemade using any convenient cross-linking methods. Suitable cross-linkingagents are well known in the art, and are disclosed in U.S. Pat. No.4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragmentshave also been described in the literature. For example, bispecificantibodies can be prepared using chemical linkage. Brennan et al.,Science, 229: 81 (1985) describe a procedure wherein intact antibodiesare proteolytically cleaved to generate F(ab′)₂ fragments. Thesefragments are reduced in the presence of the dithiol complexing agentsodium arsenite to stabilize vicinal dithiols and prevent intermoleculardisulfide formation. The Fab′ fragments generated are then converted tothionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives isthen reconverted to the Fab′-thiol by reduction with mercaptoethylamineand is mixed with an equimolar amount of the other Fab′-TNB derivativeto form the bispecific antibody. The bispecific antibodies produced canbe used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab′-SH fragmentsfrom E. coli, which can be chemically coupled to form bispecificantibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describethe production of a fully humanized bispecific antibody F(ab′)₂molecule. Each Fab′ fragment was separately secreted from E. coli andsubjected to directed chemical coupling in vitro to form the bispecificantibody.

Various techniques for making and isolating bispecific antibodyfragments directly from recombinant cell culture have also beendescribed. For example, bispecific antibodies have been produced usingleucine zippers. Kostelny et al., J. Immunol., 148(5):1547-1553 (1992).The leucine zipper peptides from the Fos and Jun proteins were linked tothe Fab′ portions of two different antibodies by gene fusion. Theantibody homodimers were reduced at the hinge region to form monomersand then re-oxidized to form the antibody heterodimers. This method canalso be utilized for the production of antibody homodimers. The“diabody” technology described by Hollinger et al., Proc. Natl. Acad.Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism formaking bispecific antibody fragments. The fragments comprise aheavy-chain variable domain (V_(H)) connected to a light-chain variabledomain (V_(L)) by a linker which is too short to allow pairing betweenthe two domains on the same chain. Accordingly, the V_(H) and V_(L)domains of one fragment are forced to pair with the complementary V_(L)and V_(H) domains of another fragment, thereby forming twoantigen-binding sites. Another strategy for making bispecific antibodyfragments by the use of single-chain Fv (sFv) dimers has also beenreported. See Gruber et al, J. Immunol, 152:5368 (1994).

Another technique for making bispecific antibody fragments is the“bispecific T cell engager” or BiTE® approach (see, e.g., WO2004/106381,WO2005/061547, WO2007/042261, and WO2008/119567). This approach utilizestwo antibody variable domains arranged on a single polypeptide. Forexample, a single polypeptide chain includes two single chain Fv (scFv)fragments, each having a variable heavy chain (V_(H)) and a variablelight chain (V_(L)) domain separated by a polypeptide linker of a lengthsufficient to allow intramolecular association between the two domains.This single polypeptide further includes a polypeptide spacer sequencebetween the two scFv fragments. Each scFv recognizes a differentepitope, and these epitopes may be specific for different cell types,such that cells of two different cell types are brought into closeproximity or tethered when each scFv is engaged with its cognateepitope. One particular embodiment of this approach includes a scFvrecognizing a cell-surface antigen expressed by an immune cell, e.g., aCD3 polypeptide on a T cell, linked to another scFv that recognizes acell-surface antigen expressed by a target cell, such as a malignant ortumor cell.

As it is a single polypeptide, the bispecific T cell engager may beexpressed using any prokaryotic cell expression system known in the art.However, specific purification techniques (see, e.g., EP1691833) may benecessary to separate monomeric bispecific T cell engagers from othermultimeric species, which may have biological activities other than theintended activity of the monomer. In one exemplary purification scheme,a solution containing secreted polypeptides is first subjected to ametal affinity chromatography, and polypeptides are eluted with agradient of imidazole concentrations. This eluate is further purifiedusing anion exchange chromatography, and polypeptides are eluted usingwith a gradient of sodium chloride concentrations. Finally, this eluateis subjected to size exclusion chromatography to separate monomers frommultimeric species.

Antibodies with more than two valencies are contemplated. For example,trispecific antibodies can be prepared. Tuft et al. J. Immunol. 147: 60(1991).

In some embodiments, the two chain protein is a part of a multispecificantibody or a bispecific antibody. A multispecific antibody or abispecific antibody may contain two or more monovalent antibodies of thepresent disclosure.

In some embodiments, the first antigen binding domain of the bispecificantibody comprises one or more heavy chain constant domains, wherein theone or more heavy chain constant domains are selected from a first CH1(CH1₁) domain, a first CH2 (CH2₁) domain, a first CH3 (CH3₁) domain; andthe second antigen binding domain of the bispecific antibody comprisesone or more heavy chain constant domains, wherein the one or more heavychain constant domains are selected from a second CH1 (CH1₂) domain,second CH2 (CH2₂) domain, and a second CH3 (CH3₂) domain. In someembodiments, at least one of the one or more heavy chain constantdomains of the first antigen binding domain is paired with another heavychain constant domain of the second antigen binding domain. In someembodiments, the CH3₁ and CH3₂ domains each comprise a protuberance orcavity, and wherein the protuberance or cavity in the CH3₁ domain ispositionable in the cavity or protuberance, respectively, in the CH3₂domain. In some embodiments, the CH3₁ and CH3₂ domains meet at aninterface between said protuberance and cavity. Exemplary sets of aminoacid substitutions in CH3₁ and CH3₂ domains are shown in Table 2 herein.In some embodiments, the CH2₁ and CH2₂ domains each comprise aprotuberance or cavity, and wherein the protuberance or cavity in theCH2₁ domain is positionable in the cavity or protuberance, respectively,in the CH2₂ domain. In some embodiments, the CH2₁ and CH2₂ domains meetat an interface between said protuberance and cavity. In someembodiments, the CH3₁ and/or CH3₂ domain of an IgG contain one or moreamino acid substitutions at residues selected from the group consistingof 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 398, 399, 405, 407,and 409 according to the amino acid numbering as shown in FIG. 5 of theU.S. Pat. No. 8,216,805. In some embodiments, the protuberance comprisesone or more introduced residues selected from the group consisting ofarginine (R) residue, phenylalanine (F) residue, tyrosine (Y) residue,and tryptophan (W) residue. In some embodiments, the cavity comprisesone or more introduced residues selected from the group consisting ofalanine (A) residue, serine (S) residue, threonine (T) residue, andvaline (V) residue. In some embodiments, the CH3 and/or CH2 domains arefrom an IgG (e.g., IgG1 subtype, IgG2 subtype, IgG2A subtype, IgG2Bsubtype, IgG3, subtype, or IgG4 subtype). In some embodiments, one CH3domain of the bispecific antibody comprises amino acid substitutionT366Y, and the other CH3 domain comprises amino acid substitution Y407T.In some embodiments, one CH3 domain comprises amino acid substitutionT366W, and the other CH3 domain comprises amino acid substitution Y407A.In some embodiments, one CH3 domain comprises amino acid substitutionF405A, and the other CH3 domain comprises amino acid substitution T394W.In some embodiments, one CH3 domain comprises amino acid substitutionsT366Y and F405A, and the other CH3 domain comprises amino acidsubstitutions T394W and Y407T. In some embodiments, one CH3 domaincomprises amino acid substitutions T366W and F405W, and the other CH3domain comprises amino acid substitutions T394S and Y407A. In someembodiments, one CH3 domain comprises amino acid substitutions F405W andY407A, and the other CH3 domain comprises amino acid substitutions T366Wand T394S. In some embodiments, one CH3 domain comprises amino acidsubstitution F405W, and the other CH3 domain comprises amino acidsubstitution T394S. The mutations are denoted by the original residue,followed by the position using the Kabat numbering system, and then theimport residues. See also numbering in FIG. 5 of U.S. Pat. No.8,216,805.

(vii) Single-Domain Antibodies

In some embodiments, an antibody of the disclosure is a single-domainantibody. A single-domain antibody is a single polypeptide chaincomprising all or a portion of the heavy chain variable domain or all ora portion of the light chain variable domain of an antibody. In certainembodiments, a single-domain antibody is a human single-domain antibody(Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 B1).In one embodiment, a single-domain antibody consists of all or a portionof the heavy chain variable domain of an antibody.

(viii) Antibody Variants

In some embodiments, amino acid sequence modification(s) of theantibodies described herein are contemplated. For example, it may bedesirable to improve the binding affinity and/or other biologicalproperties of the antibody. Amino acid sequence variants of the antibodymay be prepared by introducing appropriate changes into the nucleotidesequence encoding the antibody, or by peptide synthesis. Suchmodifications include, for example, deletions from, and/or insertionsinto and/or substitutions of, residues within the amino acid sequencesof the antibody. Any combination of deletion, insertion, andsubstitution can be made to arrive at the final construct, provided thatthe final construct possesses the desired characteristics. The aminoacid alterations may be introduced in the subject antibody amino acidsequence at the time that sequence is made.

(ix) Substitution, Insertion, and Deletion Variants

In certain embodiments, antibody variants having one or more amino acidsubstitutions are provided. Sites of interest for substitutionalmutagenesis include the HVRs and FRs. Conservative substitutions areshown in Table 1 under the heading of “conservative substitutions.” Moresubstantial changes are provided in Table 1 under the heading of“exemplary substitutions,” and as further described below in referenceto amino acid side chain classes. Amino acid substitutions may beintroduced into an antibody of interest and the products screened for adesired activity, e.g., retained/improved antigen binding, decreasedimmunogenicity, or improved ADCC or CDC.

TABLE 3 Exemplary Substitutions. Original Preferred Residue ExemplarySubstitutions Substitutions Ala (A) Val; Leu; Ile Val Arg (R) Lys; Gln;Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C)Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala AlaHis (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Ala; Phe;Norleucine Leu Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile Lys (K)Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Leu; Val; Ile;Ala; Tyr Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Ser Trp(W) Tyr; Phe Tyr Tyr (Y) Trp; Phe; Thr; Ser Phe Val (V) Ile; Leu; Met;Phe; Ala; Norleucine Leu

Amino acids may be grouped according to common side-chain properties:

a. hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;

b. neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

c. acidic: Asp, Glu;

d. basic: His, Lys, Arg;

e. residues that influence chain orientation: Gly, Pro;

f. aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one ofthese classes for another class.

One type of substitutional variant involves substituting one or morehypervariable region residues of a parent antibody (e.g. a humanized orhuman antibody). Generally, the resulting variant(s) selected forfurther study will have modifications (e.g., improvements) in certainbiological properties (e.g., increased affinity, reduced immunogenicity)relative to the parent antibody and/or will have substantially retainedcertain biological properties of the parent antibody. An exemplarysubstitutional variant is an affinity matured antibody, which may beconveniently generated, e.g., using phage display-based affinitymaturation techniques such as those described herein. Briefly, one ormore HVR residues are mutated and the variant antibodies displayed onphage and screened for a particular biological activity (e.g. bindingaffinity).

Alterations (e.g., substitutions) may be made in HVRs, e.g., to improveantibody affinity. Such alterations may be made in HVR “hotspots,” i.e.,residues encoded by codons that undergo mutation at high frequencyduring the somatic maturation process (see, e.g., Chowdhury, MethodsMol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resultingvariant VH or VL being tested for binding affinity. Affinity maturationby constructing and reselecting from secondary libraries has beendescribed, e.g., in Hoogenboom et al. in Methods in Molecular Biology178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., (2001).) Insome embodiments of affinity maturation, diversity is introduced intothe variable genes chosen for maturation by any of a variety of methods(e.g., error-prone PCR, chain shuffling, or oligonucleotide-directedmutagenesis). A secondary library is then created. The library is thenscreened to identify any antibody variants with the desired affinity.Another method to introduce diversity involves HVR-directed approaches,in which several HVR residues (e.g., 4-6 residues at a time) arerandomized. HVR residues involved in antigen binding may be specificallyidentified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3and CDR-L3 in particular are often targeted.

In certain embodiments, substitutions, insertions, or deletions mayoccur within one or more HVRs so long as such alterations do notsubstantially reduce the ability of the antibody to bind antigen. Forexample, conservative alterations (e.g., conservative substitutions asprovided herein) that do not substantially reduce binding affinity maybe made in HVRs. Such alterations may be outside of HVR “hotspots” orSDRs. In certain embodiments of the variant VH and VL sequences providedabove, each HVR either is unaltered, or contains no more than one, twoor three amino acid substitutions.

A useful method for identification of residues or regions of an antibodythat may be targeted for mutagenesis is called “alanine scanningmutagenesis” as described by Cunningham and Wells (1989) Science,244:1081-1085. In this method, a residue or group of target residues(e.g., charged residues such as arg, asp, his, lys, and glu) areidentified and replaced by a neutral or negatively charged amino acid(e.g., alanine or polyalanine) to determine whether the interaction ofthe antibody with antigen is affected. Further substitutions may beintroduced at the amino acid locations demonstrating functionalsensitivity to the initial substitutions. Alternatively, oradditionally, a crystal structure of an antigen-antibody complex toidentify contact points between the antibody and antigen. Such contactresidues and neighboring residues may be targeted or eliminated ascandidates for substitution. Variants may be screened to determinewhether they contain the desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminalfusions ranging in length from one residue to polypeptides containing ahundred or more residues, as well as intrasequence insertions of singleor multiple amino acid residues. Examples of terminal insertions includean antibody with an N-terminal methionyl residue. Other insertionalvariants of the antibody molecule include the fusion to the N- orC-terminus of the antibody to an enzyme (e.g., for ADEPT) or apolypeptide which increases the serum half-life of the antibody.

(x) Fc Region Variants

In certain embodiments, one or more amino acid modifications may beintroduced into the Fc region of an antibody provided herein, therebygenerating an Fc region variant. The Fc region variant may comprise ahuman Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fcregion) comprising an amino acid modification (e.g. a substitution) atone or more amino acid positions.

In certain embodiments, the disclosure contemplates an antibody variantthat possesses some but not all effector functions, which make it adesirable candidate for applications in which the half life of theantibody in vivo is important yet certain effector functions (such ascomplement and ADCC) are unnecessary or deleterious. In vitro and/or invivo cytotoxicity assays can be conducted to confirm thereduction/depletion of CDC and/or ADCC activities. For example, Fcreceptor (FcR) binding assays can be conducted to ensure that theantibody lacks FcγR binding (hence likely lacking ADCC activity), butretains FcRn binding ability. The primary cells for mediating ADCC, NKcells, express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII andFc(RIII. FcR expression on hematopoietic cells is summarized in Table 3on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991).Non-limiting examples of in vitro assays to assess ADCC activity of amolecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g.Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) andHellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985);U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med.166:1351-1361 (1987)). Alternatively, non-radioactive assays methods maybe employed (see, for example, ACTI™ non-radioactive cytotoxicity assayfor flow cytometry (CellTechnology, Inc. Mountain View, Calif.; andCytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.).Useful effector cells for such assays include peripheral bloodmononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively,or additionally, ADCC activity of the molecule of interest may beassessed in vivo, e.g., in an animal model such as that disclosed inClynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). C1q bindingassays may also be carried out to confirm that the antibody is unable tobind C1q and hence lacks CDC activity. See, e.g., C1q and C3c bindingELISA in WO 2006/029879 and WO 2005/100402. To assess complementactivation, a CDC assay may be performed (see, for example,Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, M. S.et al., Blood 101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie,Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance/halflife determinations can also be performed using methods known in the art(see, e.g., Petkova, S. B. et al., Int'l. Immunol. 18(12):1759-1769(2006)).

Antibodies with reduced effector function include those withsubstitution of one or more of Fc region residues 238, 265, 269, 270,297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fcmutants with substitutions at two or more of amino acid positions 265,269, 270, 297 and 327, including the so-called “DANA” Fc mutant withsubstitution of residues 265 and 297 to alanine (U.S. Pat. No.7,332,581).

Certain antibody variants with improved or diminished binding to FcRsare described. (See, e.g., U.S. Pat. No. 6,737,056; WO 2004/056312, andShields et al., J. Biol. Chem. 9(2): 6591-6604 (2001).)

In certain embodiments, an antibody variant comprises an Fc region withone or more amino acid substitutions which improve ADCC, e.g.,substitutions at positions 298, 333, and/or 334 of the Fc region (EUnumbering of residues). In an exemplary embodiment, the antibodycomprising the following amino acid substitutions in its Fc region:S298A, E333A, and K334A.

In some embodiments, alterations are made in the Fc region that resultin altered (i.e., either improved or diminished) C1q binding and/orComplement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat.No. 6,194,551, WO 99/51642, and Idusogie et al. J. Immunol. 164:4178-4184 (2000).

Antibodies with increased half lives and improved binding to theneonatal Fc receptor (FcRn), which is responsible for the transfer ofmaternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) andKim et al., J. Immunol. 24:249 (1994)), are described inUS2005/0014934A1 (Hinton et al.)). Those antibodies comprise an Fcregion with one or more substitutions therein which improve binding ofthe Fc region to FcRn. Such Fc variants include those with substitutionsat one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305,307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or434, e.g., substitution of Fc region residue 434 (U.S. Pat. No.7,371,826). See also Duncan & Winter, Nature 322:738-40 (1988); U.S.Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94/29351 concerningother examples of Fc region variants.

(xi) Antibody Derivatives

The antibodies of the disclosure can be further modified to containadditional nonproteinaceous moieties that are known in the art andreadily available. In certain embodiments, the moieties suitable forderivatization of the antibody are water soluble polymers. Non-limitingexamples of water soluble polymers include, but are not limited to,polyethylene glycol (PEG), copolymers of ethylene glycol/propyleneglycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleicanhydride copolymer, polyaminoacids (either homopolymers or randomcopolymers), and dextran or poly(n-vinyl pyrrolidone)polyethyleneglycol, propropylene glycol homopolymers, prolypropylene oxide/ethyleneoxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinylalcohol, and mixtures thereof. Polyethylene glycol propionaldehyde mayhave advantages in manufacturing due to its stability in water. Thepolymer may be of any molecular weight, and may be branched orunbranched. The number of polymers attached to the antibody may vary,and if more than one polymer are attached, they can be the same ordifferent molecules. In general, the number and/or type of polymers usedfor derivatization can be determined based on considerations including,but not limited to, the particular properties or functions of theantibody to be improved, whether the antibody derivative will be used ina therapy under defined conditions, etc.

(xii) Vectors, Host Cells, and Recombinant Methods

Antibodies may also be produced using recombinant methods. Forrecombinant production of an anti-antigen antibody, nucleic acidencoding the antibody is isolated and inserted into a replicable vectorfor further cloning (amplification of the DNA) or for expression. DNAencoding the antibody may be readily isolated and sequenced usingconventional procedures (e.g., by using oligonucleotide probes that arecapable of binding specifically to genes encoding the heavy and lightchains of the antibody). Many vectors are available. The vectorcomponents generally include, but are not limited to, one or more of thefollowing: a signal sequence, an origin of replication, one or moremarker genes, an enhancer element, a promoter, and a transcriptiontermination sequence.

(a) Signal Sequence Component

An antibody of the disclosure may be produced recombinantly not onlydirectly, but also as a fusion polypeptide with a heterologouspolypeptide, which is preferably a signal sequence or other polypeptidehaving a specific cleavage site at the N-terminus of the mature proteinor polypeptide. The heterologous signal sequence selected preferably isone that is recognized and processed (e.g., cleaved by a signalpeptidase) by the host cell. For prokaryotic host cells that do notrecognize and process a native antibody signal sequence, the signalsequence is substituted by a prokaryotic signal sequence selected, forexample, from the group of the alkaline phosphatase, penicillinase, lpp,or heat-stable enterotoxin II leaders.

(b) Origin of Replication

Both expression and cloning vectors contain a nucleic acid sequence thatenables the vector to replicate in one or more selected host cells.Generally, in cloning vectors this sequence is one that enables thevector to replicate independently of the host chromosomal DNA, andincludes origins of replication or autonomously replicating sequences.Such sequences are well known for a variety of prokaryotic host cells.For example, the origin of replication from the plasmid pBR322 issuitable for most Gram-negative bacteria.

(c) Selection Gene Component

Expression and cloning vectors may contain a selection gene, also termeda selectable marker. Typical selection genes encode proteins that (a)confer resistance to antibiotics or other toxins, e.g., ampicillin,neomycin, methotrexate, or tetracycline, (b) complement auxotrophicdeficiencies, or (c) supply critical nutrients not available fromcomplex media, e.g., the gene encoding D-alanine racemase for Bacilli.

One example of a selection scheme utilizes a drug to arrest growth of ahost cell. Those cells that are successfully transformed with aheterologous gene produce a protein conferring drug resistance and thussurvive the selection regimen. Examples of such dominant selection usethe drugs neomycin, mycophenolic acid and hygromycin.

Another selection scheme uses a prokaryotic host cell with a chromosomaldeletion removing a gene whose gene product is essential for growth in aparticular culture medium. In these examples, those cells that aresuccessfully transformed with a heterologous gene that complements thechromosomal deletion of the host cell will survive when grown in theparticular culture medium. Examples of genes useful in this schemes mayinclude auxotrophic marker genes or other genes that are required togenerate an essential nutrient when the host cell is grown in aparticular culture medium.

(d) Promoter Component

Expression and cloning vectors generally contain a promoter that isrecognized by the host organism and is operably linked to nucleic acidencoding an antibody. Promoters suitable for use with prokaryotic hostsinclude the phoA promoter, β-lactamase and lactose promoter systems,alkaline phosphatase promoter, a tryptophan (trp) promoter system, andhybrid promoters such as the tac promoter. However, other knownbacterial promoters are suitable. Promoters for use in bacterial systemsalso will contain a Shine-Dalgarno (S.D.) sequence operably linked tothe DNA encoding an antibody.

(e) Translation Initiation Region Component

As described above, translational initiation regions (TIRs) are known tobe important for translation of recombinant proteins in prokaryotic hostcells (see, e.g., Simmons L C and Yansura D G 1996 Nat. Biotechnol.14:629 and Vimberg V et al. 2007 BMC Mol. Biol. 8:100). A TIR maydetermine the efficiency of translation of a translational unit. A TIRtypically includes translational unit features such as the initiationcodon, Shine-Dalgarno (SD) sequence, and translational enhancers. A TIRmay further include a secretion signal sequence that encodes a signalpeptide. The sequence and spacing between features of a TIR may regulatetranslational initiation efficiency. For further descriptions of theuses of TIRs in protein production, see, e.g., U.S. Pat. No. 5,840,523(Simmons et al.), which describes translation initiation region (TIR)and signal sequences for optimizing expression and secretion.

(f) Transcription Termination Component

Expression vectors used in prokaryotic host cells may also containsequences necessary for the termination of transcription and forstabilizing the mRNA. In prokaryotic cells, terminators may includeRho-dependent or Rho-independent terminators. One example of aterminator useful in prokaryotic host cells includes without limitationthe λt0 terminator (Scholtissek and Grosse, Nucleic Acids Res. 15:3185,1987).

III. PROCESS OPTIMIZATION

Provided herein are methods of producing a polypeptide containing twochains in a prokaryotic host cell by culturing the host cell to expressthe two chains of the polypeptide, where upon expression the two chainsfold and assemble to form a biologically active polypeptide in the hostcell, wherein the host cell is cultured in a culture medium underconditions including: a growth phase including a growth temperature anda growth agitation rate, and a production phase including a productiontemperature and a production agitation rate, where the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate. It is a surprising discovery of the present disclosurethat certain production process optimizations have a dramatic increasein the yield of two chain proteins, as demonstrated by the datadescribed herein.

(g) Selection and Transformation of Host Cells

Certain aspects of the present disclosure relate to prokaryotic hostcells. Suitable prokaryotes for cloning or expressing the DNA in thevectors herein include eubacteria, such as Gram-negative orGram-positive organisms, for example, Enterobacteriaceae such asEscherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus,Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratiamarcescans, and Shigella, as well as Bacilli such as B. subtilis and B.licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710published 12 Apr. 1989), Pseudomonas such as P. aeruginosa, andStreptomyces. One preferred E. coli cloning host is E. coli 294 (ATCC31,446), although other strains such as E. coli B, E. coli X1776 (ATCC31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examplesare illustrative rather than limiting.

In some embodiments, the prokaryotic host cell is a gram-negativebacterium. Gram-negative bacterium refers to any bacterium that containsan outer membrane surrounding the peptidoglycan layer detected by Gramstaining. Many gram-negative bacterial host cells are known in the art.For example, gram-negative bacteria are known to include withoutlimitation proteobacteria, such as Alphaproteobacteria,Betaproteobacteria, Gammaproteobacteria, Zetaproteobacteria,Epsilonproteobacteria, Deltaproteobacteria, and Acidobacteria;cyanobacteria; and spirochaetes. Well known gram-negative bacteria mayinclude species from genera such as Eschericia, Salmonella, Shigella,Pseudomonas, Heliobacter, Legionella, Neisseria, and Klebsiella.

In some embodiments, a gram-negative bacterium of the present disclosureis E. coli. As used herein, E. coli may refer to any strain or isolateof bacteria belonging to the species E. coli. E. coli may includenaturally occurring strains or strains that have been geneticallymodified, such as by mutation or transformation with a plasmid asdescribed herein.

In some embodiments, an E. coli of the present disclosure is of a straindeficient in endogenous protease activity. Without wishing to be boundto theory, it is thought that strains deficient in endogenous proteaseactivity may allow for enhanced production of recombinant proteins, suchas periplasmic proteins of the present disclosure, because someendogenous proteases have activity against recombinantly expressedsubstrates (see Baneyx F and Georgiu G 1990 J. Bacteriol. 172(1):491 forone such example). Strains deficient in endogenous protease activity mayinclude strains in which a gene encoding an endogenous protease ismutated, deleted, or otherwise inactivated. Examples of such genes mayinclude, without limitation, degP, prc, and ompT. Methods forintroducing mutations in a wide variety of prokaryotic host cells (e.g.,for engineering strains deficient in endogenous protease activity) arewell known in the art; see, e.g., Snyder L et al. 2013 MolecularGenetics of Bacteria 4^(th) ed. ASM Press).

Two chain proteins such as full length antibody, antibody fusionproteins, and antibody fragments can be produced in bacteria, inparticular when glycosylation and Fc effector function are not needed,such as when the therapeutic antibody is conjugated to a cytotoxic agent(e.g., a toxin) that by itself shows effectiveness in tumor celldestruction. Full length antibodies have greater half-life incirculation. Production in E. coli is faster and more cost efficient.For expression of antibody fragments and polypeptides in bacteria, see,e.g., U.S. Pat. No. 5,648,237 (Carter et. al.), U.S. Pat. No. 5,789,199(Joly et al.), U.S. Pat. No. 5,840,523 (Simmons et al.), which describestranslation initiation region (TIR) and signal sequences for optimizingexpression and secretion. See also Charlton, Methods in MolecularBiology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N. J., 2003),pp. 245-254, describing expression of antibody fragments in E. coli.After expression, the antibody may be isolated from the E. coli cellpaste in a soluble fraction and can be purified through, e.g., a proteinA or G column depending on the isotype. Final purification can becarried out similar to the process for purifying antibody expressede.g., in CHO cells.

Host cells are transformed with the above-described expression orcloning vectors for two chain protein production and cultured inconventional nutrient media modified as appropriate for inducingpromoters, selecting transformants, or amplifying the genes encoding thedesired sequences.

(h) Culturing the Host Cells

Certain aspects of the present disclosure relate to culturing a hostcell in a culture medium under conditions including a growth phase and aproduction phase. Each of these phases may further refer to conditionsunder which the host cell is grown during the particular phase. Forexample, as used herein, a growth phase may include a growth temperatureand a growth agitation rate, and a production phase may include aproduction temperature and a production agitation rate.

A growth phase may refer to any time during which a culture of hostcells is exponentially growing. Growth temperature as used herein mayrefer to the temperature of a culture medium containing a host cell ofthe present disclosure during a growth phase of the host cell. A growthphase of a host cell culture may be determined by methods commonly knownin the art, e.g., by measuring the optical density of the culture (e.g.,at a wavelength of about 550 nm, about 600 nm, or a wavelength inbetween) over time and determining at what time the exponential growthphase ceases. If a host cell contains a vector with a pho promoter, agrowth phase may refer to any time during which a culture of host cellsis exponentially growing and the concentration of phosphate in theculture medium is sufficient to prevent the induction of phopromoter-mediated gene transcription.

A production phase may refer to any time during which a culture of hostcells is producing a product. Production temperature as used herein mayrefer to the temperature of a culture medium containing a host cell ofthe present disclosure during a production phase of the host cell. If ahost cell contains a vector with a pho promoter driving expression of aproduct, a production phase may refer to any time during which theconcentration of phosphate in the culture medium is sufficiently low toinduce pho promoter-mediated product gene transcription.

In some embodiments, a host cell of the present disclosure is culturedat a growth temperature from 2° C. to 10° C. above the productiontemperature. In some embodiments, a host cell of the present disclosureis cultured at a growth temperature 2° C., 3° C., 4° C., 5° C., 6° C.,7° C., 8° C., 9° C., or 10° C. above the production temperature. In someembodiments, the growth temperature is above the production temperatureby less than about any of the following amounts (in ° C.): 10, 9.5, 9,8.5, 8, 7.5, 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, or 2.5. In someembodiments, the growth temperature is above the production temperatureby greater than about any of the following amounts (in ° C.): 2, 2.5, 3,3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, or 9.5. That is, thegrowth temperature is above the production temperature by any of a rangeof amounts (in ° C.) having an upper limit of 10, 9.5, 9, 8.5, 8, 7.5,7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, or 2.5 and an independently selectedlower limit of 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5,9, or 9.5, wherein the lower limit is less than the upper limit.

In some embodiments, the growth temperature is in the range of about 30°C. to about 34° C. during the growth phase. In some embodiments, thegrowth temperature is about 30° C., about 30.5° C., about 31° C., about31.5° C., about 32° C., about 32.5° C., about 33° C., about 33.5° C., orabout 34° C. during the growth phase. In some embodiments, the growthtemperature during the growth phase is less than about any of thefollowing temperatures (in ° C.): 34, 33.5, 33, 32.5, 32, 31.5, 31, or30.5. In some embodiments, the growth temperature during the growthphase is greater than about any of the following temperatures (in ° C.):30, 30.5, 31, 31.5, 32, 32.5, 33, or 33.5. That is, the growthtemperature during the growth phase can be any of a range oftemperatures (in ° C.) having an upper limit of 34, 33.5, 33, 32.5, 32,31.5, 31, or 30.5 and an independently selected lower limit of 30, 30.5,31, 31.5, 32, 32.5, 33, or 33.5, wherein the lower limit is less thanthe upper limit.

In some embodiments, the production temperature is in the range of about25° C. to about 29° C. during the production phase. In some embodiments,the production temperature is about 25° C., about 25.5° C., about 26°C., about 26.5° C., about 27° C., about 27.5° C., about 28° C., about28.5° C., or about 29° C. during the production phase. In someembodiments, the production temperature during the production phase isless than about any of the following temperatures (in ° C.): 29, 28.5,28, 27.5, 27, 26.5, 26, or 25.5. In some embodiments, the productiontemperature during the production phase is greater than about any of thefollowing temperatures (in ° C.): 25, 25.5, 26, 26.5, 27, 27.5, 28, or28.5. That is, the production temperature during the production phasecan be any of a range of temperatures (in ° C.) having an upper limit of29, 28.5, 28, 27.5, 27, 26.5, 26, or 25.5 and an independently selectedlower limit of 25, 25.5, 26, 26.5, 27, 27.5, 28, or 28.5, wherein thelower limit is less than the upper limit.

An agitation rate refers to the rate at which a cell culture is agitated(e.g., by shaking). Growth agitation rate as used herein may refer tothe rate at which a culture containing a host cell of the presentdisclosure is agitated during a growth phase of the host cell.Production agitation rate as used herein may refer to the rate at whicha culture containing a host cell of the present disclosure is agitatedduring a production phase of the host cell. Cell cultures may beagitated to maintain aeration of the cell culture.

In some embodiments, a host cell of the present disclosure is culturedat a growth agitation rate from 50 to 250 rpm above the productionagitation rate. In some embodiments, a host cell of the presentdisclosure is cultured at a growth agitation rate of 50 rpm, 75 rpm, 100rpm, 125 rpm, 150 rpm, 175 rpm, 200 rpm, 225 rpm, or 250 rpm above theproduction agitation rate. In some embodiments, the growth agitationrate is above the production agitation rate by less than about any ofthe following rates (in rpm): 250, 225, 200, 175, 150, 125, 100, or 75.In some embodiments, the growth agitation rate is below the productionagitation rate by greater than about any of the following rates (inrpm): 50, 75, 100, 125, 150, 175, 200, or 225. That is, the growthagitation rate is above the production agitation rate by any of a rangeof rates (in rpm) having an upper limit of 250, 225, 200, 175, 150, 125,100, or 75 and an independently selected lower limit of 50, 75, 100,125, 150, 175, 200, or 225, wherein the lower limit is less than theupper limit.

In some embodiments, the growth agitation rate is in the range of about600 to 800 rpm during the growth phase. In some embodiments, the growthagitation rate is about 600 rpm, about 625 rpm, about 650 rpm, about 675rpm, about 700 rpm, about 725 rpm, about 750 rpm, about 775 rpm, orabout 800 rpm during the growth phase. In some embodiments, the growthagitation rate is less than about any of the following rates (in rpm):800, 775, 750, 725, 700, 675, 650, or 625. In some embodiments, thegrowth agitation rate is greater than about any of the following rates(in rpm): 600, 625, 650, 675, 700, 725, 750, or 775 during the growthphase. That is, the growth agitation rate during the growth phase is anyof a range of rates (in rpm) having an upper limit of 800, 775, 750,725, 700, 675, 650, or 625 and an independently selected lower limit of600, 625, 650, 675, 700, 725, 750, or 775, wherein the lower limit isless than the upper limit.

In some embodiments, the production agitation rate is in the range ofabout 300 to 500 rpm during the production phase. In some embodiments,the production agitation rate during the production phase is about 300rpm, about 325 rpm, about 350 rpm, about 375 rpm, about 400 rpm, about425 rpm, about 450 rpm, about 475 rpm, or about 500 rpm. In someembodiments, the production agitation rate during the production phaseis less than about any of the following rates (in rpm): 500, 475, 450,425, 400, 375, 350, or 325. In some embodiments, the productionagitation rate during the production phase is greater than about any ofthe following rates (in rpm): 300, 325, 350, 375, 400, 425, 450, or 475.That is, the production agitation rate during the production phase isany of a range of rates (in rpm) having an upper limit of 500, 475, 450,425, 400, 375, 350, or 325 and an independently selected lower limit of300, 325, 350, 375, 400, 425, 450, or 475, wherein the lower limit isless than the upper limit.

Without wishing to be bound to theory, it is thought that when oxygenconcentration is limited, the oxygen transfer rate (OTR) is equal to theoxygen uptake rate (OUR) or metabolic rate of the cells. Manipulation ofthe OTR may be facilitated by adjusting the agitation rate, thusmanipulating the OUR. More detailed description of OUR and itsrelationship to OTR may be found in Ochoa-Garcia et al., Biotechnol.Adv. 27:153, 2009. Techniques for measuring the OUR of a cell cultureare known in the art and include, without limitation, using a massspectrometer to monitor the composition of the off-gas from the cellculture and calculating the oxygen uptake and carbon dioxide evolutionrates of the cell culture.

In some embodiments, a host cell of the present disclosure is culturedat a growth agitation rate sufficient to achieve an oxygen uptake ratein the host cell during the growth phase of from 0.5 to 2.5 mmol/L/minabove a peak oxygen uptake rate in the host cell during the productionphase. It is a discovery of the present disclosure that decreasing theagitation rate of a cell culture during the production phase to a ratesufficient to achieve an oxygen uptake rate in the host cell less thanabout 2.5 mmol/L/min as compared to the growth phase greatly enhancesthe production of a product, such as a two chain polypeptide of thepresent disclosure.

In some embodiments, a host cell of the present disclosure is culturedat a growth agitation rate sufficient to achieve an oxygen uptake ratein the host cell during the growth phase of 0.5 mmol/L/min, 1.0mmol/L/min, 1.5 mmol/L/min, 2.0 mmol/L/min, or 2.5 mmol/L/min above apeak oxygen uptake rate in the host cell during the production phase. Insome embodiments, a host cell of the present disclosure is cultured at agrowth agitation rate sufficient to achieve an oxygen uptake rate in thehost cell during the growth phase of less than about any of thefollowing oxygen uptake rates (in mmol/L/min) above a peak oxygen uptakerate in the host cell during the production phase: 2.5, 2.0, 1.5, or1.0. In some embodiments, a host cell of the present disclosure iscultured at a growth agitation rate sufficient to achieve an oxygenuptake rate in the host cell during the growth phase of greater thanabout any of the following oxygen uptake rates (in mmol/L/min) above apeak oxygen uptake rate in the host cell during the production phase:0.5, 1.0, 1.5, 2.0, or 2.5. That is, a host cell of the presentdisclosure is cultured at a growth agitation rate sufficient to achievean oxygen uptake rate in the host cell during the growth phase of any ofa range of oxygen uptake rates (in mmol/L/min) having an upper limit of2.5, 2.0, 1.5, or 1.0 and an independently selected lower limit of 0.5,1.0, 1.5, 2.0, or 2.5 above a peak oxygen uptake rate in the host cellduring the production phase, wherein the lower limit is less than theupper limit.

In some embodiments, the peak oxygen uptake rate of the host cell duringthe growth phase is in the range of 3.5 mmol/L/min to 4.5 mmol/L/min. Insome embodiments, the peak oxygen uptake rate of the host cell duringthe growth phase is 3.5 mmol/L/min, 3.75 mmol/L/min, 4.0 mmol/L/min,4.25 mmol/L/min, or 4.5 mmol/L/min. In some embodiments, the oxygenuptake rate of the host cell during the production phase is in the rangeof 1.0 mmol/L/min to 3.0 mmol/L/min. In some embodiments, the oxygenuptake rate of the host cell during the production phase is 1.0mmol/L/min, 1.25 mmol/L/min, 1.5 mmol/L/min, 1.75 mmol/L/min, 2.0mmol/L/min, 2.25 mmol/L/min, 2.5 mmol/L/min, 2.75 mmol/L/min, or 3.0mmol/L/min.

In some embodiments, a host cell of the present disclosure is culturedat a growth agitation rate from about 10% to about 40% (rpm/rpm) higherthan the production agitation rate. In some embodiments, the host cellis cultured at a growth agitation rate that has a lower limit of atleast 10%, 15%, 20%, 25%, 30%, or 35% (rpm/rpm) and an independentlyselected upper limit of no more than 40%, 35%, 30%, 25%, 20%, or 15%(rpm/rpm) of a production agitation rate. In a preferred embodiment, ahost cell of the present disclosure is cultured in a 10 L fermentor at 1bar back pressure and an aeration rate of 20 L/min.

Host cells of the present disclosure may be cultured in a variety ofmedia. “Culture medium” as used herein refers to any composition orbroth that supports the growth of the bacteria of the presentdisclosure. Suitable culture media may be liquid or solid and containany nutrients, salts, buffers, elements, and other compounds thatsupport the growth and viability of cells. Common nutrients of a culturemedium may include sources of nitrogen, carbon, amino acids,carbohydrates, trace elements, vitamins, and minerals. These nutrientsmay be added as individual components (as in a defined culture medium)or as constituents of a complex extract (for example, yeast extract). Aculture medium may be nutrient-rich to support rapid growth or minimalto support slower growth. A culture medium may also contain any agentused to inhibit the growth of or kill contaminating organisms (e.g., anantibiotic). A culture medium may also contain any compound used tocontrol the activity of an inducible promoter or enzyme (as one example,IPTG may be included to induce expression of any polynucleotidescontrolled by a lac operon or functionally similar promoter). Manyexamples of suitable culture media are well known in the art and includewithout limitation M9 medium, Lysogeny Broth (LB), Terrific Broth (TB),NZY broth, SOB medium, and YT broth.

Any of these media may be supplemented as necessary with salts (such assodium chloride, calcium, magnesium, and phosphate), buffers (such asHEPES), nucleotides (such as adenosine and thymidine), antibiotics,antimycotics, trace elements (defined as inorganic compounds usuallypresent at final concentrations in the micromolar range), glucose,and/or an appropriate energy source. Typical ingredients found in aprokaryotic cell culture medium include yeast extract, salts (e.g.,NaCl), tryptone, buffers (e.g., phosphate buffer), glycerol, and soforth. Any other necessary supplements may also be included atappropriate concentrations that would be known to those skilled in theart. The culture conditions, such as temperature, pH, and the like, arethose previously used with the prokaryotic host cell selected forexpression, and will be apparent to the ordinarily skilled artisan.

(i) Purification of Biologically Active Polypeptide

Certain aspects of the present disclosure relate to recovering abiologically active polypeptide from a host cell. Typically recovering(the terms “purifying” or “purification” may be used interchangeablyherein) a biologically active polypeptide of the present disclosureinvolves isolating the polypeptide from the host cell (or cell culturemedium if the polypeptide is excreted into the medium) and purifying thepolypeptide from other associated macromolecules, e.g., cellular debrisand other polypeptides. Numerous techniques for purifying a variety ofproteins from a variety of host cell compartments are known in the art(see, e.g., Evans, Jr., T C and Xu M Q (eds.) Heterologous GeneExpression in E. coli (2011) Methods in Molecular Biology Vol 705,Humana Press). Exemplary techniques are described below, but these areincluded for illustrative purposes only to supplement the understandingof the skilled artisan and are in no way meant to be limiting.

When using recombinant techniques, two chain proteins such as secretoryproteins can be produced intracellularly, in the periplasmic space, ordirectly secreted into the medium. If the secretory protein is producedintracellularly, as a first step, the particulate debris, either hostcells or lysed fragments, are removed, for example, by centrifugation orultrafiltration.

In some embodiments, the secretory protein is recovered from theperiplasm of the host cell. Carter et al., Bio/Technology 10:163-167(1992) describe a procedure for isolating secretory proteins which aresecreted to the periplasmic space of E. coli. Briefly, cell paste isthawed in the presence of sodium acetate (pH 3.5), EDTA, andphenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris canbe removed by centrifugation. Where the secretory protein is secretedinto the medium, supernatants from such expression systems are generallyfirst concentrated using a commercially available protein concentrationfilter, for example, an Amicon or Millipore Pellicon ultrafiltrationunit. A protease inhibitor such as PMSF may be included in any of theforegoing steps to inhibit proteolysis and antibiotics may be includedto prevent the growth of adventitious contaminants.

The secretory protein composition prepared from the cells can bepurified using, for example, hydroxylapatite chromatography, hydrophobicinteraction chromatography, gel electrophoresis, dialysis, and affinitychromatography, with affinity chromatography being among one of thetypically preferred purification steps. With regard to antibodies, thesuitability of protein A as an affinity ligand depends on the speciesand isotype of any immunoglobulin Fc domain that is present in theantibody. Protein A can be used to purify antibodies that are based onhuman γ1, γ2, or γ4 heavy chains (Lindmark et al., J. Immunol. Meth.62:1-13 (1983)). Protein G is recommended for all mouse isotypes and forhuman γ3 (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to whichthe affinity ligand is attached is most often agarose, but othermatrices are available. Mechanically stable matrices such as controlledpore glass or poly(styrenedivinyl)benzene allow for faster flow ratesand shorter processing times than can be achieved with agarose. Wherethe antibody comprises a C_(H)3 domain, the Bakerbond ABX™ resin (J. T.Baker, Phillipsburg, N.J.) is useful for purification. Other techniquesfor protein purification such as fractionation on an ion-exchangecolumn, ethanol precipitation, Reverse Phase HPLC, chromatography onsilica, chromatography on heparin SEPHAROSE™ chromatography on an anionor cation exchange resin (such as a polyaspartic acid column),chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are alsoavailable depending on the antibody to be recovered. One of skill in theart will recognize that many of these techniques useful for antibodyrecovery may readily be applied to recover other two chain proteins,such as secretory proteins.

EXAMPLES

The disclosure will be more fully understood by reference to thefollowing examples. They should not, however, be construed as limitingthe scope of the disclosure. It is understood that the examples andembodiments described herein are for illustrative purposes only and thatvarious modifications or changes in light thereof will be suggested topersons skilled in the art and are to be included within the spirit andpurview of this application and scope of the appended claims.

Abbreviations: Ab (antibody), hAb (half antibody), HC (heavy chain),IPTG (isopropyl β-D-1-thiogalactopyranoside), LC (light chain), OD(optical density), ORF (open reading frame), OTR (oxygen transfer rate),OUR (oxygen uptake rate), Tg (growth temperature), Tp (productiontemperature), TIR (translation initiation region), xIL4(anti-interleukin-4), xIL13 (anti-interleukin-13), xIL17(anti-interleukin-17), and xIL33 (anti-interleukin-33).

Example 1 Effect of Chaperone and Oxidoreductase Levels on Half-AntibodyProduction Titer

The production of heterologous secreted proteins using recombinanttechniques is important for many therapeutic molecules. Multispecificantibodies (e.g., bispecific antibodies) are one non-limiting example ofheterologous secreted proteins with many important therapeutic uses,such as immunotherapy in cancer and other applications. Producingmultispecific antibodies for therapeutic use requires the ability toproduce the building blocks of these antibodies, such as half-antibodies(hAbs), on an industrial scale. To meet this demand, described hereinare optimized expression vectors and process steps that yieldsignificant increases in production over standard methods. Importantly,it was found that a single plasmid or a compatible plasmid system forco-expressing the heavy chain (HC) and light chain (LC) of the hAb incombination with chaperone proteins FkpA, DsbA, and DsbC significantlyenhances production of the assembled hAb. This system was tested andfound to improve the production of multiple hAbs, demonstrating its wideutility for the production of many secreted proteins. Subsequentoptimization of process steps (including, e.g., agitation rate, pH, FkpApromoter, and culture temperature at different phases of culturing)resulted in even further significant increases in product yield.

Materials and Methods

Half-Antibody (hAb) Vector Construction

Vectors were constructed in a similar fashion to those described inEP1356052. In particular, various expression vectors were made for theexpression of hAbs. For each vector, an expression cassette was clonedinto the framework of the E. coli plasmid pBR322 at the EcoRI site(Sutcliffe, Cold Spring Harbor Symp. Quant. Biol. 43:77-90, 1978). Eachexpression cassette contained at least the following components: (1) aphoA promoter for the control of transcription (Kikuchi et al., NucleicAcids Res. 9:5671-5678, 1981); (2) a Shine-Dalgarno sequence from the E.coli trp, the heat stable enterotoxin II (STII) signal sequence, or acombination of both for translation initiation (Chang et al., Gene55:189-196, 1987); and (3) a λt0 terminator to end transcription(Scholtissek and Grosse, Nucleic Acids Res. 15:3185, 1987).Additionally, the STII signal sequence or silent codon variants of thatsignal sequence preceded the coding sequence for the light or heavychain. This sequence directs the secretion of the polypeptide into theperiplasm (Picken et al., Infect. Immun. 42:269-275, 1983; and Simmonsand Yansura, Nature Biotechnology 14:629-634, 1996).

Vectors with separate cistrons were designed to provide independentexpression of the immunoglobulin light and heavy chain genes. In suchvectors, the cistron unit for each chain is under the control of its ownPhoA promoter and is followed by a λt0 terminator. Furthermore, eachcistron incorporated the TIR (translation initiation region) to modulateexpression of both light and heavy chains (Simmons et al., J. Immunol.Meth., 263:133-147, 2002). In an exemplary embodiment, the expressioncassette contains, from 5′ to 3′, a first PhoA promoter followed by thecistron for light chain (TIR-L+Light Chain) and the first λt0terminator, and a second PhoA promoter followed by the cistron for heavychain (TIR-H+Heavy Chain) and the second λt0 terminator. Alternatively,the expression cassette contains, from 5′ to 3′, a first PhoA promoterfollowed by the cistron for heavy chain (TIR-H+Heavy Chain) and thefirst λt0 terminator, and a second PhoA promoter followed by the cistronfor light chain (TIR-L+Light Chain) and the second λt0 terminator. BothTIR-L and TIR-H are contained within an STII signal sequence or avariant thereof.

For the xIL13 and xIL4 IgG4 hAb expression vectors a TIR combination of1,1 and 2,2 was evaluated. For the xIL17 and xIL33 IgG4 hAb expressionvectors a TIR2,2 was evaluated. The first number represents the TIRstrength of the light chain and the second represents the TIR strengthof the heavy chain. In addition to the xIL13, xIL4, xIL17 and xIL33 IgG4hAbs, other IgG1 isotype hAb vectors were constructed and tested.

Chaperone Expression Plasmid Construction

To determine the chaperone expression to be combined with the vectorsdescribed above to yield the highest titers of the xIL13, xIL4, xIL17and xIL33 hAbs, plasmids were provided for co-expression. A number ofknown chaperones were tested including FkpA protein, a peptidylproylcis-trans isomerase with chaperone activity. To do so, compatibleplasmids (pACYC, Novagen, Madison, Wis.) were constructed containing theORF for FkpA, as described in EP1356 052 (see, e.g., Examples 9-10, inparticular paragraph [0207]).

Expanding upon this work for the current process, a set of FkpAcompatible vectors were similarly generated to modulate the levels ofFkpA co-expression. The modulation of FkpA levels was accomplishedthrough optimization of the signal peptide as previously described(Simmons and Yansura, supra, 1996). Briefly, the 5′ end of the FkpA ORFcontained either a FkpA signal peptide (native or variant), or an STIIsignal peptide. All FkpA variant gene constructs were under the controlof a tacII promoter.

These plasmids were then co-transformed with the hAb expression plasmidsdescribed above into strain 66F8. The genotype of the host strain 66F8is W3110 ΔfhuA ΔphoA ilvG2096 (Val^(r)) Δprc spr43H1 ΔdegP ΔmanAlacI^(Q) ΔompT ΔmenE.

For the xIL13 hAb, TIR1,1 and TIR2,2 plasmids encoding the LC and HC ofthe half antibody and FkpA were constructed and used to transform 66F8.In these plasmid constructs, the expression of FkpA was controlled by aphoA promoter upstream of the ORF for the LC. The pBR322 plasmid istypically maintained at approximately 30 copies/cell (Bolivar et al.,Gene, 2:95-113, 1977) and the pACYC plasmid is typically maintained atapproximately 15 copies/cell (Chang and Cohen, J. Bacteriol.,134:1141-1156, 1978). Without wishing to be bound to theory, it isthought that an increase in copy number when FkpA is moved onto the Abexpression plasmid may result in an increase in the amount of FkpA made.

Oxidoreductase Plasmid Construction

Similar to the compatible plasmid system described for the co-expressionof FkpA, compatible plasmids were utilized to screen various knownoxidoreductases in combination with the hAb expression plasmid thatincorporated one of the FkpA TIR variants previously described. Thiswork was performed with the TIR2,2 plasmid identified aspxIL13.2.2.FkpAc13. In addition compatible plasmids were utilized toscreen FkpA and oxidoreductases in combination with xIL4 and other IgG1hAbs.

The construction of the original oxidoreductases compatible plasmids wasas described in EP 1356052 (see, e.g., Example 9). The screening of theoxidoreductases included expression from the compatible plasmid JJ247with hAb expression plasmid xIL13.2.2.FkpAc13. In the xIL13 hAb example,oxidoreductase expression was either induced with 1 mM IPTG or leftuninduced to modulate oxidoreductase levels.

Single plasmids encoding the LC and HC of the hAb and the chaperonesFkpA, DsbA and DsbC were also constructed and used to transform 66F8. Inthe xIL13 hAb example, two TIR2,2 single plasmids were constructeddiffering in the promoter used to drive the expression of FkpA. Thesingle plasmid MD157 contained a phoA promoter for FkpA expression andthe plasmid KA01 contained a tacII promoter. The utilization ofdifferent promoters allowed further modulation of FkpA expression. Inthe xIL17 hAb example, a TIR2,2 single plasmid was constructed (MD341),which utilized a phoA promoter for FkpA expression. In all singleplasmid conditions, expression of DsbA and DsbC were under the controlof a tacII promoter in a polycistronic fashion. In the xIL4 hAb example,a TIR2,2 single plasmid was constructed that incorporated the ORFs ofthe compatible chaperone plasmid AH8145, described below, and identifiedas CB1.

In addition to the single plasmid system described above, a triplechaperone compatible plasmid system was also evaluated with a number ofhAbs of both IgG1 and IgG4 isotype. In the compatible plasmid system oneof the FkpA TIR variants described previously was cloned into thepolycistronic DsbA and DsbC compatible plasmid (JJ247) and is identifiedas AH8145.

Fermentation Process

Large scale production was essentially as described in EP1356052 (see,e.g., Example 4 and paragraphs [0159]-[160]). For each 10-literfermentation, 0.5 mL of frozen stock culture (containing 10-15% DMSO)was thawed and used to inoculate a 2 L shake flask containing 500 ml ofSoy LB medium supplemented with either 0.5 ml of tetracycline solution(5 mg/ml) and/or 2 mL of kanamycin solution (5 mg/mL) and 2.5 ml 1Msodium phosphate solution. This seed culture was grown for approximately16 hours at 30° C. with shaking and was then used to inoculate the10-liter fermentor.

The fermentor initially contained approximately 7.0 liters of mediumcontaining 1.1 g of glucose, 100 ml of 1M magnesium sulfate, 10 ml of atrace element solution (100 ml hydrochloric acid, 27 g ferric chloridehexahydrate, 8 g zinc sulfate heptahydrate, 7 g cobalt chloridehexahydrate, 7 g sodium molybdate dihydrate, 8 g cupric sulfatepentahydrate, 2 g boric acid, 5 g manganese sulfate monohydrate, in afinal volume of 1 liter), either 20 ml of a tetracycline solution (5mg/ml in ethanol) or 250 mL of an ampicillin solution (2 mg/mL), 1 bagof HCD salts, (37.5 g ammonium sulfate, 19.5 g potassium phosphatedibasic, 9.75 g sodium phosphate monobasic dihydrate, 7.5 g sodiumcitrate dihydrate, 11.3 g potassium phosphate monobasic), 200 g of BL4Soy (a soy protein hydrolysate), and 100 grams of Yeast Extract.Fermentations were initially performed at 30° C. with 20 standard litersper minute (slpm) of air flow and were controlled at a pH of 7.0±0.2(although occasional excursions beyond this range occurred in somecases). The back pressure of the fermentor was maintained at 1 bar gaugeand the agitation rate was initially set to 650 rpm. As discussed indetail in Example 2 below, the agitation rate can also be varied tomanipulate the oxygen transfer rate in the fermentor, and, consequently,control the cellular respiration rate. In addition as discussed indetail in Example 3 below, the temperature during the growth andproduction phases can be adjusted to maximize product yield.

Following inoculation of the fermentor with the cell-containing mediumfrom the shake flask, the culture was grown in the fermentor to highcell densities using a computer-based algorithm to feed a concentratedglucose solution to the fermentor. Ammonium hydroxide (58% solution) andsulfuric acid (24% solution) were also fed to the fermentor as needed tocontrol pH. L-61 antifoam was also added in some cases to controlfoaming.

When the culture reached a cell density of approximately 40 OD₅₅₀, anadditional 100 ml of 1M magnesium sulfate was added to the fermentor.Additionally, a concentrated salt feed (12.5 g ammonium sulfate, 32.5 gpotassium phosphate dibasic, 16.25 g sodium phosphate monobasicdihydrate, 2.5 g sodium citrate dihydrate, 18.75 g potassium phosphatemonobasic, 10 ml of 2.7% ferric chloride and 10 ml of trace elements ina final volume of 1250 ml) was added to the fermentor and started at arate of 2.5 ml/min when the culture reached approximately 20 OD₅₅₀ andcontinued until approximately 1250 ml were added to the fermentation.Fermentations were typically continued for 70-80 hours.

Sample Preparation for Electrophoresis, Immunoblot, and HPLC Analysis

Non-reduced soluble sample prep is similar to what is described inEP1356052 (see, e.g., Example 4, in particular paragraph [0162]). Inparticular, non-reduced soluble samples were prepared as follows:frozen, 1 mL whole broth samples taken during the course of thefermentation were thawed at room temperature. 100 μL of the thawed wholebroth was added to 500 μL of extraction buffer. (Extraction buffer: 10mM Tris, pH 6.8, 5 mM EDTA, freshly added 0.2 mg/mL of hen egg lysozyme,and freshly prepared iodoacetic acid to a final concentration of 5-10mM.) The whole broth samples plus extraction buffer were incubated onice for 5-10 minutes, then sonicated 2×10 pulses, then centrifuged at 4°C. and 14,000 rpm for 15-20 minutes. The supernatant was removed as thesoluble fraction. For analysis by SDS-PAGE and immunoblots, the solublefraction was diluted 1:10 into 2× Novex Tricine sample buffer withoutreducing agent. 10 μL of this prep was loaded onto a 10 well Novex 10%Bis-Tris NuPage gel and electrophoresed at 150 V with MES buffer. Thegel was then used for either an immunoblot or stained with CoomassieBlue.

Samples of the soluble fractions were submitted for analysis by aLC-Kappa/RP assay. This assay is a 2-dimensional HPLC assay where thefirst column is an affinity column that captures kappa-light-chaincontaining IgG components and the second column is a reversed-phasecolumn. An integral HPLC workstation was configured in the dual columnmode. The solvent reservoirs were: Solvent 1A, affinity loading buffer;Solvent 1B, affinity elution buffer, 0.2% TFA in water; Solvent 2A,reversed-phase aqueous buffer, 0.1% TFA in water; Solvent 2B,reversed-phase organic elution buffer, 0.1% TFA in 80% acetonitrile. Thefirst column was POROS® CaptureSelect™ LC Kappa affinity column (2.1×30mm) purchased from Life Technologies (Carlsbad, Calif.). All proceduresinvolving the affinity column were performed at ambient temperature.

The second column was POROS® R2 20 μm reversed-phase column (2.1×30 mm)purchased from Life Technologies (Carlsbad, Calif.). The reversed-phasecolumn temperature was maintained at 80° C.

The affinity column was equilibrated in loading buffer, and a sample wasloaded at a flow rate of 2 ml/min. The flow-through was directed towaste. After the sample was loaded, the affinity column was washed withloading buffer (3 ml) to reduce non-specifically bound components. Then,by valve switching, the affinity column was connected to thereversed-phase column and eluted with elution buffer (5 ml) at a flowrate of 2 ml/min to transfer the affinity captured components to thereversed-phase column. During this transfer step, the Integral UVdetector was located after the affinity column and before thereversed-phase column, hence monitoring the elution of the affinitycolumn, which became the load to the reversed-phase column. Afterelution and disconnection from the reversed-phased column, the affinitycolumn was washed by water (2 ml) and subsequently re-equilibrated withloading buffer (4 ml).

The loaded reversed-phase column was washed with aqueous 0.1% TFA (1.1ml). The flow rate was set to 2 ml/min and a rapid gradient (0.25 min)was run to 35% solvent 2B (0.1% TFA/80% acetonitrile) followed by ashallow gradient to 50% solvent 2B over 3 min. Elution was completed bya gradient to 100% solvent 2B in 0.5 min and held for 1.5 min. Thereversed phase column was then returned to initial conditions in 0.05min and held for 2 min to re-equilibrate. The column eluate wasmonitored at 280 and 214 nm. Quantitation was performed by comparison ofthe integrated peak areas with those of standards of knownconcentrations based on separation from the reversed-phase column.

The soluble and total amounts of LC and HC produced during thefermentation process were also quantitated. To perform the total RP-HPLCquantification fermentation broth samples were diluted 10 fold with 100mM DL-Dithiothreitol (Sigma cat. #43816) in 6 M Guanidine HCL, 360 mMTRIS, 2 mM EDTA pH 8.6) with 200 mM. Samples were vortexed, incubated at60° C. for 20 mins and centrifuged at 13,000 RPM for 15 min at 4° C. Thesoluble fraction was filtered using a 0.22 um filter prior to injectionon the HPLC. The HPLC system used was an Agilent Technologies 1290Infinity system. Samples were injected onto a Zorbax 300SB-C3 RapidResolution (4.6×150 mm 3.5 micron) analytical column (cat. #863973-909).Mobile phase A consisted of 0.1% Trifluoroacetic acid (Thermo cat.#28901) in SQH2O and mobile phase B 0.08% Trifluoroacetic acid inHPLC-grade acetonitrile (Honeywell cat. # AH015-4).

To perform the total soluble RP-HPLC quantification fermentation brothsamples were both homogenized (10,000 RPM) and sonicated (88% amplitude)for 10 sec four times with a Pro-Scientific DPS-20. Samples were thencentrifuged at 4° C. and 14,000 rpm for 15-20 minutes. The supernatantwas removed as the soluble fraction and denatured and processed on theRP-HPLC as described above.

Bispecific Anti-IL13/IL17 Antibody Assembly

The affinity-purified anti-IL13 and anti-IL17 half antibodies werecombined in a 1:1 mass ratio followed by the titration to pH 8.5. 100×excess molar ratio of L-glutathione, reduced (GSH) with respect to thetheoretical maximum amount of bispecific antibody expected from theassembly process was added to the mixture and the temperature wasadjusted from room temperature to 35° C. The two half antibodiesassembled in vitro in the redox reaction to form the anti-IL13/anti-IL17bispecific antibody. The redox reaction continued for 12-24 hrs at 35°C. The assembly reaction was quenched by adjusting the pH to 6.5 and thepool was diluted with water before the bispecific antibody was subjectedto purification by ion exchanger or hydrophobic column chromatography,either alone or in combination

Results

Effect of FkpA Expression on hAb Titer

As shown in FIG. 1A, production of light and heavy chain subunits fromthe xIL13 hAb TIR1,1 vector resulted in total amounts of light and heavychains production of 2.9 g/L and 1.2 g/L, respectively. For the TIR2,2the total amount of light and heavy chains produced was 6.4 g/L and 4.1g/L, respectively.

However, the amount of total subunit production did not result insignificant soluble subunit accumulation. Using the xIL13 TIR1,1 hAbplasmid, the total soluble amount of light and heavy chains produced was0.2 g/L and less than 0.1 g/L, respectively (FIG. 1B). For the TIR2,2hAb the total soluble amounts of light and heavy chains produced was 0.3g/L and 0.3 g/L, respectively (FIG. 1C). The titer of assembled xIL13hAb produced for the TIR1,1 fermentation was only 0.1 g/L, and for theTIR2,2 fermentation the titer was less than 0.2 g/L (FIG. 2). Theseresults suggest the presence of significant inefficiencies in thefolding and/or assembly of the hAb product. Therefore, further work wasperformed evaluating the effect on titer of using the TIR1,1 and TIR2,2plasmids with the co-expression of chaperones.

Several classes of chaperone proteins are known to promote proteinfolding and assembly (FIG. 3A-B). Particular chaperones of interestinclude FkpA, which is known to function as a peptidyl-prolyl cis-transisomerase and a chaperone, and DsbA and DsbC, which are known tofunction as oxidoreductases. Experiments were undertaken to test whetherexpression of FkpA, DsbA, and DsbC affected hAb production.

In particular, the effect of expressing FkpA using a separate plasmid(compatible plasmid system) or the same plasmid (single plasmid system)encoding the hAb HC and LC ORFs was examined (FIG. 4A-B). Use of asingle expression plasmid eliminates the need to use multipleantibiotics or other means of selective pressure to ensure plasmidretention. In the single plasmid system used for xIL13 hAb, the promoterdriving FkpA expression was changed from an IPTG-inducible tacIIpromoter to a phoA promoter. Therefore, phosphate depletion in theculture leads to expression of the HC, LC, and FkpA.

Increased levels of FkpA chaperone co-expression correlated withincreased amounts of soluble monomeric heavy chain accumulation inaddition to increased assembled hAb for an IgG1 isotype hAb (xVEGF)(FIG. 5A). In this experiment a set of FkpA expression variants, asdescribed previously, was screened with 1 mM IPTG induction. WithoutFkpA co-expression, the titer of the xVEGF hAb was 0.2 g/L and in thecondition with the highest level of FkpA co-expression (FkpA(wt)) thehAb titer was approximately 0.4 g/L (FIG. 5B).

For the production of xIL13 hAb, a compatible plasmid system (expressionof xIL13 HC and LC from one plasmid and FkpA from another, as shown inFIG. 4A) using a TIR1,1 or TIR2,2 antibody expression vector was tested.For the compatible plasmid systems induced with 1 mM IPTG to driveco-expression of FkpA, the titer for the TIR1,1 plasmid was 0.2 g/L and0.4 g/L for the TIR2,2 plasmid (FIG. 6A, lanes 3 and 4). This resultedin an approximate two-fold increase in titer compared with TIR1,1 andTIR2,2 conditions with endogenous levels of FkpA (FIG. 6A, lanes 1 and2). FIG. 6B shows the amount of FkpA expression induced in thecompatible system, as compared to endogenous expression, as measured byultra performance liquid chromatography (UPLC) in milliabsorption units(mAu) and Western blot.

The single plasmid system for FkpA expression and hAb production shownin FIG. 4B was also tested. For the xIL13 hAb, the titers for the singleplasmid TIR1,1 and TIR2,2 were 0.4 g/L and 0.7 g/L, respectively (FIG.6A). This represented an approximately two-fold increase in titer overthe compatible plasmid system. The expression level of FkpA in thesingle plasmid system was also approximately two-fold higher than in theinduced compatible plasmid system (FIG. 6B). Increased levels of FkpAexpression correlated with increased amounts of soluble monomeric heavychain accumulation in both TIR conditions.

A third hAb (xIL4 IgG4) was tested with both TIR1,1 and TIR2,2conditions with induced FkpA co-expression from a compatible plasmidsystem. In this experiment FkpA(wt) co-expression increased the amountof soluble monomeric heavy chain in both TIR conditions (FIG. 7A), butdid not result in an increase in the titer of hAb produced (FIG. 7B).

A fourth hAb (xVEGFC IgG1) was tested with induced FkpA co-expressionfrom a compatible plasmid system. In this experiment FkpA(wt)co-expression increased the amount of soluble monomeric heavy chain andincreased the titer from 0.5 g/L to 0.8 g/L (FIG. 8A). The increasedFkpA expression as determined by Coomassie stain (FIG. 8B) correlated toan increase in soluble monomeric HC chain accumulation (FIG. 8C). Insum, these results suggest that FkpA expression enhances theaccumulation of soluble monomeric heavy chain, but that the effect onassembled hAb titer is variable. This indicates that furtheroptimization is desirable.

Effect of DsbA and DsbC Expression on hAb Titer

xIL13 hAb production was further optimized by combining thepxIL13.2.2.FkpAc13 (single plasmid) described above with a compatibleplasmid for the expression of the oxidoreductases DsbA and DsbC (FIG.9). A plasmid expressing both DsbA and DsbC (JJ247) withpxIL13.2.2.FkpAc13 increased hAb titers. FIG. 10 shows the titer of thexIL13 hAb produced over time, in the presence and absence of IPTGinduction of DsbA and DsbC. The highest titer for the pxIL13.2.2.FkpAc13with JJ247 was achieved at 52 hours into the fermentation. At this timepoint, in the condition without IPTG (non-induced condition) the xIL13titer was 1.2±0.2 g/L and in the condition with IPTG (induced condition)the xIL13 titer was 1.0±0.2 g/L (FIG. 10). The drop in titer from 52 to72 hours for both conditions tested was significant and was attributedto a drop in oxygen uptake rate (OUR) and rise in osmolality during thefermentation process as described in Example 2.

A compatible system for expressing DsbA, DsbC, and FkpA (AH8145) wasalso evaluated with the xIL4 TIR1,1 and TIR2,2 Ab expression plasmids(FIG. 11A). The non-induced co-expression of all three chaperonesresulted in a TIR1,1 and TIR2,2 titer of 0.8 g/L and 1.2 g/L,respectively (FIG. 12 lanes 5 and 6). This represented an approximatelysix-fold increase in titer for the TIR2,2 condition as compared to thepreviously described FkpA compatible TIR2,2 condition (FIG. 12 lanes 3and 4).

The compatible non-induced AH8145 plasmid system was further evaluatedwith another hAb. Using a TIR2,2-based vector to produce the xVEGFC IgG1hAb, the non-induced compatible AH8145 condition increased the titer to1.0 g/L from 0.8 g/L, as compared to FkpA co-expression only (FIG. 13).A fifth hAb (xVEGFA IgG1) with both TIR1,1 and TIR2,2 conditions wastested with the AH8145 compatible plasmid. Without chaperoneco-expression the titers for both the TIR1,1 and TIR2,2 conditions weresimilar, about 0.9 g/L (FIG. 14 lanes 1 and 3). With the compatibleplasmid in the non-induced AH8145 condition, the titer for the TIR1,1and TIR2,2 plasmids was 1.2 g/L and 1.7 g/L, respectively (FIG. 14 lanes2 and 4).

The creation of a xIL4 TIR2,2 single plasmid that incorporated thechaperone ORFs of AH8145 was generated (CB1) and is illustrated in FIG.11B. The CB1 plasmid without the addition of IPTG produced slightlyhigher titers than observed with the compatible plasmid system (FIG.15). It should be noted that the hAb titers reported in this comparisonwere generated from fermentations that utilized an optimized agitationstrategy as described in Example 2. By western blot, the levels of allthree chaperones was slightly higher with CB1 (FIG. 15). Without wishingto be bound to theory, the single plasmid system may allow for higherplasmid copy number, which may result in higher yields.

The xIL13 single plasmid system MD157 was compared to the uninducedcompatible pxIL13.2.2.FkpAc13 and JJ247 compatible plasmid system (FIG.16). The MD157 single plasmid condition produced titers of 2.1±0.3 g/Lcompared to 1.9±0.04 g/L in the compatible system (FIG. 17). It shouldbe noted that the titers reported in this comparison were generated fromfermentations that utilized an optimized agitation strategy as describedin Example 2.

Taken together, these results demonstrate that co-expression of FkpAalong with DsbA and DsbC increases the production of assembled hAb,using multiple hAb constructs to confirm these effects.

Example 2 Effect of Oxygen Uptake on Half-Antibody Production

The above results demonstrate an improvement in hAb production achievedby the co-expression of FkpA, DsbA, and DsbC along with the hAb HC andLC. However, even with this enhanced production, titers were found toplateau or even diminish at time points after 52 hours of production.Therefore, additional experiments were undertaken to further optimizehAb production.

As described previously, fermentations were initially performed at 30°C. with 20 standard liters per minute (slpm) of air flow and werecontrolled at a pH of 7.0±0.2. The back pressure of the fermentor wasmaintained at 1 bar gauge and the agitation rate was initially set to650 rpm. The additional bar gauge of backpressure resulted in an initialdissolved oxygen concentration (dO₂) of 200%. The concentrated glucosesolution was fed after the dO₂ signal dropped below 2% of the startinglevel, typically about two hours into the production culture, and wasfed continuously over the course of the fermentation such that glucosewas a non-limiting nutrient.

At 12 hours the cell density in the culture was sufficient to maintainthe dO₂ concentration at or near zero percent. Without wishing to bebound to theory, it is thought that when oxygen concentration islimited, the oxygen transfer rate (OTR) is equal to the oxygen uptakerate (OUR) or metabolic rate of the cells. Manipulation of the OTR wasfacilitated by adjusting the agitation rate and had a direct effect onthe culture OUR. A mass spectrometer was used to monitor the compositionof the off-gas from the fermentations and enabled the calculation of theoxygen uptake and carbon dioxide evolution rates in the fermentations.

As shown in FIG. 18, in the pxIL13.2.2.FkpAc13 with JJ247 plasmid systemdescribed above, both the induced and non-induced TIR2,2 cultures had apeak OUR of 4.25 mmol/L/min at hour 12, after which point the dO₂ becamelimited. These cultures were grown under agitation at a constant rate of650 rpm. FIG. 19 shows the osmolality of these cultures over time. Takentogether, FIGS. 18-19 show that after 50 hours, cell culture OURdeclined sharply and osmolality rose.

FIG. 20 shows the xIL13 hAb titer produced over time in these cultures.A drop in titer from 1.2 g/L±0.2 g/L at 52 hours to 0.7±0.04 g/L at 72hours was observed. Similarly, in the induced condition, a drop from1.0±0.2 g/L at 52 hours to 0.5±0.05 g/L at 72 hours was observed.Intriguingly, this drop in production occurred at the same time OURdropped and osmolality rose in these cultures.

To mitigate the drop in titer and eliminate the rise in osmolality, anagitation shift at 26 hours was evaluated with the non-induced TIR2,2condition. The agitation rate was shifted from 650 rpm to a level thatachieved a target OUR set point. Four different OUR target set pointswere tested: approximately 1.5, 1.75, 2.0 and 2.5 mmol/L/min. Agitationshifts with OUR set points between approximately 1.5 and 2.0 mmol/L/mineliminated the drop in OUR (FIG. 21) and the rise in osmolality (FIG.22).

Importantly, in all of the agitation shift conditions, the titer washigher than in the non-shifted condition at 54 hours (FIG. 23). In theapproximate 2.5 mmol/L/min condition the OUR dropped at ˜60 hours (FIG.21) and the osmolality rose to a peak of 1200 mOsm at 72 hours (FIG.22). At 72 hours, the approximate 2.5 mmol/L/min condition titer (0.7g/L) dropped to similar levels as the non-shifted condition (0.6±0.1g/L). The average titer for the approximate 2.0 mmol/L/min condition wasthe highest (2.4±0.6 g/L) of the four conditions tested; however, therewas some variability in the titers and there appeared to be a slightdecline in the OUR profile. The approximate 1.5 mmol/L/min condition hadboth reproduced average titers of 2.1±0.3 g/L, but again there appearedto be some variability in the OUR profile late in the fermentation. Theapproximate 1.75 mmol/L/min condition had both reproducible titers(1.8±0.2 g/L), as well as consistent OUR trends so it was chosen as thepreferred set point.

These results demonstrate that shifting the agitation rate of culturesmitigates the observed decline in OUR and rise in osmolality.Importantly, these agitation shifts also allow enhanced hAb productiontiter, particularly at later production time points.

Example 3 Effect of Temperature on Half-Antibody Production

While the previous Examples demonstrate significant gains in hAbproduction, additional tests were undertaken to still further optimizethe production process. Therefore, for xIL13 hAb production, the highperforming single plasmid system described in Example 1 and the OUR setpoint of approximately 1.75 mmol/L/min described in Example 2 were usedas starting points. The process was still further optimized to yieldsignificantly greater production yields, as described below.

The fermentation process of a preferred embodiment of the presentdisclosure may be divided into two different segments: the growth phaseand the production phase. In the growth phase, most nutrients are inexcess, and the culture density increases rapidly. In the productionphase, phosphate becomes limited, growth stops, and expression of theproduct of interest begins. The effect of temperature on hAb productionwas tested for each of these phases.

In combination with the temperature experiments a second host wasevaluated. In these experiments the MD157 plasmid was transformed intothe 67A6 production host. The genotype of the 67A6 strain is W3110 ΔfhuAΔphoA ilvG+ Δprc spr43H1 ΔdegP ΔmanA lacIQ ΔompT ΔmenE742 degPS210A.

The 67A6 strain contains a knockin of a protease deficient allele of thedegP gene (also known as htrA and ptd), which encodes DegP. DegP (alsoknown as Protease Do) is a periplasmic serine protease required forsurvival at high temperatures. Additionally, DegP acts as a molecularchaperone. The substitution of a alanine for serine eliminates theproteolytic activity of DegP but does not affect its chaperone function(Spiess et al., Cell, 97:339-347, 1999).

Temperature optimization was performed for both the growth phase (Tg)and production phase (Tp) for the xIL13 TIR2,2 single plasmid system.FIG. 24 shows the growth of cultures grown with a constant Tg/Tp of 30°C. or 28° C. A constant Tg/Tp of 28° C. resulted in a lag in growth rateas compared to the constant Tg/Tp of 30° C. FIG. 25 shows the OUR ofcultures grown at these temperatures. Similar to growth rate, OUR isdelayed when cultures are grown at a constant Tg/Tp of 28° C., ascompared to 30° C.

As shown in FIG. 26, phosphate was depleted at 22±2 hours using aconstant Tg/Tp of 30° C. When the Tg/Tp was shifted down to 28° C., thegrowth rate of the culture was retarded as described above, andphosphate depletion was shifted to 26±2 hours.

FIG. 27 shows the xIL13 hAb production of these cultures. For eachcondition, product expression began at the time when phosphate depletionoccurred. The constant 28° C. Tg/Tp condition achieved a final titer of2.5±0.2 g/L, as compared to 1.3±0.2 g/L for the constant 30° C. Tg/Tpcondition.

In an effort to increase the amount of time in the production phase, atemperature shift strategy was tested. In this experiment the growthphase temperature was set at 30° C. and at 20 hours the temperature wasshifted to 28° C. The growth (FIG. 28), phosphate (FIG. 29), and OUR(FIG. 30) profiles between 0 and 20 hours were similar for theTg30/Tp28° C. shift and constant Tg/Tp 30° C. conditions.

As shown in FIG. 31, the use of a temperature shift to 28° C. at thetime of product induction provided a further 0.6 g/L increase in titer,comparing a final titer of 3.1 g/L produced under the Tg30/Tp28° C.conditions to a final titer of 2.5 g/L produced under the constant Tg/Tp28° C. condition. These results demonstrate that growing the culture ata higher temperature, then decreasing the culture temperature at thetime of production can result in a significant increase in productformation.

A partial factorial design of experiment (DoE) was performed todetermine the optimal operating conditions for the xIL13 hAb utilizingthe 67A6 host strain. The DoE focused on three operating parameters andthe level of FkpA.

TABLE 3-1 xIL13 hAb Parameters Growth Production Temp. Temp. FkpA TiterPattern (Tg) (Tp) pH promoter (g/L) −+−+ 30 28 6.7 phoA 2.8 0001 32 26.56.85 phoA 1.9 −−−− 30 25 6.7 tac 1.4 +−+− 34 25 7 tac 2.9 +−−+ 34 25 6.7phoA 4.6 −−++ 30 25 7 phoA 1.8 −++− 30 28 7 tac 1.6 ++++ 34 28 7 phoA2.8 ++−− 34 28 6.7 tac 1.6 0002 32 26.5 6.85 phoA 3.3

As shown in Table 3-1, the operating parameters included Tg and Tp aswell as pH. The pattern refers to the operating range for a specificparameter; (−) refers to a low value parameter, (+) refers to a highvalue parameter, and 0001 and 0002 refer to a center point parameter.The Tg ranged from 30 to 34° C., the Tp ranged from 25 to 28° C., andthe pH ranged between 6.7 and 7.0. The amount of FkpA produced wasmodulated by the promoter used. High levels of FkpA were generated fromthe phoA promoter on MD157 and low levels of FkpA were generated fromthe non-induced tac promoter on KA01. Partial factorial analysis wasperformed by running 10 experiments.

As shown in FIG. 32, these factors had significant effects on the titerof xIL13 hAb produced. The titer of hAb produced by the conditions usedfor the DoE experiments described in Table 3-1 ranged from approximately1.5 to approximately 4.5 g/L.

The xIL4 single plasmid (CB1) was tested with the optimal fermentationconditions identified from the xIL13 DoE (Tg 34° C., Tp 28° C., pH 7.0).However in the CB1 condition a tacII promoter without IPTG induction wasused to drive FkpA expression. The xIL14 hAb titer was compared to afermentation condition in which the Tg/Tp was held constant at 30° C.and the pH was maintained at 7.0. The xIL4 hAb titer increased from 1.3g/L to 3.1 g/L with the new process conditions without the addition ofIPTG (FIG. 33).

A partial factorial DoE was performed to determine the optimal operatingconditions for the xIL17 hAb. The MD341 single plasmid was constructedby replacing the ORFs for the xIL13 hAb single plasmid (MD157) LC and HCwith the ORF of the xIL17 LC and HC. The promoters used for theexpression of the antibody fragments and chaperones were identical tothe xIL13 (MD157) plasmid. The DoE focused on three operatingparameters.

TABLE 3-2 xIL17 hAb Parameters Growth Production Temp. Temp. TiterPattern (Tg) (Tp) pH (g/L) −+− 30 30 6.7 0.38 0001 32 27.5 7.0 2.0 −−−30 25 6.7 2.5 −−+ 30 25 7.3 2.6 +−+ 34 25 7.3 2.6 0002 32 27.5 7.0 1.9++− 34 30 6.7 0.34 +−− 34 25 6.7 2.0 −++ 30 30 7.3 0.2 +++ 34 30 7.30.12

As shown in Table 3-2 the operating parameters included Tg and Tp, aswell as pH. The Tg ranged from 30 to 34° C., the Tp ranged from 25 to30° C., and the pH ranged between 6.7 and 7.3. FIG. 34 shows that themost significant titer accumulation was achieved in conditions with a Tpof 25° C.

FIG. 35 shows the effects of first optimizing chaperone proteinco-expression and then optimizing the process steps (e.g., agitationrate, Tg, and Tp) on production of xIL13 hAb titer. In an exemplaryembodiment, molecular optimization (e.g., chaperone protein expressionand vector characteristics) provided an approximately 16-fold increasein titer. This level of production was further enhanced by approximately3.5-fold through process development (e.g., agitation rate, Tg, and Tp).Taken together, these results demonstrate that significant gains inproduction and robustness can be achieved through optimizing variablesincluding chaperone expression, vector systems, agitation rate, pH, andgrowth/production temperatures. Ultimately, it was determined that theconditions with a Tg at 34° C., Tp at 25° C., a pH of 6.7, and the levelof FkpA produced by the phoA promoter resulted in the highest xIL13 hAbtiter.

Example 4 Effect of Host Strain on Half-Antibody Production

While the previous Examples demonstrate significant gains in hAbproduction, additional tests were undertaken to characterize thepotential differences in hAb production between the host strains 66F8and 67A6. Therefore, for hAb production, the high performing singleplasmid system described in Example 1, the OUR shift described inExample 2, and the temperature shift described in Example 3 wereevaluated in the two E. coli host strains: 66F8 and 67A6. The genotypeof the 66F8 strain is W3110 ΔfhuA ΔphoA ilvG+ Δprc spr43H1 ΔdegP ΔmanAlacIQ ΔompT ΔmenE742. The genotype of the 67A6 strain is W3110 ΔfhuAΔphoA ilvG+ Δprc spr43H1 ΔdegP ΔmanA lacIQ ΔompT ΔmenE742 degPS210A.

The xIL13 hAb was expressed in both the 66F8 and 67A6 host strains.Fermentations were performed under conditions employing temperature andagitation rate shifts as described above. The use of the 67A6 strainresulted in an increase in soluble xIL13 hAb titer (FIG. 36A) and intotal subunit accumulation of both LC and HC as compared to the 66F8strain (FIG. 36B).

The xIL4 hAb was also expressed in both the 66F8 and 67A6 host strains.When the xIL4 hAb fermentations were performed at a constant temperatureof 30° C., similar titers of about 1.5 g/L were obtained from bothstrains (FIG. 37A). However, under fermentation conditions in which theTg was reduced from 34° C. to a Tp of 25° C. the 67A6 strain produced anaverage of 3.0 g/L and the 66F8 strain produced an average of 2.0 g/L(FIG. 37B). In addition, the total subunit accumulation of both LC andHC in the 67A6 fermentations was greater than in the 66F8 fermentationsunder conditions employing a temperature shift (FIG. 38A and FIG. 38B).

Thus, both xIL13 hAb and xIL4 hAb are two examples of a titer benefitprovided by the 67A6 host strain and a decreased production temperaturerelative to the growth temperature. Without being bound by theory,recombinant protein accumulation appeared to plateau in host strainsdevoid of DegP, while in the host strain with the mutant DegPS210A,recombinant protein appeared to accumulate until the fermentation ended.

Example 5 Production of xIL33 hAb Using an Optimized Expression Vectorand Optimized Culture Conditions

The xIL33 hAb (MD501 plasmid) was constructed by replacing the ORFs forthe xIL13 hAb single plasmid (MD157) LC and HC with the ORF of the xIL33LC and HC. The promoters used for the expression of the antibodyfragments and chaperones were identical to the xIL13 (MD157) plasmid(FIG. 39). A single fermentation was performed with an xIL33 hAbexpression vector that contained only the ORFs for the xIL33 LC and HC(MD481). The MD481 plasmid did not contain ORFs for the molecularchaperones DsbA, DsbC or FkpA. The fermentation was performed at aconstant temperature of 30° C., pH of 7.0, and an agitation rate of 650RPM (base case of FIG. 40). Next, a single fermentation was performedwith an xIL33 hAb expression vector that contained ORFs for the xIL33 LCand HC, as well as ORFs for the molecular chaperones DsbA, DsbC or FkpA(MD501). The same operating conditions were used for the MD501fermentation as for the MD481 fermentation. The use of the singleplasmid (MD501) resulted in an approximate 10-fold increase in xIL-33hAb titer as compared to the base case.

A partial factorial DoE was performed to determine the optimal cultureconditions for the xIL33 hAb MD501 single plasmid. The DoE focused onfour parameters in a fractional factorial with 10 experiments includingtwo center point replicates in the 67A6 host (Table 5-1). Agitation rateand temperature shifts were done at OD₅₅₀ of 150.

TABLE 5-1 xIL33 hAb Parameters Growth Production Temp. Temp. TargetTiter Pattern (Tg) (Tp) pH OUR (g/L) −++− 34 30 6.7 1.9 2.7 −−++ 30 306.7 2.8 1.7 +−+ 30 30 7.3 1.9 3.2 0000 32 27.5 7.0 2.3 4.1 −+−+ 34 256.7 2.8 3.0 ++ 30 25 7.3 2.8 3.3 ++−− 34 25 7.3 1.9 3.2 0000 32 27.5 7.02.3 4.0 ++++ 34 30 7.3 2.8 2.6 −−−− 30 25 6.7 1.9 2.5

As shown in Table 5-1, the Tg ranged from 30 to 34° C., the Tp rangedfrom 25 to 30° C., the pH ranged between 6.7 and 7.3, and the OUR setpoint ranged from 1.9 to 2.8 mmol O₂/L/min. FIG. 41 shows that thecenter point conditions provided the most significant benefit to titerwith the highest titer achieved being 4.0±0.05 g/L, which amounts to afurther increase in hAb titer as compared to the base case operatingconditions (FIG. 40). The best culture conditions included a pH of 7.0,a Tg of 32° C., a Tp of 27.5° C. (2 hr ramp), and a target OUR ofapproximately 2.3 mmol/Lmin (2 hr agitation rate ramp).

Example 6 FkpA Optimization

In an effort to optimize the expression levels of FkpA, two additionalFkpA TIR variants were tested in the single plasmids for xIL13, xIL17and xIL33 hAbs (MD157, MD341 and MD501 plasmids). FkpA TIR variants werecharacterized as described in comparison to the endogenous FkpA signalsequence (FIG. 42). The MD157, MD341 and MD501 plasmids incorporated theORF for FkpAc13, which was correlated with a TIR strength of three (FIG.43). In the MD157, MD341 and MD501 single plasmids the FkpAc13 ORF wasreplaced with the FkpA TIR1 or TIR2 ORF and tested in the previouslyidentified optimized fermentation conditions for each hAb.

Increased levels of FkpA expression correlated with increased xIL13 hAbaccumulation (FIG. 44). The FkpA TIR1 and TIR2 conditions resulted infinal FkpA amounts of 0.5 and 2.5 g/L and xIL13 hAb titers of 1.5 and2.5 g/L, respectively. The TIR 3 condition produced 4 g/L of FkpA and3.8 g/L of hAb. Levels of FkpA expression also had an impact on theproduction phase OUR profiles. Overall the titration of FkpA increasedthe amount of hAb produced by about 3 fold.

In the xIL33 hAb fermentations, the lowest titer accumulation profilecorrelated with the FkpA TIR1 condition with an end of run titer of 2.4g/L (FIG. 45). The xIL33 TIR2 and TIR3 conditions resulted in anapproximate 2 fold increase in xIL33 hAb titer (FIG. 45) when comparedto the TIR1 condition. The data suggest that increased levels of FkpAare beneficial to hAb production.

In the xIL17 hAb fermentations, the lowest titer accumulation profilecorrelated with the FkpA TIR1 condition with an end of run titer of 2.0g/L (FIG. 46).

Two additional FkpA TIR variants were tested (TIR2.3 and TIR6) using thepreviously described best conditions for the xIL13 hAb. The TIR2.3 titerprofile trended higher than the previously tested TIR2 condition, butwas still lower than the control TIR3 condition (FIG. 47A). The TIR6condition resulted in a titer accumulation profile similar to the TIR2.3 condition, but again lower than the TIR3 control. FkpA accumulationas determined by western blot analysis showed the titration of FkpAacross the TIR variants (FIG. 47B). The data suggests there is anoptimal amount of FkpA expression that correlates with hAb production,which in the case of the xIL13 hAb (MD157 single plasmid) is TIR3.

Example 7 Effect of Oxygen Transfer Rate (OTR) Conditions

The xIL13 hAb best conditions identified in Example 3, were also testedwith a second OTR strategy. In the experiments (N=3) the vesselbackpressure (BP) and sparge rates were decreased from 1.0 to 0.3 barand 20 to 13 SLPM, respectively. In an effort to recover the loss in OTRdue to the decreases in back pressure and sparge rate, the growth andproduction phase agitation rates were increased from 650 to 880 RPM and475 to 650 RPM. Different combinations of vessel backpressure, spargerates, and agitation rates can be used to achieve similar OTR conditionsas those cited in previous examples.

Fermentations were performed with a constant BP for the entirety of thefermentation process. In the altered OTR conditions, the backpressurewas maintained at 0.3 bar (N=3) and in the control conditions, thebackpressure was maintained at 1.0 bar (N=5). Fermentations wereperformed with a constant air flow for the entirety of the fermentationprocess. In the altered OTR conditions, the air flow was maintained at13 SLPM (N=3) and in the control conditions, the air flow was maintainedat 20 SLPM (N=5). Fermentations implemented an agitation shift at 150OD₅₅₀ in both the altered OTR and control conditions. In the altered OTRconditions, the initial agitation rate was set to 880 RPM and shifted to650 RPM, and in the control conditions, the initial agitation rate wasset to 650 RPM and shifted to 475 RPM.

The increase in agitation rate compensated for the drop in OTR due tothe reductions in sparge and backpressure. The altered OTR conditionsresulted in similar peak and production phase OURs (FIG. 48A) and growthprofiles (FIG. 48B) to the control condition. The altered OTR conditionresulted in a similar accumulation profile and peak titer (4.1±0.4 g/L)as the control condition (FIG. 49).

SEQUENCES

All polypeptide sequences are presented N-terminal to C-terminal unlessotherwise noted.

All polynucleotide sequences are presented 5′ to 3′ unless otherwisenoted.

Human IL13 precursor polypeptide (SEQ ID NO: 1)MALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFRE GRFNMature human IL13 polypeptide (SEQ ID NO: 2)SPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN Human IL17A precursor polypeptide (SEQ ID NO: 3)MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA  Mature human IL17A polypeptide(SEQ ID NO: 4)GITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIV HHVAHuman IL17F precursor polypeptide (SEQ ID NO: 5)MTVKTLHGPAMVKYLLLSILGLAFLSEAAARKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ Mature human IL17F polypeptide(SEQ ID NO: 6)RKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPV IHHVQAnti-IL13 heavy-chain variable domain (SEQ ID NO: 7)EVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS Anti-IL13 light-chain variable domain (SEQ ID NO: 8)DIVLTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKR  Anti-IL13 HVR-H1(SEQ ID NO: 9) AYSVN Anti-IL13 HVR-H2 (SEQ ID NO: 10) MIWGDGKIVYNSALKSAnti-IL13 HVR-H3 (SEQ ID NO: 11) DGYYPYAMDN Anti-IL13 HVR-L1(SEQ ID NO: 12) RASKSVDSYGNSFMH Anti-IL13 HVR-L2 (SEQ ID NO: 13) LASNLESAnti-IL13 HVR-L3 (SEQ ID NO: 14) QQNNEDPRTAnti-IL13 IgG4 heavy chain with knob-forming T366W mutation(SEQ ID NO: 15)EVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGAnti-IL13 IgG4 heavy chain with knob-forming T366W mutation(SEQ ID NO: 16) EVTLRESGPA LVKPTQTLTL TCTVSGFSLS AYSVNWIRQP PGKALEWLAMIWGDGKIVYN SALKSRLTIS KDTSKNQVVL TMTNMDPVDT ATYYCAGDGYYPYAMDNWGQ GSLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDYFPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYTCNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLMISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRVVSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLPPSQEEMTKNQ VSLWCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDGSFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK  Anti-IL13 light chain(SEQ ID NO: 17)DIVLTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAnti-IL17A F cross reactive Ab heavy-chain variable domain(SEQ ID NO: 18)EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS Anti-IL17A F cross reactive Ab light-chain variable domain(SEQ ID NO: 19)EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK Anti-IL17A F cross reactive Ab HVR-H1 (SEQ ID NO: 20) DYAMHAnti-IL17A F cross reactive Ab HVR-H2 (SEQ ID NO: 21) GINWSSGGIGYADSVKGAnti-IL17A F cross reactive Ab HVR-H3 (SEQ ID NO: 22) DIGGFGEFYWNFGLAnti-IL17A F cross reactive Ab HVR-L1 (SEQ ID NO: 23) RASQSVRSYLAAnti-IL17A F cross reactive Ab HVR-L2 (SEQ ID NO: 24) DASNRATAnti-IL17A F cross reactive Ab HVR-L3 (SEQ ID NO: 25) QQRSNWPPATAnti-IL17A F cross reactive Ab IgG4 heavy chain with hole-forming T366S/L368A/Y407V mutations (SEQ ID NO: 26)EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GAnti-IL17A F cross reactive Ab IgG4 heavy chain with hole-forming T366S/L368A/Y407V mutations (SEQ ID NO: 27)EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GKAnti-IL17A F cross reactive Ab light chain (SEQ ID NO: 28)EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-IL13 heavy-chain variable domain polynucleotide sequence(SEQ ID NO: 29)GAAGTTACCCTGCGCGAGAGCGGCCCAGCCCTGGTGAAGCCAACCCAGACCCTGACCCTGACCTGCACCGTCAGCGGCTTCAGCCTGAGCGCCTACAGCGTGAACTGGATCCGCCAGCCACCAGGCAAGGCCCTGGAGTGGCTGGCCATGATCTGGGGCGACGGCAAGATCGTGTACAACAGCGCCCTGAAGAGCCGCCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGACCATGACCAACATGGACCCAGTGGACACCGCCACCTACTACTGCGCCGGCGACGGCTACTACCCATACGCCATGGACAACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGC Anti-IL13 light-chain variable domain polynucleotide sequence(SEQ ID NO: 30)GATATCGTGCTGACCCAGAGCCCAGACAGCCTGTCTGTGAGCCTGGGCGAGCGCGCCACCATCAACTGCCGCGCCAGCAAAAGCGTGGACAGCTACGGCAACAGCTTCATGCACTGGTATCAGCAGAAGCCAGGCCAGCCACCCAAGCTGCTGATCTACCTGGCCAGCAACCTGGAGAGCGGCGTGCCAGACCGCTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCTCTCTGCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGCAGAACAACGAGGACCCACGCACCTTCGGTGGCGGTACCAAGGTGGAGATCAAA Anti-IL13 IgG4 heavy chain polynucleotide sequence with knob-forming T366W mutation (SEQ ID NO: 31)GAAGTTACCCTGCGCGAGAGCGGCCCAGCCCTGGTGAAGCCAACCCAGACCCTGACCCTGACCTGCACCGTCAGCGGCTTCAGCCTGAGCGCCTACAGCGTGAACTGGATCCGCCAGCCACCAGGCAAGGCCCTGGAGTGGCTGGCCATGATCTGGGGCGACGGCAAGATCGTGTACAACAGCGCCCTGAAGAGCCGCCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGACCATGACCAACATGGACCCAGTGGACACCGCCACCTACTACTGCGCCGGCGACGGCTACTACCCATACGCCATGGACAACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGCGCTTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTGCTCCCGCAGTACTTCTGAGTCCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCTAGCAGCTTGGGCACCAAGACCTACACGTGCAACGTGGATCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGTGGTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGT Anti-IL13 IgG4 heavy chain polynucleotide sequence with knob-forming T366W mutation (SEQ ID NO: 32)GAAGTTACCCTGCGCGAGAGCGGCCCAGCCCTGGTGAAGCCAACCCAGACCCTGACCCTGACCTGCACCGTCAGCGGCTTCAGCCTGAGCGCCTACAGCGTGAACTGGATCCGCCAGCCACCAGGCAAGGCCCTGGAGTGGCTGGCCATGATCTGGGGCGACGGCAAGATCGTGTACAACAGCGCCCTGAAGAGCCGCCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGACCATGACCAACATGGACCCAGTGGACACCGCCACCTACTACTGCGCCGGCGACGGCTACTACCCATACGCCATGGACAACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGCGCTTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTGCTCCCGCAGTACTTCTGAGTCCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCTAGCAGCTTGGGCACCAAGACCTACACGTGCAACGTGGATCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGTGGTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAATAA Anti-IL13 light chain polynucleotide (SEQ ID NO: 33)GATATCGTGCTGACCCAGAGCCCAGACAGCCTGTCTGTGAGCCTGGGCGAGCGCGCCACCATCAACTGCCGCGCCAGCAAAAGCGTGGACAGCTACGGCAACAGCTTCATGCACTGGTATCAGCAGAAGCCAGGCCAGCCACCCAAGCTGCTGATCTACCTGGCCAGCAACCTGGAGAGCGGCGTGCCAGACCGCTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCTCTCTGCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGCAGAACAACGAGGACCCACGCACCTTCGGTGGCGGTACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCTTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGTGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAA Anti-IL17A F cross reactive Ab heavy-chain variable domain polynucleotide(SEQ ID NO: 34)GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAATTGGAGCAGTGGTGGCATAGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTGCAAGAGATATCGGGGGGTTCGGGGAGTTTTACTGGAACTTCGGTCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCA Anti-IL17A F cross reactive Ab light-chain variable domain polynucleotide(SEQ ID NO: 35)GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCCGGCCACTTTCGGCGGAGGGACCAAGGTGGAGAT CAAA Anti-IL17A F cross reactive Ab IgG4 heavy chain polynucleotide with hole-forming T366S/L368A/Y407V mutations (SEQ ID NO: 36)GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAATTGGAGCAGTGGTGGCATAGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTGCAAGAGATATCGGGGGGTTCGGGGAGTTTTACTGGAACTTCGGTCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTGCTCCCGCAGTACTTCTGAGTCCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCTAGCAGCTTGGGCACCAAGACCTACACGTGCAACGTGGATCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGAGCTGCGCTGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTTAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG GGT Anti-IL17A F cross reactive Ab IgG4 heavy chain polynucleotide with hole-forming T366S/L368A/Y407V mutations (SEQ ID NO: 37)GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAATTGGAGCAGTGGTGGCATAGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTGCAAGAGATATCGGGGGGTTCGGGGAGTTTTACTGGAACTTCGGTCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTGCTCCCGCAGTACTTCTGAGTCCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCTAGCAGCTTGGGCACCAAGACCTACACGTGCAACGTGGATCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGAGCTGCGCTGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTTAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAATAA  Anti-IL17A F cross reactive Ab light chain polynucleotide(SEQ ID NO: 38)GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCCGGCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCTTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGTGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAA Codon optimized anti-IL17A F cross reactive Ab IgG4 heavy chain polynucleotide with hole-forming T366S/L368A/Y407V mutations(SEQ ID NO: 39)GAAGTTCAGCTGGTTGAAAGCGGTGGTGGTCTGGTTCAGCCTGGTCGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGTTTTACCTTTGATGATTATGCCATGCATTGGGTTCGTCAGGCACCGGGTAAAGGTCTGGAATGGGTTAGCGGTATTAATTGGAGCAGCGGTGGTATTGGTTATGCAGATAGCGTTAAAGGTCGTTTTACCATTAGCCGTGATAATGCCAAAAATAGCCTGTACCTGCAGATGAATAGTCTGCGTGCAGAAGATACCGCACTGTATTATTGTGCACGTGATATTGGTGGTTTTGGCGAATTCTATTGGAATTTTGGTCTGTGGGGTCGTGGCACCCTGGTTACCGTTAGCAGCGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTGCTCCCGCAGTACTTCTGAGTCCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCTAGCAGCTTGGGCACCAAGACCTACACGTGCAACGTGGATCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGAGCTGCGCTGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTTAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG GGT Codon optimized anti-IL17A F cross reactive Ab IgG4 heavy chain polynucleotide with hole-forming T366S/L368A/Y407V mutations(SEQ ID NO: 40)GAAGTTCAGCTGGTTGAAAGCGGTGGTGGTCTGGTTCAGCCTGGTCGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGTTTTACCTTTGATGATTATGCCATGCATTGGGTTCGTCAGGCACCGGGTAAAGGTCTGGAATGGGTTAGCGGTATTAATTGGAGCAGCGGTGGTATTGGTTATGCAGATAGCGTTAAAGGTCGTTTTACCATTAGCCGTGATAATGCCAAAAATAGCCTGTACCTGCAGATGAATAGTCTGCGTGCAGAAGATACCGCACTGTATTATTGTGCACGTGATATTGGTGGTTTTGGCGAATTCTATTGGAATTTTGGTCTGTGGGGTCGTGGCACCCTGGTTACCGTTAGCAGCGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTGCTCCCGCAGTACTTCTGAGTCCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCTAGCAGCTTGGGCACCAAGACCTACACGTGCAACGTGGATCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGAGCTGCGCTGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCGTTAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAATAA Codon optimized anti-IL17A F cross reactive Ab light chain polynucleotide(SEQ ID NO: 41)GAAATTGTTCTGACCCAGAGTCCGGCAACCCTGAGCCTGAGTCCGGGTGAACGTGCCACCCTGAGCTGTCGTGCAAGCCAGAGCGTTCGTAGCTATCTGGCATGGTATCAGCAGAAACCGGGTCAGGCACCGCGTCTGCTGATTTATGATGCAAGCAATCGTGCAACCGGTATTCCGGCACGTTTTAGCGGTAGCGGTAGTGGCACCGATTTTACCCTGACCATTAGCAGCCTGGAACCGGAAGATTTTGCAGTGTATTATTGTCAGCAGCGTAGCAATTGGCCACCGGCAACCTTTGGTGGTGGCACCAAAGTTGAAATTAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCTTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGTGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAA FkpA TIR1 (SEQ ID NO: 42)GAATTATGAA GTCCCTGTTT AAAGTGACGC TGCTGGCGAC CACAATGGCCGTTGCCCTGC ATGCACCAAT CACTTTTGCT  FkpA TIR2 (SEQ ID NO: 43)GAATTATGAA GTCGCTATTC AAAGTGACGC TGCTGGCGAC CACAATGGCCGTTGCCCTGC ATGCACCAAT CACTTTTGCT  FkpA TIR3 (c13) (SEQ ID NO: 44)GAATTATGAA GTCGCTGTTT AAAGTTACGC TGCTGGCGAC CACAATGGCCGTTGCCCTGC ATGCACCAAT CACTTTTGCT  FkpA signal peptide (SEQ ID NO: 45)MKSLFKVTLLATTMAVALHAPITFA

1. A method of producing a polypeptide comprising two chains in aprokaryotic host cell, the method comprising: (a) culturing the hostcell to express the two chains of the polypeptide in a culture mediumunder conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,whereby upon expression the two chains fold and assemble to form abiologically active polypeptide in the host cell; wherein the host cellcomprises a polynucleotide comprising (1) a first translational unitencoding a first chain of the polypeptide; (2) a second translationalunit encoding a second chain of the polypeptide; and (3) a thirdtranslational unit encoding at least one chaperone protein selected fromthe group consisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the biologically active polypeptidefrom the host cell.
 2. A method of producing a polypeptide comprisingtwo chains in a prokaryotic host cell, the method comprising: (a)culturing the host cell to express the two chains of the polypeptide ina culture medium under conditions comprising: a growth phase comprisinga growth temperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,whereby upon expression the two chains fold and assemble to form abiologically active polypeptide in the host cell; wherein the host cellcomprises a polynucleotide comprising: (1) a first translational unitencoding a first chain of the polypeptide; (2) a second translationalunit encoding a second chain of the polypeptide; (3) a thirdtranslational unit encoding a first chaperone protein; (4) a fourthtranslational unit encoding a second chaperone protein; and (5) a fifthtranslational unit encoding a third chaperone protein, wherein thefirst, second and third chaperone proteins are selected from the groupconsisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the biologically active polypeptidefrom the host cell.
 3. The method of claim 1, wherein the polynucleotidefurther comprises three copies of a promoter, wherein a first copy is inoperable combination with the first translational unit, a second copy isin operable combination with the second translational unit, and a thirdcopy is in operable combination with the third translational unit todrive transcription of the first chain, the second chain and thechaperone protein.
 4. The method of claim 3, wherein the promoter is aninducible promoter.
 5. The method of claim 4, wherein the induciblepromoter is an IPTG-inducible promoter that drives transcription of thefirst chain, the second chain and the chaperone protein in the absenceof IPTG induction.
 6. The method of claim 4, wherein the induciblepromoter is a Pho promoter that drives transcription of the first chain,the second chain and the chaperone protein when phosphate in the culturemedium has been depleted.
 7. The method of claim 1, wherein thepolynucleotide further comprises a selectable marker and the culturemedium comprises a selection agent consisting of a single antibiotic tocause the host cell to retain the polynucleotide.
 8. The method of claim1, wherein the first translational unit comprises a first translationinitiation region (TIR) in operable combination with a coding region ofthe first chain, and the second translational unit comprises a secondtranslation initiation region (TIR) in operable combination with acoding region of the second chain, wherein the relative translationstrength of the first and second TIR is from about 1.0 to about 3.0. 9.The method of claim 1, wherein the at least one chaperone proteincomprises a peptidyl-prolyl isomerase.
 10. The method of claim 9,wherein the peptidyl-prolyl isomerase is an FkpA protein.
 11. The methodof claim 10, wherein the FkpA is E. coli FkpA.
 12. The method of claim9, wherein the at least one chaperone protein further comprises aprotein disulfide oxidoreductase.
 13. The method of claim 12, whereinthe protein disulfide oxidoreductase is one or both of a DsbA proteinand a DsbC protein.
 14. The method of claim 13, wherein the at least oneprotein disulfide oxidoreductase is one or both of E. coli DsbA and E.coli DsbC.
 15. The method of claim 1, wherein the prokaryotic host cellis a gram-negative bacterium.
 16. The method of claim 15, wherein thegram-negative bacterium is E. coli.
 17. The method of claim 16, whereinthe E. coli is a strain with a degpS210A mutation.
 18. The method ofclaim 17, wherein the E. coli is a strain with a genotype of W3110 ΔfhuAΔphoA ilvG2096 (Val^(r)) Δprc spr43H1 ΔdegP ΔmanA lacI^(Q) ΔompT ΔmenEdegpS210A.
 19. The method of claim 1, wherein the polypeptide is amonomer of a heterodimer.
 20. The method of claim 1, wherein the twochains of the polypeptide are linked to each other by at least onedisulfide bond.
 21. The method of claim 1, wherein the polypeptide is amonovalent antibody in which the first chain and the second chaincomprise an immunoglobulin heavy chain and an immunoglobulin lightchain.
 22. The method of claim 21, wherein the monovalent antibody iscapable of specifically binding an antigen.
 23. The method of claim 1,wherein the polypeptide is a secretory protein.
 24. The method of claim23, wherein the secretory protein is recovered from the periplasm of thehost cell.
 25. The method of claim 1, wherein the growth temperature isin the range of about 30° C. to about 34° C. during the growth phase,and the production temperature in the range of about 25° C. to about 29°C. during the production phase.
 26. The method of claim 1, wherein thegrowth agitation rate is sufficient to achieve an oxygen uptake rate inthe host cell during the growth phase of from 0.5 to 2.5 mmol/L/minabove a peak oxygen uptake rate in the host cell during the productionphase.
 27. The method of claim 1, wherein the peak oxygen uptake rate ofthe host cell during the growth phase is in the range of 3.5 to 4.5mmol/L/min, and the oxygen uptake rate of the host cell during theproduction phase is in the range of 1.0 to 3.0 mmol/L/min.
 28. A methodof producing a half antibody comprising a heavy chain and a light chainin a prokaryotic host cell, the method comprising: (a) culturing thehost cell to express the heavy chain and the light chain in a culturemedium under conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,whereby upon expression the heavy chain and the light chain assemble toform a half antibody in the host cell; wherein the host cell comprises apolynucleotide comprising: (1) a first translational unit encoding theheavy chain of the half antibody; (2) a second translational unitencoding the light chain of the half antibody; (3) a third translationalunit encoding a first chaperone protein; (4) a fourth translational unitencoding a second chaperone protein; and (5) a fifth translational unitencoding a third chaperone protein, wherein the first, second and thirdchaperone proteins are selected from the group consisting ofpeptidyl-prolyl isomerases, protein disulfide oxidoreductases, andcombinations thereof; wherein the growth temperature is from 2 to 10° C.above the production temperature, and the growth agitation rate is from50 to 250 rpm above the production agitation rate; and (b) recoveringthe half antibody from the host cell.
 29. The method of claim 28,wherein the half antibody comprises at least one hole-forming mutationor at least one knob-forming mutation.
 30. A method of producing ananti-IL13 half antibody comprising a heavy chain and a light chain in aprokaryotic host cell, the method comprising: (a) culturing the hostcell to express the heavy chain and the light chain in a culture mediumunder conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,wherein (i) the heavy chain comprises a heavy chain variable domaincomprising an HVR-H1 of SEQ ID NO:9, an HVR-H2 of SEQ ID NO:10, and anHVR-H3 of SEQ ID NO:11; and (ii) the light chain comprises a light chainvariable domain comprising an HVR-L1 of SEQ ID NO:12, an HVR-L2 of SEQID NO:13, and an HVR-L3 of SEQ ID NO:14, whereby upon expression theheavy chain and light chain assemble to form an anti-IL13 half antibodyin the host cell; wherein the host cell comprises a polynucleotidecomprising: (1) a first translational unit encoding the heavy chain ofthe half antibody; (2) a second translational unit encoding the lightchain of the half antibody; (3) a third translational unit encoding afirst chaperone protein; (4) a fourth translational unit encoding asecond chaperone protein; and (5) a fifth translational unit encoding athird chaperone protein, wherein the first, second and third chaperoneproteins are selected from the group consisting of peptidyl-prolylisomerases, protein disulfide oxidoreductases, and combinations thereof;wherein the growth temperature is from 2 to 10° C. above the productiontemperature, and the growth agitation rate is from 50 to 250 rpm abovethe production agitation rate; and (b) recovering the anti-IL13 halfantibody from the host cell.
 31. The method of claim 30, wherein theanti-IL13 half antibody comprises at least one knob-forming mutation.32. A method of producing an anti-IL17 half antibody comprising a heavychain and a light chain in a prokaryotic host cell, the methodcomprising: (a) culturing the host cell to express the heavy chain andthe light chain in a culture medium under conditions comprising: agrowth phase comprising a growth temperature and a growth agitationrate, and a production phase comprising a production temperature and aproduction agitation rate, wherein (i) the heavy chain comprises a heavychain variable domain comprising an HVR-H1 of SEQ ID NO:20, an HVR-H2 ofSEQ ID NO:21, and an HVR-H3 of SEQ ID NO:22; and (ii) the light chaincomprises a light chain variable domain comprising an HVR-L1 of SEQ IDNO:23, an HVR-L2 of SEQ ID NO:24, and an HVR-L3 of SEQ ID NO:25, wherebyupon expression the heavy chain and the light chain assemble to form ananti-IL17 half antibody in the host cell; wherein the host cellcomprises a polynucleotide comprising: (1) a first translational unitencoding the heavy chain of the half antibody; (2) a secondtranslational unit encoding the light chain of the half antibody; (3) athird translational unit encoding a first chaperone protein; (4) afourth translational unit encoding a second chaperone protein; and (5) afifth translational unit encoding a third chaperone protein, wherein thefirst, second and third chaperone proteins are selected from the groupconsisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein the growthtemperature is from 2 to 10° C. above the production temperature, andthe growth agitation rate is from 50 to 250 rpm above the productionagitation rate; and (b) recovering the anti-IL17 half antibody from thehost cell.
 33. The method of claim 32, wherein the anti-IL17 halfantibody comprises at least one hole-forming mutation.
 34. The method ofclaim 28, wherein the polynucleotide further comprises three copies of apromoter, wherein a first copy is in operable combination with the firsttranslational unit, a second copy is in operable combination with thesecond translational unit, and a third copy is in operable combinationwith the third translational unit to drive transcription of the heavychain, the light chain and the chaperone protein.
 35. The method ofclaim 34, wherein the promoter is an inducible promoter.
 36. The methodof claim 35, wherein the inducible promoter is an IPTG-induciblepromoter that drives transcription of the heavy chain, the light chainand the chaperone protein in the absence of IPTG induction.
 37. Themethod of claim 35, wherein the inducible promoter is a pho promoterthat drives transcription of the heavy chain, the light chain and thechaperone protein when phosphate in the culture medium has beendepleted.
 38. The method of claim 28, wherein the polynucleotide furthercomprises a selectable marker and the culture medium comprises aselection agent consisting of a single antibiotic to cause the host cellto retain the monovalent antibody.
 39. The method of claim 28, whereinthe first translational unit comprises a first translation initiationregion (TIR) in operable combination with a coding region of the heavychain, and the second translational unit comprises a second translationinitiation region (TIR) in operable combination with a coding region ofthe light chain, wherein the relative translation strength of the firstand second TIR is from about 1.0 to about 3.0.
 40. The method of claim28, wherein the first chaperone protein comprises a peptidyl-prolylisomerase.
 41. The method of claim 40, wherein the peptidyl-prolylisomerase is an FkpA protein.
 42. The method of claim 41, wherein theFkpA is E. coli FkpA.
 43. The method of claim 40, wherein one or both ofthe second chaperone protein and the third chaperone protein comprises aprotein disulfide oxidoreductase.
 44. The method of claim 43, whereinthe protein disulfide oxidoreductase is one or both of a DsbA proteinand a DsbC protein.
 45. The method of claim 44, wherein the proteindisulfide oxidoreductase is one or both of E. coli DsbA and E. coliDsbC.
 46. The method of claim 28, wherein the prokaryotic host cell is agram-negative bacterium.
 47. The method of claim 46, wherein thegram-negative bacterium is E. coli.
 48. The method of claim 47, whereinthe E. coli is of a strain deficient in endogenous protease activity.49. The method of claim 28, wherein the growth temperature is in therange of about 30° C. to about 34° C. during the growth phase, and theproduction temperature in the range of about 25° C. to about 29° C.during the production phase.
 50. The method of claim 28, wherein thegrowth agitation rate is sufficient to achieve an oxygen uptake rate inthe host cell during the growth phase of from 0.5 to 2.5 mmol/L/minabove a peak oxygen uptake rate in the host cell during the productionphase.
 51. The method of claim 28, wherein the peak oxygen uptake rateof the host cell during the growth phase is in the range of 3.5 to 4.5mmol/L/min, and the oxygen uptake rate of the host cell during theproduction phase is in the range of 1.0 to 3.0 mmol/L/min.
 52. A methodof producing a bi-specific antibody comprising a first half antibodycapable of binding a first antigen and a second half antibody capable ofbinding a second antigen, the method comprising: combining in a reducingcondition, the first half antibody with the second half antibody toproduce a bi-specific antibody, wherein the first half antibodycomprises at least one knob-forming mutation and the second halfantibody comprises at least one hole-forming mutation, and wherein boththe first half antibody and the second half antibody are produced by themethod of claim
 28. 53. The method of claim 52, wherein the first halfantigen and the second half antigen are different antigens.
 54. Themethod of claim 52, wherein the first half antibody is capable ofbinding IL-13.
 55. The method of claim 52, wherein the second halfantibody is capable of binding IL-17.
 56. The method of claim 52,further comprising the step of adding a reducing agent to achieve thereducing condition.
 57. The method of claim 56, wherein the reducingagent is glutathione.
 58. A method of producing a bispecific antibodycomprising a first half antibody capable of binding IL13 and a secondhalf antibody capable of binding IL17, the method comprising: (a)culturing a first prokaryotic host cell to express a first heavy chainand a first light chain of the first half antibody, wherein (i) thefirst heavy chain comprises a first heavy chain variable domaincomprising an HVR-H1 of SEQ ID NO:9, an HVR-H2 of SEQ ID NO:10, and anHVR-H3 of SEQ ID NO:11; and (ii) the first light chain comprises a firstlight chain variable domain comprising an HVR-L1 of SEQ ID NO:12, anHVR-L2 of SEQ ID NO:13, and an HVR-L3 of SEQ ID NO:14, whereby uponexpression the first heavy chain and the first light chain assemble toform the first half antibody in the host cell; and (a′) culturing asecond prokaryotic host cell to express a second heavy chain and asecond light chain of the second half antibody, wherein (i) the secondheavy chain comprises a second heavy chain variable domain comprising anHVR-H1 of SEQ ID NO:20, an HVR-H2 of SEQ ID NO:21, and an HVR-H3 of SEQID NO:22; and (ii) the second light chain comprises a second light chainvariable domain comprising an HVR-L1 of SEQ ID NO:23, an HVR-L2 of SEQID NO:24, and an HVR-L3 of SEQ ID NO:25, whereby upon expression thesecond heavy chain and the second light chain assemble to form thesecond half antibody in the host cell; wherein the first host cellcomprises a first polynucleotide comprising: (1) a first translationalunit encoding the first heavy chain; (2) a second translational unitencoding the first light chain; and the second host cell comprises asecond polynucleotide comprising: (1′) a third translational unitencoding the second heavy chain; (2′) a fourth translational unitencoding the second light chain; wherein both the first polynucleotideand the second polynucleotide further comprise: (3) a fifthtranslational unit encoding a first chaperone protein; (4) a sixthtranslational unit encoding a second chaperone protein; and (5) aseventh translational unit encoding a third chaperone protein, whereinthe first, second and third chaperone proteins are selected from thegroup consisting of peptidyl-prolyl isomerases, protein disulfideoxidoreductases, and combinations thereof; wherein both the first hostcell and the second host cell are separately cultured in a culturemedium under conditions comprising: a growth phase comprising a growthtemperature and a growth agitation rate, and a production phasecomprising a production temperature and a production agitation rate,wherein the growth temperature is from 2 to 10° C. above the productiontemperature, and the growth agitation rate is from 50 to 250 rpm abovethe production agitation rate; (b) recovering the first half antibodyfrom the first host cell; (b′) recovering the second half antibody fromthe second host cell; and (c) combining the first half antibody with thesecond half antibody in a reducing condition to produce a bi-specificantibody capable of binding to both IL-13 and IL-17.
 59. The method ofclaim 58, wherein the first half antibody comprises at least oneknob-forming mutation, and the second half antibody comprises at leastone hole-forming mutation.
 60. The method of claim 58, furthercomprising the step of adding a reducing agent to achieve the reducingcondition.
 61. The method of claim 60, wherein the reducing agent isglutathione.
 62. A composition comprising the bi-specific antibodyproduced by the method of claim
 52. 63. The method of claim 30, whereinthe heavy chain variable domain of the anti-IL13 half antibody comprisesthe amino acid sequence of SEQ ID NO:7 and the light chain variabledomain of the anti-IL13 antibody comprises the amino acid sequence ofSEQ ID NO:8.
 64. The method of claim 30, wherein the heavy chain of theanti-IL13 half antibody comprises the amino acid sequence of SEQ IDNO:15 or SEQ ID NO:16.
 65. The method of claim 30, wherein the lightchain of the anti-IL13 half antibody comprises the amino acid sequenceof SEQ ID NO:17.
 66. The method of claim 32, wherein the heavy chainvariable domain of the anti-IL17 half antibody comprises the amino acidsequence of SEQ ID NO:18 and the light chain variable domain of theanti-IL17 half antibody comprises the amino acid sequence of SEQ IDNO:19.
 67. The method of claim 32, wherein the heavy chain of the antiIL17 half antibody comprises the amino acid sequence of SEQ ID NO:26 orSEQ ID NO:27.
 68. The method of claim 32, wherein the light chain of theanti-IL17 half antibody comprises the amino acid sequence of SEQ IDNO:28.
 69. The method of claim 1, wherein the growth agitation rate isfrom about 10% to about 40% higher than the production agitation rate.